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Zusammenfassung 
Der ABC-Transporter ABCA1 ist unmittelbar in die zelluläre Lipidhomeostasie einbezogen, in dem 
er die Freisetzung von Cholesterol an plasmatische Rezeptoren, wie ApoA-I, vermittelt. Trotz 
intensiver Untersuchungen ist dieser molekulare Mechanismus nicht verstanden. Verschiedene 
Studien deuten daraufhin, dass durch die Aktivität von ABCA1 bedingte Veränderungen in der 
Lipidphase der äußeren Hälfte der Plasmamembran (PM) wichtig für die Freisetzung des 
Cholesterols sind. 
In der vorliegenden Arbeit wird die Lipidumgebung von ABCA1 in der PM lebender Säugetierzellen 
unter Anwendung der Fluoreszenzlebenszeitmikroskopie von fluoreszierenden Lipidsonden 
untersucht. Es wurde eine breite Verteilung der Fluoreszenzlebenszeiten der Sonden gefunden, die 
sensitiv gegenüber Veränderungen der lateralen und transversalen Organisation der Lipide ist. Im 
Einklang mit Studien an riesengroßen unilamellaren Vesikeln und Plasmamembranvesikeln weisen 
unsere Ergebnisse die Existenz einer größeren Vielfalt submikroskopischer Lipiddomänen auf. 
Die FLIM-Untersuchungen an ABCA1 exprimierenden HeLa-Zellen weisen eine die Lipidphase 
destabilisierende Funktion des Transportes aus. Dieses wurde unterstützt durch die Lipidanalyse von 
Fraktionen der PM. Auf der Basis unserer Untersuchungen und früheren Daten stellen wir die 
Hypothese auf, dass die Exponierung von Phosphatidylserin (PS) auf der Zelloberfläche ein 
zentrales Ereignis der ABCA1 bedingten Veränderungen ist. Allerdings zeigen vergleichende Studien 
an ABCA7 exprimierenden Zellen, dass dies nicht ausreicht, um die ABCA1 verursachten 
Veränderungen in der Lipidpackung der PM zu erklären. 
Unsere Ergebnisse beweisen, dass die Fähigkeit von ABCA1, den Cholesterolefflux zu vermitteln, 
auf durch den Transporter bedingte Veränderungen in der LP der PM zurückzuführen sind, die 
unabhängig von der Bindung von ApoA-1 sind und dieser vorausgehen. Diese Veränderungen sind 
notwendig für die Lipidierung von ApoA-1 und der Generierung von HDL-Partikeln. 
Schlagwörter: ABCA1, Plasmamembran, Cholesterol, Lipiddomänen, FLIM 
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Abstract 
The ABCA1 transporter organizes cellular lipid homeostasis by promoting the release of cholesterol 
to plasmatic acceptors such as ApoA-I. Despite intensive investigation, the molecular mechanism of 
such a process has not yet been clarified.  
In the present study we report on the analysis of the ABCA1 lipid microenvironment at the plasma 
membrane of living cells, by a novel approach based on fluorescence lifetime imaging microscopy 
(FLIM). In the plasma membrane of mammalian cells, a broad fluorescence lifetime distribution 
sensitive to treatments interfering with the membrane lateral and transbilayer organization was 
found. In agreement with investigations in giant unilamellar vesicles and giant plasma membrane 
vesicles, our results are consistent with the existence of a large variety of submicroscopic lipid 
domains. 
Based on that, FLIM in HeLa cells expressing ABCA1 revealed the destabilizing function of the 
transporter on the lipid arrangement at the membrane, indicating that lipid packing was a primary 
target of ABCA1 activity. This was corroborated by the analysis of plasma membrane fractions 
isolated by density fractionation. On the basis of our analysis and previous data, we speculate that 
the exposure of phosphatidylserine on the cell surface is a central event for ABCA1-dependent 
modifications. However, a comparative study of cells expressing ABCA7, the member of the ABCA 
subfamily with the highest homology to ABCA1, revealed that exposure of PS alone cannot account 
for the detected effects.  
Collectively, our data suggest that the ability of ABCA1 to promote cholesterol efflux is independent 
and precedes its actual binding to ApoA-I. Rather, ABCA1-induced plasma membrane modifications 
are necessary for the lipidation of ApoA-I and the generation of high density lipoprotein particles. 
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1 Introduction 
1.1 The plasma membrane 
Eukaryotic cells use about 5% of their genes to synthesize thousands of different lipids [1]. The main 
biological functions of lipids include energy storage, acting as structural components of cell 
membranes, and participating in signalling pathways. Triacylglycerols and steryl esters, stored in 
adipose tissue, constitute the major form of energy storage in animals and provide a reservoir of fatty 
acid and sterol components that are needed for the biogenesis of membranes. Second, the 
amphipathic character of polar lipids is at the basis for the formation of cellular membranes. This 
compartmentalization enables the segregation of the internal constituents of the cell from the 
external environment and the restriction of specific chemical reactions into organelles. In addition to 
this barrier function, lipids provide membranes with the potential for budding, tubulation, fission and 
fusion, properties that are fundamental for the biological processes [2]. Finally, lipids can act as first 
and second messengers in the processes of signal transduction. The most important example is the 
phosphoinositide system, which is involved in many different processes including cell proliferation, 
hormone secretion, smooth muscle contraction and transduction of visual information. Indeed, the 
production and inactivation of inositol lipids is controlled by almost a hundred of (isoforms of) 
kinases and phosphatases. 
1.1.1 The repertoire of membrane lipids 
The main classes of eukaryotic membrane lipids are glycerolipids, sphingolipids and sterols. 
Glycerolipids are based on glycerol with two fatty acid chains linked at position 1 and 2 (Fig. 1). A 
cis-double bond is usually present in the fatty acid that is linked at position 2, causing a kink in the 
acyl chain and decreasing the packing density of the lipid. A phosphate can be attached at position 3 
(forming phosphatidic acid, PA). This phosphate can carry a head group, which either produces a 
zwitterionic lipid (PC, PE), or gives a net acidic charge (PS, PI). The most abundant phospholipid in 
eukaryotic membranes is PC (>50%). 
Sphingolipids are based on a sphingosine, with a saturated C16-C26 fatty acid linked via an amide 
bond, yielding ceramide (Cer). The linkage of a phosphocholine headgroup to Cer forms 
sphingomyelin (SM). Alternatively, addition of glucose or galactose gives rise to glucosylceramide 
(GluCer) or galactosylceramide (GalCer), respectively. Sphingolipids have saturated tails that allow 
them to be in a more packed configuration, with cholesterol filling the spaces between the acyl 
chains and increasing the density of lipid packing [3,4]. 
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Sterols are the major non polar lipids of cell membranes, with cholesterol predominating in 
mammals and ergosterol in yeast. They are based on a planar and rigid four-ring structure. Besides 
being a fundamental constituent of cellular membranes, cholesterol is also a precursor molecule for 
the production of bile salts and steroid hormones.  
 
 
Fig. 1: Structure of mammalian membrane lipids. The main eukaryotic membrane lipids are 
glycerophospholipids, sphingolipids and cholesterol. The most abundant glycerolipid is PC, which consists of 
glycerol (yellow shading), two fatty acid chains on the sn-1 and as-2 position and phosphate carrying the 
headgroup choline (blue shading). A cis-double bond, usually present in the fatty acid that is linked at the sn-2 
position, causes a kink in the acyl chain and increases the membrane area of the lipid. The 
phosphosphingolipid SM and the glycosphingolipid GlcCer have a ceramide backbone, consisting of a 
sphingoid base, such as sphingosine (yellow shading), linked to a fatty acid via an amide bond. Addition of 
glucose or galactose to Cer gives rise to GluCer or GalCer, respectively. LacCer: lactosyl ceramide. 
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1.1.2 Phase separation in model membranes 
Membrane lipids can occur in various phases depending on their structure and environment. At a 
temperature that is characteristic of the particular lipid species (defined as melting temperature, Tm), 
phospholipids (PL) can undergo a phase transition from a gel phase (or solid-ordered, So) to a liquid 
disordered (Ld) phase. In the gel phase the lateral mobility of the lipids is highly restricted, with the 
acyl chains mainly in all-trans configuration, packed together in a rigid conformation. In the Ld 
phase, the lateral mobility of the lipids increases and the acyl chains become disordered. If the 
membrane contains sufficient amount of cholesterol, the formation of a third phase, the liquid 
ordered (Lo) phase, is possible. This phase is characterized by a high degree of acyl chain ordering, 
typical of the gel phase, but with a relatively fast diffusion of lipids, only two- to three-fold slower 
than in the Ld phase [5].  
Appropriate mixtures of SM, unsaturated PL and cholesterol at the opportune temperature can form 
membranes with coexisting Ld and Lo phases. The Ld phases are enriched with unsaturated PL, 
whereas cholesterol and sphingolipids preferentially accumulate to the Lo phase [6,7,8]. The 
interaction of cholesterol with the fatty acid chains of sphingo- or phospholipids leads to a higher 
degree of order and, accordingly, to a more stretched configuration of the fatty acid chains, 
responsible for the local increase in the thickness of the bilayer. 
Although it is not completely clear how cholesterol drives the formation of a Lo phase, several 
explanations have been proposed. The packing of cholesterol with the saturated acyl chains of 
sphingolipids is entropically more favorable than with unsaturated acyl chains [9]. Moreover, 
possible hydrogen bonding between the hydroxyl group of cholesterol and the amide group of 
sphingolipids and ceramides can also contribute to this preferential association [10,11,12]. It was 
suggested that, in a bilayer, the non polar cholesterol relies on the coverage provided by the 
headgroup of polar phospholipids to avoid the unfavorable free energy of its contact with water [13]. 
This explanation is often referred to as the “umbrella model”. Alternatively, cholesterol was 
suggested to form reversible, condensed complexes of defined stoichiometry with sphingolipids and 
saturated phospholipids [14,15]. The uncomplexed sterol molecules, i.e. those that exceed the 
association capacity of the bilayer lipids, are proposed to have a high escape tendency [14], likely 
because of enhanced projection into the aqueous compartment. This tendency is also referred to as 
cholesterol chemical activity. Recently, based on molecular dynamics simulations, Pandit et al. 
proposed that cholesterol molecules may assist the process of domain formation by decreasing the 
line tension between Lo and Ld domains. This conclusion was based on the observation that, in the 
ternary system DOPC/SM/cholesterol 1/1/1, cholesterol preferentially localized at the interface 
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between the ordered SM region and the disordered DOPC region, without showing any preference 
for SM or DOPC [16].  
The process of phase separation has been extensively studied in giant unilamellar vesicles (GUVs), 
as in these membranes the formation of large, micrometer-scale domains (> 200 μm) can be directly 
visualized by using fluorescent dyes that differentially partition into the two phases (Fig. 2A). In 
biomembranes, it has been questioned whether such phase separation could be hampered by the 
presence of thousands of different lipid species and membrane proteins. However, this was recently 
demonstrated not to be the case, as giant plasma membrane vesicles (GPMVs) directly prepared 
from cells by chemically induced blebbing spontaneously separate into coexisting fluid phases at 
temperatures ≤ 25ºC (Fig. 2B) [17,18].  
 
Fig. 2: Phase separation in GUVs (A) and GPMVs (B). (A) GUVs prepared from DOPC/SM/cholesterol 
(1/1/1) can undergo phase separation into a Ld (red) and Lo (green) phase. Coexisting phases can be visualized 
by the addition of fluorescent probes that preferentially enrich into one phase (in this case, the Ld phase is 
visualized by DiIC18 and the Lo phase by GM1-ctxB-488). This figure is taken from [19]. (B) GPMVs 
prepared from mammalian cells are also able to form distinct phases. In this case the Ld phase, in red, is 
visualized by the enrichment of DiIC12 and the Lo phase, in green, by the preferential accumulation of C6-
NBD-SM (own result). Bars correspond to 10 μm. 
Very recently, Lingwood et al. demonstrated that the cross-linking of the ganglioside GM1 could 
also induce phase separation at 37ºC in plasma membrane spheres (PMS) prepared by cell swelling 
procedures [20]. The authors conclude that the plasma membrane is compositionally poised for raft 
activation at physiological temperature and that this underlines its capacity to be selectively 
stimulated to evoke a large-scale lateral reorganization. 
These results demonstrate that the complex mixture of lipids and proteins in biological membranes 
can support fluid/fluid phase coexistence, and are consistent with the presence of nanoscopic Ld/Lo 
fluctuations in the plasma membrane of living cells [21]. 
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1.1.3 Lipid rafts in the plasma membrane 
Research into lateral heterogeneity in cell membranes started more than three decades ago. After the 
presentation of the fluid mosaic model of the plasma membrane in 1972, which denoted the 
membrane as a uniform, fluid phospholipid bilayer with proteins dispersed at low concentration [22], 
the concept of the lateral segregation of lipids first came up in 1987 from van Meer and Simons, who 
proposed the necessity of lipid domains to explain the sorting of sphingolipids in the Golgi apparatus 
[23,24]. Few years later, Brown and Rose showed that, after treating cells with cold, non-ionic 
detergents such as Triton X-100, GPI (glycosylphosphatidylinositol) -anchored proteins and 
sphingolipids could be recovered in the low density, detergent insoluble fractions [25]. Similarly, 
detergent resistant membranes (DRM) prepared from model membranes were found to be enriched 
in cholesterol and sphingolipids and to contain a subset of GPI-anchored proteins [26]. These 
observations, among others, led to the assumption that the plasma membrane is organized into 
microdomains, with structure similar to that of the Lo phases of model membranes, dispersed among 
lipids in a Ld phase [12]. These “rafts” were proposed to function as platforms for proteins and to 
serve trafficking and signalling events. 
As the limitations of the detergent-based biochemical approaches became evident (see [27] for a 
review), since it was shown that detergent extraction can even induce formation of microdomains 
per se [28], detergent-free techniques developed to isolate lipid rafts. These techniques are 
considered more faithful indicators of the native situation in the membrane, although recent work 
has pointed out that also the application of mechanical stress and the induction of membrane tension 
can induce coalescence of microdomains [29]. 
The development of sophisticated biophysical techniques has led to the idea of the plasma 
membrane as a very heterogeneous and dynamic composite, with raft proteins organized into 
nanoclusters with radii of 5-20 nm [30,31,32,33]. For instance, based on homo-FRET and 
fluorescence anisotropy measurements on the surface of CHO cells, GPI-anchored proteins have 
been suggested to localize in small clusters with about three to four copies [30]. In a recent study, 
FRET measured between carbocyanine lipid probes has been used to investigate the lateral 
organization of lipid components in the plasma membrane of living cells [34], supporting the 
existence of nanometer-scale phase heterogeneity of lipids. 
In addition, the sensitivity of the fluorescence lifetime to local properties of lipid bilayers has been 
recently used to study the lateral organization of lipids in GUVs and in the plasma membrane of 
living cells [35,36,37]. The newest development comes from the group of Hell [38]. These authors 
demonstrate, by using stimulated emission depletion (STED) far-field fluorescence nanoscopy, that 
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sphingolipids and GPI-anchored proteins, but not phosphoglycerolipids, are transiently trapped in 
cholesterol-mediated molecular complexes, residing within areas with diameters < 20 nm. 
From this picture, it emerges that, although the research in this field started already many years ago, 
the evaluation of the raft organization on biological membranes has been difficult because of the 
lack of proper tools, able to reliably measure fluctuating nanoscale heterogeneities with minimal or 
no disturbance [5]. However, a new epoch of investigations has recently started and will follow, 
along with the advances in the biophysical techniques and imaging methodologies.  
 
1.1.4 Lipid asymmetry and protein-mediated lipid translocation 
Besides lipids, the other fundamental constituents of the plasma membrane are proteins, which 
constitute approximately an equal mass to lipids [39]. Membrane proteins can contribute to the 
organization and to the physical properties of the plasma membrane by their mere presence or by 
influencing the distribution of lipids. Reciprocally, also lipids can affect the distribution and function 
of membrane-associated proteins (for reviews, see [40,41].  
It is long known that in the plasma membrane of animal cells, lipids are asymmetrically distributed 
between the two leaflets, with PC and SM enriched in the exoplasmic leaflet and PE and PS in the 
cytosolic leaflet (reviewed in [42]). Whereas SM and glycosphingolipids are basically present only 
in the outer leaflet, and PS only in the inner leaflet, PC and PE have less pronounced asymmetrical 
distributions. Conversely, the transbilayer distribution of cholesterol remains unclear. Cholesterol 
was proposed to be enriched in the exoplasmic leaflet, due to its high affinity for SM [6], to be 
symmetrically distributed [43,44] or even preferentially present in the cytoplasmic leaflet of 
erythrocytes [45].  
Three classes of proteins are involved in the maintaining and regulation of the transbilayer 
asymmetry: lipid flippases, lipid floppases and scramblase proteins (Fig. 3). Flippases and floppases 
use the energy derived from the hydrolysis of ATP to drive the translocation of specific phospholipid 
species towards or away from the cytosolic leaflet, respectively.  
Flippases are members of the type 4 subfamily of P-type ATPases, whereas members of the 
superfamily of ATP binding cassette (ABC) transporters are thought to be floppase candidates. 
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Fig. 3: Lipid asymmetry in the plasma membrane of mammalian cells. This asymmetric lipid arrangement 
is thought to derive as the result of the action of ATP-dependent proteins that move specific lipids towards 
(flippases) or away from the cytosolic leaflet (floppases). Cellular activation triggered by cytosolic calcium 
can collapse the lipid asymmetry by the transient activity of an ATP-independent scramblase. The figure is 
adapted from [46]. 
 
Scramblases are calcium-dependent, bidirectional activities involved in the elimination of the plasma 
membrane phospholipid asymmetry in critical cellular events like cell activation, injury and 
apoptosis. Efforts have been made to isolate and clone the potential scramblase PLSCR1 [47]. 
Moreover, its function as a phospholipid translocase has been recently challenged [48]. 
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1.2 ATP-Binding Cassette (ABC) transporters 
1.2.1 General features 
The superfamily of ATP-binding cassette (ABC) transporters is one of the largest family of proteins 
known. It comprises a large number of transporters, channels and regulators, with representatives in 
all phyla, from prokaryotes to humans [49].  
ABC transporters are highly conserved, multispan transmembrane molecules that use the energy 
derived from ATP hydrolysis to translocate a wide variety of substrates across different cell 
membranes. Substrates can be sugars, inorganic ions, amino acids, peptides, proteins, lipids and 
various organic and inorganic compounds. These processes are fundamental for many aspects of cell 
physiology, including uptake of nutrients, elimination of waste products, generation of metabolic 
energy, antigen processing, bacterial immunity, cholesterol and lipid trafficking, developmental stem 
cell biology and cell signalling [50]. 
The human ABC transporter family consists of 49 members divided into 7 subfamilies, denoted 
ABC A-G, based on their sequence similarity and structural homology [51]. The high physiological 
importance of these proteins is underlined by the fact that mutations in their genes are tightly related 
to genetic disorders. Indeed, most insights into their functions come from the analysis of loss-of-
function diseases and genetically modified mice.  
Structurally, ABC proteins can be divided into two groups: full-size transporters, which consist of 
two similar structural units covalently bound, and half-size transporters, composed of single units 
that form active homo- or heterodimers. One structural unit consists of a nucleotide binding fold 
(NBF), or ATP binding cassette, and of transmembrane domains (TMDs). The NBFs are highly 
conserved among all ABC transporters. They contain characteristic motifs, the Walker A and the 
Walker B regions, typically separated by 90-120 amino acids, and a third, short and highly-
conserved motif, called the signature C, located just upstream of the Walker B site. The Walker A 
and Walker B motifs are found in most proteins that hydrolyze ATP; conversely, the signature C 
motif is unique for ABC transporters. The TMDs can vary considerably between different ABC 
proteins. They consist of α-helices which can cross the phospholipid bilayer multiple times, usually 
from 6 to 11, and are believed to provide for substrate specificity [52].  
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1.2.2 Domain organization and transport cycle 
The eukaryotic ABC proteins typically possess two NBFs and two TMDs. However, many variations 
in this topographical arrangement are also observed (Fig. 4). The class of (TMD-NBF)2 represents 
the full-size transporters, and can be found in the ABCB (also called MDR/TAP), ABCC 
(MRP/CFTR) and in the members of the ABCA subfamily. Possibly, a third transmembrane domain, 
TMD0, composed of five helices, is attached to the N-terminus of several members of the ABCC 
family. This configuration is designated as TMD0(TMD-NBF)2 arrangement. 
 
Fig. 4: Domain organization of the human ABC protein subfamilies involved in membrane transport. 
Transmembrane domains (TMDs) are shown as membrane-spanning helices and nucleotide binding folds are 
indicated as NBF. The most common arrangement of the members of the indicated subfamilies is shown. 
ABCE and ABCF subfamilies are not represented, as they are composed of only NBFs and are not involved in 
any transport function. 
Two variations of half transporters are represented among the human ABC proteins: TMD-NBF 
configuration is present in the ABCB subfamily, in the ABCD (ALD) subfamily of peroxisomal 
transporters and, in “reverse” configuration, in the ABCG (White) subfamily. ABC proteins of the 
subfamilies E and F possess only nucleotide binding folds and, therefore, are likely not involved in 
membrane transport, but rather have regulatory functions [50]. 
The mechanism used by ABC transporters to drive the substrate translocation has not yet been 
completely defined. Biochemical, structural and genetic studies have led to the “ATP switch model”, 
so called because it hypothesizes a switch between two main conformations of the NBFs, an open 
and a closed one. This model is depicted in Fig. 5 [53,54]. In the first step, the binding of the ligand 
to a high-affinity pocket formed by the TMDs induces a conformational change in the NBFs, which 
enhances their affinity for ATP. Two molecules of ATP bind, cooperatively, to generate the close 
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dimer. The energy released by the formation of the NBF closed dimer causes a conformational 
change in the TMDs that drives the translocation of the substrate. ATP hydrolysis initiates the 
resetting of the transporter to its basal configuration, by destabilizing the closed NBF dimer. Finally, 
the sequential release of Pi and ADP restores the transporter to the open NBF dimer configuration, 
ready for the subsequent cycle. 
 
Fig. 5: The ATP switch model for ABC transporters [54]. In its basal state, the transporter has the NBFs in 
an open dimer configuration, with low affinity for ATP. The transport cycle is initiated by binding of the 
substrate to its high affinity site on the TMDs from the inner leaflet of the membrane. The affinity for ATP is 
increased, and two ATP molecules bind to generate the closed dimer. This closed NBF dimer induces a 
conformational change in the TMDs, which drives the translocation of the substrate. The hydrolysis of ATP 
destabilizes the closed NBF dimer and the sequential release of Pi and ADP restores the transporter to its basal 
configuration. 
 
1.2.3 ABC transporters and the transport of lipids 
The fact that several ABC proteins were found to be mutated in lipid-linked diseases suggested their 
potential involvement in lipid transport. However, it was first in 1992 that Higgins and Gottesman 
formulated the hypothesis that ABCB1 (also called MDR1 or Pgp) was a 'floppase' capable to 
transport drugs from the inner to the outer leaflet of the lipid bilayer or to the external medium [55]. 
Since then, a large body of evidence has been accumulating, indicating that ABC proteins can 
transport lipids across cellular membranes and, in few cases, also in model membranes containing 
the purified proteins. The specificity in the transport function is reflected in the tissue distribution of 
the different proteins. At the cellular level, all biological membranes except the nuclear membrane 
possess ABC transporters, although the vast majority is expressed at the plasma membrane. 
The multi-drug resistance protein ABCB1/ MDR1 Pgp was shown to expel a variety of short-chain 
and long-chain (NBD- and radiolabelled) lipids and amphiphilic drugs from the cell [56,57,58]. 
Among endogenous lipids, outward transport of PAF (platelet-activating factor, a short-chain PC) 
was suggested [59]. However, ABCB1 was unable to restore transport of PC into the bile of mice 
lacking Mdr2 [60], the homologous to human ABCB4 in mouse. ABCB4 (MDR2/3 Pgp) is 
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responsible for secretion of PC into the bile, as the bile of mice lacking this protein displays absence 
of this lipid [60]. In addition, ABCB4 was shown to exclusively transport short-chain NBD 
analogues of PC in transfected cells [58], differently from the broad substrate specificity of ABCB1. 
Therefore, the question was raised whether natural long-chain PC is indeed a substrate of ABCB1. 
In the process of bile formation, another essential step is the excretion of bile salts, which is 
mediated by ABCB11 (BSEP), the major canalicular bile salt export pump in man. This process 
occurs in concert with the translocation of PC. Indeed, mutations in either ABCB4 or ABCB11 cause 
a familial cholestatic liver disease [61]. 
Members of the D subfamily of ABC transporters localize in the peroxisomal membrane and are 
involved, as homo- and/or heterodimers, in the β-oxidation of long and very long chain fatty acids, 
in the synthesis of bile acids and cholesterol plasmalogens, in the metabolism of amino acids and 
purines and in the generation and degradation of hydrogen peroxide [62]. These proteins are thought 
to be involved in the transport of fatty acids into the peroxisomal matrix [63,64]. Mutations in 
ABCD1/ALDP result in the X-linked neurometabolic disorder adrenoleukodystrophy [65], 
characterized by elevated levels of very long chain fatty acids in the nervous system [66]. 
A number of members of the ABCG family are thought to be implicated in the transport of steroids, 
phospholipids and toxins. ABCG1 acts, as a homo- or heterodimer, possibly with ABCG2, as a 
regulator of cholesterol and phospholipid transport in macrophages [67]. In fact, its gene expression 
was described to be induced during cholesterol influx and suppressed by lipid efflux via high density 
lipoproteins (HDLs). Inhibition of ABCG1 expression resulted in reduced HDL-dependent efflux of 
cholesterol and PC. It was proposed that ABCG1 and ABCG4 act in concert with ABCA1 in the 
removal of excess cholesterol from macrophages [68]. In this process, ABCA1 would mediate the 
transport of cholesterol to lipid-poor apolipoprotein A-1 (ApoA-I), whereas ABCG1 and ABCG4 to 
HDL. 
Defects in ABCG5 and ABCG8 are the cause of sitosterolemia, an inherited lipid metabolic disorder 
characterized by hyperabsorption and decreased biliary excretion of dietary sterols [69,70]. These 
two half transporters are localized to the apical membrane of enterocytes and hepatocytes and likely 
function as heterodimers to promote efflux of sterols into the bile [71,72,73]. Since cholesterol was 
argued not to require a transporter to redistribute between the two leaflets of the plasma membrane, 
it was proposed that ABCG5/G8 may function as a “liftase”, pushing the substrate out of the bilayer 
and making it available for extraction [74]. Wang et al. recently purified ABCG5/G8 from mouse 
liver and reconstituted sterol transfer in membrane vesicles [75]. 
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To date, many ABC transporters that are supposed to have a role in lipid transport belong to the 
ABCA subfamily. An overview of the members of this subgroup and of the related genetic disorders 
can be found to follow. 
 
1.2.4 The ABCA subfamily  
In 1994, the group of G. Chimini reported the identification of two novel mammalian ABC 
transporters by a PCR-based approach, named ABC1 (later ABCA1) and ABC2 (ABCA2) [76]. Both 
proteins were found to possess novel features compared to the other members of ABC transporters 
known, namely the presence of a large regulatory domain interrupted by an extra hydrophobic 
segment. Therefore the novel ABCA subclass was defined. In the following years, a large group of 
transporters sharing similar features were identified [77,78,79]. 
The ABCA subfamily consists of 17 full size proteins. They all have a broad tissue distribution, with 
the exceptions of ABCA3, predominantly expressed in the lung, ABCA4, which is selectively 
expressed in the retina, ABCA12, mostly found in the skin epidermis and ABCA17, in testis [80].  
ABCA1 is the defective gene in Tangier Disease (TD), an inherited HDL deficiency characterized by 
very low levels of HDLs in the plasma, peripheral accumulation of cholesterol and increased 
incidence of atherosclerosis. This protein will be extensively described in section 1.3. 
ABCA2 is predominantly expressed in the brain and in neural tissues [81]. This protein was shown to 
be associated with lysosomes, where it may play an important role in neuronal lipid transport 
[82,83]. Recent works have also indicated a relationship between ABCA2 and Alzheimer’s disease 
[84]. 
ABCA3 was described to be predominantly expressed in alveolar type II cells in the lung [85]. 
Staining of the lung tissue with ABCA3-specific antibodies suggested that this protein is specifically 
concentrated in the membrane of lamellar bodies. These are lysosome-like structures that store 
pulmonary surfactant, a mixture of phospholipids and proteins which reduce the surface tension at 
the air-liquid interface. ABCA3 is hypothesized to have a role in the excretion of the lipid fraction of 
the pulmonary surfactant and is associated with a neonatal respiratory failure [86]. The transport 
process appears to depend on the lipidation of an amphipatic, helical acceptor protein, surfactant 
protein B [87]. 
Defective ABCA4, also known as ABCR or Rim protein, is responsible for Stargardt’s disease, a 
form of macular degeneration [79]. Mutations in the ABCA4 gene have also been attributed to some 
cases of cone-rod dystrophy, retinitis pigmentosa, and age-related macular degeneration. ABCA4 is 
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localized in the photoreceptor outer segment disc membranes of the retina, where it is thought to 
have a role in the visual cycle mediating the recycling of all-trans-retinal to 11-cis-retinal. Studies on 
the ATPase activity of the reconstituted ABCA4 suggested, as a substrate, all-trans-N-retinylidene-
PE, the lipid product generated from the photobleaching of rhodopsin [88]. 
ABCA5 is expressed in brain, lung, heart, and thyroid gland. Subcellular localization analysis 
showed the accumulation of the protein in lysosomes and late endosomes [89]. At present, the 
function of ABCA5 is poorly understood. 
ABCA6, 8, 9 and 10 transporters have a striking sequence similarity and are therefore referred to as 
“ABCA6-like transporters”. They are thought to represent a subgroup more recently emerged in the 
evolution of the ABCA family [90]. A potential role for these proteins in macrophage lipid 
homeostasis was suggested [90,91,92]. 
ABCA7 has been reported to mediate efflux of cellular phospholipids in response to stimulation by 
apolipoprotein A-I (ApoA-I), similarly to ABCA1. However, both its involvement in cholesterol 
efflux and its physiological function are still controversial [93]. A more detailed description of 
ABCA7, with highlighted similarities and differences to ABCA1, is presented in 1.2.4.2. 
ABCA11 is a pseudogene. 
ABCA12 has been linked to two congenital keratinization disorders: lamellar ichthyosis and the more 
severe harlequin ichthyosis. The latter is characterized by a profound thickening of the keratin layer 
in the fetal skin. Recent studies in abca12 knock out mice revealed a reduction in skin linoleic esters 
of long chain omega-hydroxy-ceramides and a corresponding increase in their glucosyl ceramide 
precursors. As omega-hydroxy-ceramides are required for the barrier function of the skin, these 
results establish that ABCA12 activity is needed for the generation of long chain ceramide esters, 
which are essential for the development of a normal skin structure and function [94]. 
ABCA13 is the largest ABC transporter described to date. The ABCA13 gene maps to chromosome 
7p12.3. This region is genetically linked to Schwachman-Diamond syndrome, a genetic disorder that 
affects the pancreas, and to a locus involved in T-cell tumor invasion and cancer metastasis [95]. At 
present, the exact function and substrates of this protein are unknown. 
Recently, four new members, ABCA14-17, were added to the ABCA subfamily, but they have only 
been cloned from mouse and rat. All these proteins are predominantly expressed in testis, which 
suggests that their function may be related to testicular development and/or spermatogenesis [84]. 
Indeed, ABCA17 was found to be localized, by in situ hybridization, in germ cells in the 
seminiferous tubulus. When the protein was transfected in HEK293 cells, it localized to the 
endoplasmic reticulum (ER). Metabolic labelling analysis revealed a reduction, in this cell line, in 
   INTRODUCTION   14 
the amount of esterified lipids, suggesting that ABCA17 may function in the regulation of the lipid 
composition in the sperm [96]. The human ortolog of the murine abca17 was recently identified, 
although it was suggested to be a transcribed pseudogene [97]. 
 
In conclusion, during the past years evidence has been accumulating suggesting that ABCA 
transporters are needed in critical functions in human physiology, which, when defective, lead to 
several pathological conditions. These proteins appear to mediate the translocation of lipid 
compounds across different biological membranes. Potential substrates of ABCA transporters 
include phospholipids (ABCA1, ABCA3, ABCA4, ABCA7), cholesterol (ABCA1) and 
sphingolipids (ABCA12). However, many members still lack the identification of their potential 
substrates. The molecular details of the process of substrate translocation await, as well, further 
clarification. 
1.2.4.1 ABCA1: the key controller of cholesterol efflux 
ABCA1 is the prototype of the A subfamily of ABC proteins and probably one of the most studied 
ABC transporters. Since its discovery as the mutated gene in TD, a HDL deficiency syndrome, it has 
undergone through intensive investigation. A detailed description of the protein structure, of its 
regulation and of the proposed models for its function is presented in section 1.3.   
1.2.4.2 ABCA7: a molecule with unknown function 
ABCA7 is the member of the A subfamily with the highest homology to ABCA1 (54% based on 
amino acid identity). It is highly expressed in the thymus and in other immune and hematopoietic 
tissues [98]. In addition, strong expression in the brain has also been reported [99,100]. This 
expression pattern is substantially different from that one of ABCA1, which is, conversely, 
ubiquitously expressed, with a preferential localization in the liver [101].  
Given the central role of ABCA1 in the formation of HDL particles, it was assumed that ABCA7 
may also function in lipid or cholesterol metabolism. Indeed, transfection of ABCA7 in several 
mammalian cell lines mediates efflux of phospholipids (and cholesterol) to apolipoproteins such as 
ApoA-I (reviewed in [93]), which is the initial step in the production of HDLs. However, deficiency 
of ABCA7 in mice does not cause evident phenotypic alterations [100], whereas the loss of ABCA1 
in mice or humans leads to a dramatic decrease in circulating HDL levels. Genetic knockdown of 
abca7 in mouse peritoneal macrophages did not affect phospholipid or cholesterol efflux to ApoA-I. 
Moreover, in macrophages isolated from abca1 knockout mice, ApoA-I-stimulated phospholipid 
efflux was not detected [102]. These results are inconsistent with a residual role of ABCA7 in lipid 
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efflux in vivo, and its physiological function remains essentially unknown. Efflux of cholesterol is 
still controversial. Whereas some groups reported no cholesterol efflux to ApoA-I [102,103], others 
showed low but positive cholesterol release [99,104,105]. A second isoform of ABCA7, so called 
Type II, has been described [99]. This isoform was shown to mediate neither cholesterol nor 
phospholipid release and appeared to be mainly localized in the ER when transfected in HEK293 
cells, in contrast to the plasma membrane localization of the Type I protein. 
Given the high levels of ABCA7 expression in platelets [106], a possible role for this protein in the 
secretion of various lipid mediators was also suggested. Moreover, the observation that ABCA7 is 
upregulated during the differentiation of keratinocytes [107] may indicate its potential role in 
epidermal lipid reorganization.  
Very recently, ABCA7 was shown to stimulate efflux of cellular cholesterol to ApoE discs and to 
regulate the processing of the amyloid precursor protein in vitro, inhibiting the production of β-
amyloid peptides [108]. Therefore, a role for this transporter in the brain lipid metabolism was 
proposed.
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1.3 ABCA1 
1.3.1 General features 
1.3.1.1 Once upon a time… 
In 1960s, in a small isle some kilometers west of the eastern shore of Virginia, Tangier Island, the 
case of a child with unusually large tonsils of grey-yellowish colour was reported. Histopathological 
examination revealed the presence of many foam cells accumulating cholesteryl esters along the 
surface of the tonsils and the patient showed almost completely absence of HDLs in the plasma. This 
disease was named Tangier disease (TD). 
At that time, little was known about lipoprotein physiology and its link to atherosclerosis. However, 
already in the 70s, the discovery of a receptor for low density lipoproteins (LDLs) and the finding of 
its deficiency in familial hypercholesterolemia pointed out the crucial role of LDL particles in 
atherosclerosis [109]. Some years later, plasma HDL cholesterol level was inversely related to the 
risk of coronary heart disease (CHD) [110]. This observation confirmed the hypothesis previously 
drawn that HDLs act as shuttles in a process termed reverse cholesterol transport (RCT), in which 
excess cholesterol is removed from peripheral tissues, such as the arterial wall, and transported to the 
liver for excretion [111]. Early on, HDL binding sites were also described in fibroblasts. 
Interestingly, the density of the HDL binding sites was found to be reciprocally related to the cellular 
levels of cholesterol [112,113]. This gave rise to the hypothesis that TD was caused by a defect, or 
deficiency, in one HDL receptor. In the following years more than 40 HDL binding proteins were 
described, but none of them was proved to be missing or not functional in TD [114,115,116]. 
It was finally in the mid 1990s that 4 groups independently reported that Tangier cells were impaired 
in the efflux of cholesterol and phospholipids not to HDL particles, but to lipid-free or lipid-poor 
ApoA-I [117,118,119,120]. Other 5 years had to pass until the genetic defect in TD could be 
identified to chromosome 9q31 and to the ATP binding cassette transporter A1 [121,122,123]. 
Nowadays, ABCA1 is known to be responsible for the efflux of cellular phospholipids and 
cholesterol to ApoA-I, which is the first and rate-limiting step in the formation of HDL particles and 
in the process of reverse cholesterol transport. Mutations in ABCA1 gene lead to two HDL-
deficiency syndromes: familial hypoalphalipoproteinemia, in its heterozygous form, and TD, in its 
homozygous or compound heterozygous form. Impairment of ABCA1 is associated with a large 
spectrum of signs, including large, orange tonsils, peripheral neuropathy, enlarged spleen and liver, 
development of atherosclerosis and early and increased onset of cardiovascular disease [124]. 
However, despite intense investigations, the exact molecular mechanism by which ABCA1 drives 
this process has not yet been fully clarified. 
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1.3.1.2 Topological model 
ABCA1, as all the members of the A subfamily of ABC transporters, is a full-size protein. It has a 
symmetrical structure, with two transmembrane domains (TMDs) consisting of 6 helices and two 
nucleotide binding folds (NBFs). The NBFs possess the conserved sequences present in many 
proteins that utilize ATP, the Walker A and the Walker B motifs, and the Signature C motif, a 
sequence unique of ABC transporters (Fig. 6). The NH2 terminus of ABCA1 is predicted to be at the 
cytosolic side of the membrane. All members of the ABCA subfamily present two large extracellular 
loops, located between the transmembrane segments 1 and 2 and between 7 and 8. These loops are 
highly glycosylated and can be linked by one or more cysteine bonds [125,126]. 
 
Fig. 6: Topological model of ABCA1. Full-length ABC transporters of the A subfamily are composed of two 
hydrophobic transmembrane domains (TMDs), each containing six α-helices, and two nucleotide binding folds 
(NBFs). The NBFs contain conserved motifs, namely the Walker A, Walker B and Signature C, characteristic 
of all ABC transporters. This topological model is based on studies on ABCA1 and its close homologue 
ABCA4 [101,125,127] (Y indicates the approximate glycosylation sites, S-S indicates one predicted disulfide 
bond). 
 
A missense mutation in one of the conserved cysteine residues in the second extracellular loops 
(C1478R) was shown to cause TD. This highlights the importance of the formation of disulfide 
bonds, which play a crucial role in protein folding and stability [123]. Furthermore, the quaternary 
structure of ABCA1 is also important for its function, as transition from dimers into highly 
oligomeric forms has been observed during the ATP catalytic cycle [128]. 
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1.3.1.3 Regulation of ABCA1 
ABCA1 expression is highly controlled at both transcriptional and posttranscriptional level. A 
fundamental role in the regulation of the ABCA1 gene is played by nuclear orphan receptors [129]. 
They are a large group of ligand-dependent transcription factors characterized by an amino-terminal 
domain responsible for DNA binding and transcriptional activation, and by a carboxy-terminal 
ligand-binding domain. Among them, the major regulator of lipid homeostasis is the liver X receptor 
(LXR) [130]. LXR, that functions as a heterodimer with the retinoid X receptor (RXR), is activated 
by a wide range of hydroxylated cholesterol metabolites and intermediates including oxysterols 
[131,132]. This likely provides the cells with a “read-out” of the unesterified cholesterol content, as 
LXR can trigger the activation of various mechanisms that protect the cells from cholesterol 
overload, including the transcription of many ABC transporters such as ABCA1 and ABCG1 [131]. 
Conversely, RXR binds and is activated by retinoic acid. RXR receptors typically do not function 
alone, but rather serve as regulators of several metabolic pathways [133].  
Peroxisome proliferator-activated receptors (PPARs) also participate in the up-regulation of ABCA1 
expression [134,135]. Conversely, down-regulation of ABCA1 transcription is achieved by the 
activation of pregnane X receptors (PXRs), or through thyroid hormone receptor (TR)/RXR dimers 
[135] and geranylgeranyl phyrophosphate (ggPP) [136]. 
In mouse, but not in human, macrophages, expression of ABCA1 is induced by cAMP analogues 
[137]. The cAMP responsive element was recently identified in intron 2 of the murine abca1, 
whereas the human ABCA1 gene is not responsive due to a disruption in this element caused by an 8-
basepair insertion [138]. 
Besides being controlled by orphan receptors and by intracellular cAMP levels, PKC-dependent 
phosphorylation, hormone-sensitive lipase activity and certain fatty acids can also modulate ABCA1 
expression [139]. In addition, pro-inflammatory cytokines, tumor necrosis factor α, interleukin-1β 
and interferon-γ were shown to down-regulate the LXR-mediated enhancement of ABCA1 
expression [140], whereas transforming growth factor β induces ABCA1 expression [141]. 
In addition to ABCA1 mRNA abundance, the protein levels are also strictly regulated. ABCA1 is 
rapidly degraded by calpain-mediated proteolysis, with an estimated t1/2 of about 1 h. This 
proteolytic degradation is promoted by the presence, in one of the cytoplasmic loops of ABCA1, of a 
sequence that resembles a PEST motif, which targets proteins for degradation [142]. The binding of 
ApoA-I to the protein is necessary to slow ABCA1 rapid degradation. Conversely, unsaturated fatty 
acids were shown to reduce the macrophage ABCA1 content by enhancing its degradation rate 
[143]. Direct interaction of ABCA1 with the β 1-syntrophin through the protein-protein interaction 
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PDZ binding motif also stimulated ABCA1 activity and reduced its degradation rate [144]. Recently, 
one subunit of the serine palmitoyltransferase enzyme, SPTLC1, was co-purified with ABCA1 and 
found to negatively regulate its function [145].  
1.3.1.4 Tissue and intracellular distribution of ABCA1 
ABCA1 is expressed in several tissues in humans, such as the liver, intestine, trachea, lung, adrenal 
gland, spleen, heart and uterus of pregnant women [129,146]. In some of these tissues, the 
expression is steroid-dependent [147]. Moreover, ABCA1 can be found in cells of the myeloid 
lineage, such as activated monocytes, macrophages and foam cells of atherosclerotic lesions, 
whereas in mice it has been detected in both peritoneal and bone marrow-derived macrophages. 
ABCA1 expressed in the liver and in the intestine is responsible for the formation of essentially all 
circulating HDL particles, whereas the impairment of ABCA1 function leads to accumulation of 
cholesterol mainly in macrophages [148].  
When expressed in several cell lines, ABCA1 is mainly localized at the plasma membrane and in 
intracellular compartments corresponding to the Golgi apparatus, early and late endosomes and 
lysosomes [149,150]. In polarized hepatocytes, ABCA1 was shown to be localized at the basolateral 
membrane [151], where it contributes to the maintaining of circulating HDL levels. 
The localization of the protein at the cell surface is in agreement with its hypothesized function in 
lipid transport. However, intracellular ABCA1 could also be involved in the efflux of lipids. Indeed, 
the existence of a complex intracellular trafficking pathway was described, in which ABCA1-
containing lipid vesicles rapidly traffic between intracellular sites and the plasma membrane 
[152,153]. This trafficking pathway may play, as well, important roles in modulating ABCA1 
transport activity and formation of HDL particles [154]. 
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1.3.2 Physiological function of ABCA1 
Since its discovery, several functions have been attributed to ABCA1. When it was first identified, it 
was reported to have a role in macrophage engulfment of apoptotic cells through exposure of PS on 
the outer leaflet of the plasma membrane [155]. Later on, its identification as the mutated gene in TD 
has highlighted its role in cholesterol efflux. 
Cholesterol, besides being one of the essential components of the plasma membrane, is also a 
precursor for the synthesis of bile acids and all steroid hormones. Cholesterol can be introduced with 
the diet and synthesized de novo from almost all animal cells. However, it cannot be completely 
catabolized, and therefore, it has to be transported into the bile for its elimination. In humans, 
approximately two thirds of cholesterol is transported by LDLs, about 20% by HDLs and the rest by 
VLDLs. LDLs contribute to the loading of cells with cholesterol through receptor-mediated 
endocytosis. Conversely, HDLs function as cholesterol acceptors and promote its efflux out from the 
cells. 
In the intestine, cholesterol (C) absorption across the enterocytes is performed on the apical surface 
by the Niemann-Pick C1-like1 protein (NPC1L1) (Fig. 7). On the same membrane, the heterodimers 
ABCG5/G8 mediate the transport of cholesterol in the opposite direction (see also section 1.2.3). 
ABCA1 is localized at the basolateral membrane, where it mediates the efflux of cholesterol and 
phospholipids to ApoA-I to form nascent HDLs (Fig. 7, 1). Similarly, in the liver hepatocytes, 
ABCA1 functions at the basolateral surface (2) to form nascent HDL particles. In addition, 
hepatocytes secrete cholesterol esters (CE), formed by the reaction of acyl-CoA cholesteryl acyl 
transferase (ACAT), to produce nascent VLDL particles. Also in this case, at the apical membrane, 
the dimer ABCG5/G8 transports cholesterol into the bile canaliculi. Finally, ABCA1 prevents the 
overloading of macrophages with cholesterol, delivered from modified LDLs through scavenger 
receptors, by transporting it out of the cell (3). 
A more detailed description of these steps, as well as the experimental evidence that allowed 
drawing the described model is presented in the chapters to follow.  
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Fig. 7: Cholesterol and phospholipid transport by ABCA1 in the intestine, liver and macrophages.  A 
detailed description of the figure is presented in the text and in the following sections. C: cholesterol, CE: 
cholesteryl esters, TG: triglycerides, PL: phospholipids, NPC1L1: Niemann-Pick C1-like1 protein 1, ACAT: 
acyl-CoA cholesteryl acyl transferase, HDL: high density lipoprotein, LDL: low density lipoprotein, VLDL: 
very low density lipoprotein. This figure is adapted from [148]. 
 
1.3.2.1 Liver ABCA1: lipid efflux and HDL formation 
HDLs are one of the 5 major groups of lipoproteins (chylomicrons, VLDL, IDL, LDL, HDL) which 
enable cholesterol and triglycerides to be transported within the blood stream. They consist of about 
50% apoproteins, where ApoA-I and ApoA-II are the most abundant, 20% of free and esterified 
cholesterol, 15% of phospholipids and 5% of triglycerides. One of the major functions of HDLs 
consists in the transport of cholesterol from peripheral tissues to the liver for elimination into the 
bile, process called reverse cholesterol transport [101]. The starting step in the process of formation 
of HDL particles is the efflux of cholesterol and phospholipids to lipid-free or lipid-poor ApoA-I, 
which is controlled by ABCA1. Therefore, ABCA1 is a major determinant of circulating plasma 
HDL levels. Fundamental knowledge about the physiological function of this protein has been 
gained from the observation of the clinical phenotypes of patients affected by TD or familial 
hypoalphalipoproteinemia. These patients display almost null or reduced level of plasma HDLs, 
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respectively, and high risk of developing atherosclerosis. In the clinical phenotypes wide 
heterogeneity is observed [156]. This has been proposed to be a consequence of different mutations 
in ABCA1, that give rise to the large spectrum of effects observed. To date, 73 ABCA1 mutations 
have been identified [157], the majority of which are in the extracellular and intracellular loops of 
the protein. In addition, numerous single nucleotide polymorphisms in ABCA1, that are associated 
with mild changes in HDL levels, have been described [156]. 
The generation of animal models with inactivated ABCA1 has largely contributed to the 
accumulating evidence of the involvement of this protein in HDL and lipoprotein metabolism. Abca1 
knock out mice have phenotypes similar to those with TD [149], although few different features, 
such as differences in the distribution of accumulated lipids and difficulties in breeding [158], are 
present. Investigations of abca1 transgenic mice demonstrated that overexpression of ABCA1 in the 
liver increases the levels of HDLs [159,160]. 
A natural animal model of TD exists, the Wisconsin hypoalpha mutant (WHAM) chicken. This 
animal shows impaired transport of cholesterol introduced with the diet from the intestine to the 
blood stream [161], highlighting the importance of the ABCA1 pool localized in the intestine. 
Moreover, the chicken displays normal ApoA-I secretion, but fast clearance, similarly as in abca1 
knock out mice or in TD patients [162]. 
1.3.2.2 Macrophage ABCA1 and atherosclerosis 
Atherosclerotic cardiovascular disease is the primary cause of death in the Western countries. 
Atherosclerosis is a progressive inflammatory disease characterized by the accumulation of lipids 
and fibrous elements in the arteries [140]. This leads to the formation of plaques that can cause a 
narrowing of the lumen of arteries, eventually leading to their complete blockage. Macrophages have 
a central role in atherogenesis, the process of plaque formation. Deposition of excessive amounts of 
cholesterol in macrophages leads to their transformation into foam cells, a hallmark of 
atherosclerosis. Since macrophages cannot limit their uptake of cholesterol via scavenger receptors 
[163], cholesterol efflux is the central mechanism to prevent development of atherosclerotic lesions. 
An inverse relationship between HDL levels and the risk of atherosclerosis has been established 
[164]. ABCA1 expressed in macrophages prevents them from becoming overloaded with cholesterol 
by transporting it out of the cells. The role of ABCA1 in atherosclerosis was established by studying 
mice specifically deficient in macrophage ABCA1 [165]. In these animals, an increase in 
atherosclerotic lesions was observed, in spite of normal HDL levels. Along the same line, 
overexpression of macrophage ABCA1 was shown to protect against atherosclerosis, with minimal 
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effect on plasma lipoproteins [166]. This suggests that the macrophage ABCA1 plays its 
atheroprotective function independently from its role in maintaining plasma HDL levels. 
1.3.2.3 ABCA1 and engulfment of apoptotic cells 
Engulfment is a specialized form of phagocytosis dedicated to the clearance of cell corpses 
generated by the apoptotic program. This process is mainly performed by locally recruited 
macrophages. One of the signals used from apoptotic cells to be “eaten” is the exposure of PS, 
normally confined in the inner leaflet, to the outer leaflet of the plasma membrane, alone or bound to 
bridging molecules [167]. 
A role of ABCA1 in engulfment is suggested by several studies. The ability of peritoneal 
macrophages to engulf apoptotic thymocytes was impaired by blocking ABCA1 function with 
antibodies interfering with the NBF [155]. A close structural relative of ABCA1 was identified as the 
product of ced-7, one of the engulfment genes in the nematode C. elegans [168]. In addition, using 
in vivo loss-of-function and in vitro gain-of-function models, it was shown that ABCA1 promotes 
Ca2+-induced exposure of PS at the plasma membrane, as determined by a prothrombinase assay, 
membrane microvesiculation and measurement of transbilayer redistribution of spin-labelled 
phospholipids. Consistently with a role of ABCA1 in engulfment, knock out mice showed defective 
engulfment during development and in adult life [149]. 
The lipid transport activity of ABCA1 may also be involved in other cellular processes, such as 
endocytosis. Indeed, an enhanced endocytotic activity in Tangier disease cells, associated with an 
impairment of PS exposure, was assessed [169]. Moreover, both receptor-mediated and fluid-phase 
endocytosis were shown to be reduced in cells expressing ABCA1 [170]. 
 
 
 
 
   INTRODUCTION   24 
1.3.3 Mechanism of ABCA1-mediated lipid efflux 
1.3.3.1 Lipid efflux to ApoA-I 
ABCA1 promotes the cellular efflux of phospholipids (mainly PC and SM) and cholesterol to ApoA-
I. Although this was already recognized 10 years ago, to date, the exact molecular mechanism 
involved in the ABCA1-dependent mobilization of lipids has not yet been established. 
There is considerable disagreement as to whether ABCA1 promotes the direct efflux of both PL and 
cholesterol to ApoA-I, or whether ABCA1 is primarily a phospholipid transporter and stimulates 
cholesterol efflux only after generating a lipidated ApoA-I, which would, then, function as an 
acceptor for cholesterol. Smith et al. reported concomitant phospholipid and cholesterol efflux in 
macrophages after induction of ABCA1 expression by cAMP [171]. Other studies have provided 
evidence that apolipoproteins simultaneously remove PL and cholesterol from cells by 
microsolubilizing the plasma membrane [172,173].  
On the other hand, based on a large body of experimental evidence, it was also suggested that efflux 
of phospholipids and cholesterol are uncoupled events. For instance, Fielding et al. reported 
dissociation between PL and cholesterol efflux to ApoA-I in the presence of the ABC transporter 
inhibitors vanadate and okadaic acid [174]. Recently, an inhibitor of PKA (protein kinase A) was 
shown to block cholesterol but not PL efflux [175]. Cholesterol depletion from membranes by 
cyclodextrin abolished ABCA1-mediated cholesterol efflux but did not affect efflux of PL [176]. In 
addition, in the same study, no binding of a photoactivable cholesterol analogue to ABCA1 was 
detected. An increased ability of ApoA-I to promote cholesterol efflux, after being transferred from 
ABCA1-transfected HEK293 cells to ABCA1-deficient cells, was reported [174,176], but it could 
not be confirmed by another study in BHK cells [177]. These results suggest that ABCA1 may 
promote the efflux of only phospholipids and that cholesterol efflux occurs indirectly. Indeed, 
ABCA1 was shown to induce exposure of PS on the outer leaflet of the plasma membrane 
[170,178]. This event was proposed to alter the general properties of the membrane and to be at the 
basis of the impact of ABCA1 on the lipid physiology of the cell [149]. 
Interestingly, it was recently described that the phospholipid translocation activity of ABCA1 
induces bending of the membrane bilayer to create highly curved sites to which ApoA-I can bind 
[179]. These highly curved sites may represent unstable regions at the membrane, prone to 
microsolubilization by ApoA-I. The authors speculated that the binding of ApoA-I may be enhanced 
by the presence of PS molecules translocated to the exofacial leaflet by ABCA1. It was indeed 
reported that PS enhances vesicle curvature [180] and binding of ApoA-I to synthetic vesicles [179]. 
ApoA-I binding to protruding structures in the plasma membrane was previously shown by Lin and 
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Oram [173]. In the same study, it was also shown that these structures were absent in fibroblasts 
isolated from a subject with TD. 
1.3.3.2 ABCA1/ApoA-I interaction 
The interaction between ABCA1 and ApoA-I is of fundamental importance in the process of cellular 
lipid efflux. However, the nature of this molecular interaction is not fully understood.  
Chemical cross-linking studies suggest that a direct binding between these two molecules occurs 
[127,137]. If this is the case, this interaction should be of low specificity, as ABCA1 can facilitate 
cholesterol transfer also to many amphipathic proteins [181]. Fitzgerald et al. have demonstrated that 
the extracellular loops between the transmembrane segments 1 and 2 and between 7 and 8 of 
ABCA1 can be the ones responsible for the binding to ApoA-I. However, there is no clear 
correlation between this binding and the efflux of lipids. In fact, a mutant ABCA1 protein (T590S) 
that binds to ApoA-I, but that does not promote lipid efflux, was described [182,183]. This implies 
that the binding of ApoA-I to ABCA1 may be necessary but is not sufficient to promote cholesterol 
efflux. Moreover, a simple receptor-ligand interaction would not explain why the ATPase activity of 
ABCA1 is required for the binding [178]. Corroborating this hypothesis, the diffusion parameters of 
membrane-associated ApoA-I indicate an interaction with membrane lipids rather than proteins 
[178].  
A second model proposes that the lipid translocase activity of ABCA1 can modify the lipid 
distribution at the plasma membrane, creating a site required for the docking of ApoA-I [178]. 
Indeed, the identification of a “high-capacity binding site” at the plasma membrane was recently 
reported [184]. Interestingly, another group demonstrated that ABCA1 activity creates two types of 
binding sites for ApoA-I at the cell surface [185]. A first, low-capacity site involves direct ApoA-
I/ABCA1 interaction and has regulatory functions stabilizing the transporter. Conversely, a second, 
high-capacity site at the membrane, created by the activity of ABCA1, involves the binding of a 
larger pool of ApoA-I that functions in the assembly of nascent HDL particles. 
1.3.3.3 ABCA1 and membrane domains 
In addition to its role in the lipidation of ApoA-I, ABCA1 was recently reported to influence 
cholesterol packing at the plasma membrane. Oram and colleagues first documented that ABCA1-
expressing cells are more susceptible to cholesterol oxidase [177], an enzyme that preferentially 
modifies cholesterol in disordered membrane domains [186]. They proposed that ABCA1 
redistributes cholesterol to cell surface domains readily accessible to apolipoproteins. In another 
study, ABCA1 expression in BHK cells was shown to alter the micro-organization of the plasma 
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membrane, whereas this alteration was not observed upon expression of a non-functional mutant 
transporter [187]. Based on detergent- and non detergent-based fractionation methods, the authors 
concluded that ABCA1 activity expands the non-raft membrane fraction. 
Furthermore, macrophages isolated from abca1 knock out mice were shown to exhibit increased 
lipid rafts [188], as visualized by labelling the cells with two probes, the θ-toxin derivative BCθ, 
which selectively binds to membrane cholesterol in lipid rafts [189], and the fluorescent 
polyethylene glycol cholesteryl ether fPEG-chol, which can bind to cholesterol-rich membranes 
[190]. 
Very recently, it was reported that, in the absence of ApoA-I, ABCA1 expression leads to the release 
of cholesterol/phospholipid rich non HDL microparticles, which was prevented by rigidifying the 
plasma membrane with wheat germ agglutinin [191]. The authors speculated that this process can 
derive from the ABCA1-induced bending of the membrane. 
 
In conclusion, the intense study performed on ABCA1 in the last nine years has provided a huge 
amount of data. A final model for its function has to take in consideration several evidence: i) 
ABCA1 is required for the efflux of lipids and cholesterol to ApoA-I; ii) ApoA-I is able to bind, at 
least in a small pool, to ABCA1, even though this binding is not sufficient to trigger lipid efflux; iii) 
ABCA1 expressing cells show highly curved membrane protrusions to which ApoA-I preferentially 
binds and iv) enhanced exposure of PS on the outer leaflet of the plasma membrane; v) ABCA1 
influences the micro-organization of the plasma membrane through its ATPase activity. 
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2 Aim of the study 
ABCA1 is a member of the ABC transporter superfamily with extremely high physiological 
importance, as mutations in its gene are associated with HDL deficiency and premature development 
of atherosclerosis. Atherosclerosis is the primary cause of heart disease and, in the Western 
countries, is the underlying cause of about 50% of all deaths [140]. Thus, it is critical to understand 
the exact molecular mechanism of ABCA1 function. Despite the intensive study over the last nine 
years, there is still no clear picture of how and where ABCA1 mediates the transfer of cholesterol 
and phospholipids to ApoA-I. Strong evidence indicates that this transfer of lipids occurs at the 
plasma membrane. In particular, an increasing body of work has emerged proposing that ABCA1 
can form lipid domains at the cell surface even in the absence of ApoA-I, even though controversy is 
still present concerning the nature of such domains. To date, no study assessing the lipid 
microenvironment of ABCA1 in living cells was performed, also because of the lack of tools 
suitable to study a complex time- and space-fluctuating system such as the plasma membrane. 
The aim of this study was i) to develop a new fluorescence lifetime-based approach that allows 
investigating the domain structure in the plasma membrane of living cells and ii) to apply this 
technique for studying the influence of ABCA1 on the lipid microenvironment at the plasma 
membrane. The strategy chosen was to characterize this technique in systems with increasing 
complexity as a basis for the interpretation of the study in the cell plasma membrane. GUVs would 
constitute a well controlled and characterized system that allows the direct visualization of lipid 
domains by fluorescence microscopy, whereas GPMVs would highlight the influence of a highly 
heterogeneous protein and lipid composition.  
The characterization of the fluorescence lifetime in the plasma membrane of cells would allow 
evaluating the influence of ABCA1 on its physicochemical properties, integrating the previously 
proposed models for ABCA1 function. In parallel, the use of well established biochemical 
approaches would permit the comparison, corroboration and integration of the results. Not less 
important, this would underline the suitability of new biophysical approaches to study the influence 
of membrane proteins on the lateral and transbilayer arrangement of lipids. 
 
  MATERIAL AND METHODS   28 
3 Material and methods 
3.1 Material 
3.1.1 Chemicals and reagents 
Chemicals, reagents and devices were purchased as indicated. All solvents (chloroform, methanol 
and acetonitrile) were obtained in highest commercially available purity from Fluka GmbH 
(Schnelldorf, Germany) and used as supplied. Indium tin oxide (ITO) coated glass slides were from 
Präzisions Glas & Optik (Iserlohn, Germany). High performance TLC plates were from Merck 
(Darmstadt, Germany). Common buffers and reagents used for SDS-PAGE and Western blotting 
analysis are indicated in Table 1.  
Table 1: Common buffers used for SDS-PAGE and Western Blotting analysis. 
SDS-PAGE 
Gel composition Resolving Stacking 
 6% 10% 3% 
dH2O 5.3 ml 4 ml 2.3 ml 
30% acrylamide/bisacrylamide (Rotiforese, Carl 
Roth, Karlsruhe, Germany) 2 ml 3.3 ml 300 μl 
0.5 M Tris/HCl, pH 6.8   750 μl 
1.5 M Tris/HCl, pH 8.8 2.5 ml 2.5 ml  
10% SDS (w/v) 100 μl 100 μl 30 μl 
10% APS 100 μl 100 μl 30 μl 
TEMED 8 μl 4 μl 3 μl 
Sample buffer(2x) 
10% SDS 2 ml 
8 M Urea 4.8 g 
0.5 M Tris/HCl, pH 6.8 2.5 ml 
β-mercaptoethanol 560 μl 
1% glycerol 100 μl 
0.01% bromophenol blue 1 μl 
dH2O until 10 ml 
Western Blotting 
Antibody dilution buffer 1% milk, 0.1% Tween-20 in DPBS 
Washing buffer DPBS, 0.1% Tween-20 
Blocking buffer 5% milk, 0.1% Tween-20 in DPBS 
 
Lipids and lipid analogues used were purchased from Avanti Polar Lipids (Alabaster AL, USA) and 
used without further purification. They are indicated in Table 2. 
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Table 2: Lipids and lipid analogues used. All are purchased from Avanti Polar Lipids (see reference 
numbers). 
Lipid 
(analogue) Description Ref. 
DOPC 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine 850375 
SM (brain) (2S,3R,4E)-2-acylaminooctadec-4-ene-3-hydroxy-1-Phosphocholine 860062 
Cholesterol  700000 
C6-NBD-PC 1-Palmitoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-sn-Glycero-3-Phosphocholine 810130 
C6-NBD-PS 1-Palmitoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino] hexanoyl] -sn-Glycero-3-Phospho-L-Serine (Ammonium Salt) 810192 
C6-NBD-LacCer N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-Lactosyl-b1-1'-Sphingosine 810226P 
C6-NBD-PA 1-Palmitoyl-2-[6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)]-phosphatidic acid (C6-NBD-PA) 810173 
Rho-DOPE 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-(Lissamine Rhodamine B Sulfonyl)  (Ammonium Salt) 810150 
 
Media and buffers used for propagation of E. coli and for culturing of mammalian cells are indicated 
in Table 3. 
Table 3: Common media and buffers used for E. coli propagation and mammalian cell culture. 
Medium/Buffer Description/Origin 
LB medium 
10 g/l BactoTM Tryptone, BD Biosciences, Heidelberg, Germany 
5 g/l BactoTM Yeast extract, BD Biosciences 
5 g/l NaCl 
0.1% 1 M NaOH (v/v) 
LB agar LB medium + 15 g/l agar 
DMEM Dulbecco’s modified Eagle’s medium, PAN Biotech, Aidenbach, Germany 
RPMI 1640 Biochrom, Berlin, Germany 
FCS Foetal calf serum, Invitrogen, Karlsruhe, Germany 
Trypsin-EDTA PAN Biotech 
DPBS Dulbecco’s phosphate buffered saline, PAN Biotech 
 
Antibodies against human or mouse transferrin receptor and Rab5 were a kind gift of P. Pierre, M. 
Pierres and H.T. He (CIML, Marseille, France). OKT3 antibody was a kind gift of C. Freund (FMP, 
Berlin, Germany). Antibodies against ABCA1 and related molecules were provided by D. Trompier 
and M. Pierres (CIML, Marseille, France). Primary and secondary antibodies used are indicated in 
Table 4. Proteins were transferred to nitrocellulose membranes (Amersham, Freiburg, Germany) and 
signals were detected with ECL reagents (Amersham). 
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Table 4: Primary and secondary antibodies used for the detection of the indicated molecules by Western 
blotting and confocal microscopy. 
 
3.1.2 Biological material 
A short description of the E. coli strain used for plasmid propagation as well as of the mammalian 
cell lines used is reported in Table 5. 
Table 5: E. coli strains and mammalian cell lines used (ATCC: American type culture collection). 
Cell line Description Ref. 
E. coli strains 
DH5α F
- endA1 recA1 hsdR17(rk- mk+) supE44 λ- thi-1 gyrA(Na1) relA1 
Φ80 lacZΔM15Δ (lacZY A-argF)  
Mammalian cell lines 
HeLa Tet Off 
Human cervical epithelioid carcinoma-derived cell line that 
expresses the tetracycline-controlled transactivator (tTA). High-
level gene expression system can be generated by transfecting 
these cells with a plasmid that expresses the gene of interest 
under the control of a suitable Tet Response Element.  
Doubling time is approximately 20 h during log phase. Adherent, 
elongated cells with filopodia. 
 
630905 
(Clontech) 
 
 
HepG2 
Human hepatocellular liver carcinoma cell line. Adherent, 
epithelial-like cells growing as monolayers and in small 
aggregates. Doubling time is approximately 50-60 h. 
HB 8065 
(ATCC) 
Jurkat, clone E6-1 Human T cell leukemia. Round cells growing singly or in clumps in suspension. Doubling time is approximately 25-35 h. 
TIB-152 
(ATCC) 
MDCKII Madin-Darby canine kidney cells. Adherent, epithelial-like cells growing as monolayers and aggregates. Doubling time is 30-35 h. 
CCL-34 
(ATCC) 
 
Antibody Description Ref. 
Primary antibodies 
β-COP Rabbit, monoclonal; 1:500 Sigma (Lyon, France) 
Calnexin Mouse, monoclonal; 1:200 Stressgen (Ann Arbor, Michigan, USA) 
Calreticulin Rabbit, monoclonal; 1:2000 Calbiochem (Darmstadt, Germany) 
Caveolin Rabbit, polyclonal; 1:1000 BD Biosciences (Heidelberg, Germany) 
CD-14 Rat, monoclonal; 1:250 Pharmingen (san Diego, CA, USA) 
Flotillin-1 Mouse, monoclonal; 1:200 BD Biosciences (Le Pont de Claix, France) 
Hsp70 Rabbit, polyclonal; 1:100 Abcam (Cambridge, United Kingdom) 
LAMP 2 Mouse, monoclonal; 1:500 Pharmingen (san Diego, CA, USA) 
Secondary antibodies 
HRP-conjugated  Anti-rabbit,-mouse,-rat (goat); 1:10000 
Jackson Immunoresearch (West Grove, PA, 
USA) 
TRITC-labelled Anti-mouse IgG (goat); 1:1000 Sigma (Taufkirchen, Germany) 
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3.2 Methods 
3.2.1 Molecular biology 
Competent bacteria (50 μl) were incubated with 1 ng of plasmidic DNA (whose volume was kept 
less than 10% of the total volume) for 10 min on ice before placing them at 42°C for 90 s. The tube 
was then transferred on ice for 2 min before adding 800 μl of LB medium and subsequently 
incubating for 30 min at 37°C under mixing (1400 rpm). 50 μl of this solution were spread on LB 
agar plates with 100 μg/ml ampicillin and incubated for 16 h at 37°C. One colony was then selected 
and let grow in a flask with LB medium overnight. Plasmids were purified with the Plasmid Maxi 
Kit (Qiagen, Hilden, Germany). Sample concentration and purity was determined by 
spectrophotometric analysis at 260 nm and 280 nm, respectively, with a Nano-Drop 
spectrophotometer (Eppendorf, Hamburg, Germany). Plasmidic DNA was kindly provided by Dr. G. 
Chimini, CIML, Marseille, France. 
 
3.2.2 Cellular biology 
3.2.2.1 Cell culture 
HeLa Tet-Off cells, HepG2 and MDCKII cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% foetal calf serum (FCS), penicillin, streptomycin and sodium 
pyruvate (all from Invitrogen, Karlsruhe, Germany) and maintained at 37°C under 5% CO2. HepG2 
cells were grown in cell culture flasks coated with collagen A (Biochrom, Berlin, Germany). 
Jurkat E6-1 cells were cultured in suspension below a concentration of 2 x 105 cells/ml in RPMI 
1640 medium supplemented with 2 mM L-glutamine (both Biochrom AG, Berlin, Germany), 2 g/l 
sodium pyruvate and 10% FCS and maintained at 37°C under 5% CO2. Jurkat cells were kindly 
provided by C. Freund (FMP, Berlin, Germany).  
Aliquot of cells at early passage were stored in liquid nitrogen at -196°C in DMEM supplemented 
with 20% FCS and 10% DMSO (Sigma, Taufkirchen, Germany). Frozen cells were rapidly thawed 
and cultured for at least 2 days before seeding as needed. Cells were counted with a Fuchs-
Rosenthaler hemocytometer. 
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3.2.2.2 Cell transfection 
Plasmids containing ABCA1, ABCA7 and the respective variants fused with EGFP, EYFP or ECFP 
were generated in pBI vector (Clontech, Mountain View, CA, USA) [149]. All constructs were 
verified by sequencing. For transient transfection, cells at the third passage were thawed and grown 
for 10-16 h before transfection.  
Transient transfection with ABCA1, ABCA1MM and ABCA7, tagged with the indicated fluorescent 
proteins, was performed on a 60-70% confluent monolayer of HeLa Tet-Off cells with 5 µg of 
plasmid DNA in ExGen 500 (Euromedex, Souffelweyersheim, France) according to the 
manufacturers’ instructions. Briefly, 5 x 105 HeLa Tet-Off cells were incubated overnight with the 
transfection mix (5 μg of pBI ABCA1-GFP and 100 ng of pTK-Hyg mixed with 20 μl of ExGen 500 
in 0.15 M NaCl) and then seeded as required. Transfection efficiency was monitored by flow 
cytometry (FACScan, BD Biosciences) before seeding. Typically, transfection efficiency was about 
40%. Cells were utilized for microscopy about 60 h post-transfection.  
Transient transfection with Hemagglutinin-cerulean was performed similarly. In this case, 
microscopy analysis of cells was done about 48 h post-transfection, when the majority of the protein 
localized to the plasma membrane. Hemagglutinin-cerulean plasmid was kindly provided by S. 
Engel (Free University, Berlin, Germany). 
For creation of stable-transfected cells, hygromycin B (20 μg/ml, Sigma, Taufkirchen, Germany) 
selection was started 48 h after transfection. Three-week-old individual cell clones were picked with 
cloning cylinders and subsequently expanded on the basis of GFP-positive cells, visualized by 
fluorescence microscopy. Cells were cultured for few passages in complete medium containing 20 
μg/ml hygromycin B. 
3.2.2.3 Cell treatments 
For treatment of Jurkat cells with antibodies or sphingomyelinase, 0.5 x 106 cells were pelleted (5 
min; 200 g). For activation with OKT3 antibody, the pellet was resuspended in 25 µl RPMI 1640 
and 25 µl OKT3 for 20 min at 37°C. Cells were again pelleted to remove unbound antibodies and 
incubated with 200 µl RPMI 1640 containing 4 µl TRITC-labelled anti-mouse IgG (diluted 1:100) 
for 10 min. For sphingomyelinase treatment, the pellet was resuspended in 200 µl RPMI 1640 
containing 0.1 U/ml sphingomyelinase (from Staphylococcus aureus; Sigma-Aldrich, Taufkirchen, 
Germany) and subsequently incubated for 30 min at 37°C. Labelling of the cells was achieved by 
resuspending the pellet with 200 µl 2.5 µM C6-NBD-PC (in RPMI 1640) and incubated for 10 min 
on ice. To remove the staining solution, the cells were again pelleted and resuspended in 200 µl PBS. 
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Cytochalasin D treatment was performed on HeLa cells (105) grown in glass bottom microwell 
dishes (MatTek, Ashland, MA, USA). Cells were treated with 0.4 μM solution of cytochalasin D in 
complete medium for 10 min at 37°C before labelling with C6-NBD-PC as described in section 
3.2.3.1. 
Ionomycin treatment was performed for 10 min at 37°C in DPBS with Ca2+ and Mg2+ at the 
indicated concentrations or in DPBS without Ca2+ and Mg2+. The calcium-chelating agent EGTA was 
used at a concentration of 1 mM. In each case, control samples were prepared in which cells were 
subjected to the same treatments but in the present of the solvent alone (DMSO, EtOH or medium). 
3.2.2.4 Radiolabelling of cells and cholesterol efflux 
For measurement of cholesterol efflux, 106 cells were seeded on 6-well tissue culture plates and 
grown for one day. Cells were labelled with 1 µCi/ml of [3H]-cholesterol (GE Healthcare, Freiburg, 
Germany) in DMEM containing 1 mg/ml BSA for 24 h. After extensive washing with DPBS or 
DMEM, cells were either incubated on ice with 1 ml of an ice-cold 5 mM MβCD solution in DPBS 
for 1 min or with 10 µg/ml ApoA-I in DMEM supplemented with 0.1% FCS for 16 h. The medium 
was collected and the cells washed with additional 200 µl of DPBS, subsequently pooled together 
with the medium. The medium was centrifuged (1000 g, 7 min, 4°C) to remove cell debris and 
cholesterol crystals. Cells were dissolved in 600 μl of 0.1 M NaOH solution at room temperature for 
30 min. Radioactivity in media and cells was measured by liquid scintillation counting (Lumasafe 
Plus, Lumac Lsc. B.V, Groningen, The Netherlands) with a Canberra-Packard 1600TR liquid 
scintillation analyzer (Dreieich, Germany). Cholesterol efflux rate was calculated as the percentage 
of radioactivity in the medium relative to the total radioactivity in cells and medium. 
3.2.2.5 Cholesterol subcellular distribution 
For determination of subcellular [3H]-cholesterol distribution, ~106 cells were labelled with 0.5 
µCi/ml of [3H]-cholesterol for 24 h in DMEM, 1 mg/ml BSA. After washing with cold buffer A (250 
mM sucrose, 2 mM EDTA, 40 mM Tricine, pH 7.8, Complete Protease Inhibitor Cocktail, Roche, 
Basel, Switzerland), cells were scraped into 3 ml of cold buffer A and spun down by centrifugation 
before being resuspended into 1 ml of buffer A. Cells were homogenized with a dounce 
homogenizer and centrifuged (1000 g, 10 min, 4°C) to remove nuclei. The post nuclear supernatant 
(PNS) was collected and the volume was completed until 2 ml with buffer A. 45–10% continuous 
sucrose gradients were formed in SW41 tubes (Beckman, Krefeld, Germany) and the 2-ml 
postnuclear supernatant fractions were layered on the top of the gradients. Gradients were subjected 
to centrifugation (137000 g, 20 h, 4°C) and 12 fractions of 1 ml each were collected from the top. 
Equal volumes of each fraction were analyzed by SDS-PAGE, blotted onto nitrocellulose 
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membranes (Amersham, Freiburg, Germany) and probed for the indicated proteins. [3H]-cholesterol 
levels in each fraction were analyzed by mixing 300 μl of sample with 2 ml of liquid scintillation 
mixture and radioactivity was detected using a Canberra-Packard 1600TR liquid scintillation 
analyzer. The refraction index of the fractions was measured using a Bausch & Lomb refractometer 
at 20°C. 
 
3.2.3 Microscopy 
3.2.3.1 Labelling of cells with NBD-lipid analogues 
Aliquots of NBD-labelled phospholipid analogues, stored at -20°C in chloroform or 
chloroform/methanol (1/1), were transferred into a glass tube and dried under a nitrogen flow, before 
being resuspended in DPBS at the desired concentration. 105 HeLa cells seeded on 35 mm glass-
bottom microwell dishes (MatTek, Ashland, MA), were washed with cold DPBS and labelled with 
C6-NBD-PC or C6-NBD-LacCer for 20 min on ice. Cells were then extensively washed with DPBS 
at 25°C and immediately analyzed by FLIM to ensure that NBD-lipids localized essentially in the 
outer leaflet of the plasma membrane. HepG2 cells, seeded on poly-D-lysine-coated dishes, were 
prepared similarly. In this case, all washing steps were done with HBSS (Hank’s balanced salt 
solution, PAN). 
3.2.3.2 Labelling of actin microfilaments with phalloidin 
Cells grown in glass-bottom microwell dishes were washed with DPBS and fixed for 10 min at room 
temperature in fixative solution (4% formaldehyde in DPBS, pH 7). Cells were washed, 
permeabilized with a 0.5% solution of Triton X-100 in DPBS for 5 min and washed again. Staining 
of actin filaments was performed by incubating the cells with a 100 nM solution of rhodamin 
phalloidin (Tebu-Bio, Offenbach, Germany) in DPBS for 30 min, at room temperature in the dark. 
Subsequently, cells were washed and DNA was stained for 30 s with a 100 nM solution of DAPI 
(Invitrogen) in DPBS. Cells were extensively washed and imaged in DPBS at room temperature.  
3.2.3.3 Confocal laser scanning microscopy 
Confocal laser scanning microscopy was performed using an inverted Fluoview 1000 microscope 
(Olympus, Tokyo, Japan) and a 60 x (N.A. 1.35) oil immersion objective at 25°C, if not stated 
otherwise. Images with a frame size of 512 x 512 pixels were acquired. GFP and NBD fluorescence 
were excited with the 488 nm laser line of an Ar-ion laser; fluorescence emission was recorded 
between 500 nm and 600 nm. CFP was excited with a 440 nm diode laser and detected between 460 
nm and 490 nm. EYFP was excited at 515 nm using an Ar laser and detected between 530 and 630 
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nm. The red rhodamine, Texas Red and TRITC fluorescence was excited with a 559 nm diode laser 
and recorded from 570 to 670 nm. When multiple dyes were used, the appropriate settings were 
determined to avoid overlap between the different signals. 
3.2.3.4 Fluorescence lifetime imaging microscopy (FLIM) 
Images were taken by confocal laser scanning microscopy using an inverted Fluoview 1000 
microscope (Olympus, Tokio, Japan) with a 60x (N.A. 1.35) oil-immersion objective at 25°C. 
Images with a frame size of 512 x 512 pixels were acquired. For confocal images of NBD-labelled 
cells, NBD-fluorescence was excited with a 488 nm Ar-ion laser and recorded between 500 and 530 
nm. FLIM images were acquired by a commercial FLIM upgrade kit (PicoQuant, Berlin, Germany). 
NBD was excited with a pulsed diode laser (pulse width: 60 ps; pulse frequency: 10 MHz; 4 
μs/pixel) with a wavelength of 468 nm. Emission was recorded using a 540/40 bandpass filter. 
Single photons were registered with a single photon avalanche photo diode (SPAD). For each image, 
50-70 frames were acquired with an average photon count rate of ~2-4 x 104 counts/s. Images were 
pseudocolor-coded according to the average lifetime (τav) of the pixels, defined as  
∑
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where αi is the respective amplitude. 
3.2.3.5 Fluorescence lifetime determination 
For the analysis of fluorescence lifetime parameters of NBD-analogues in mammalian cells, cell 
membrane compartments were selected applying an intensity threshold to exclude fluorescence from 
background or cytoplasm (Fig. 8A). If necessary the selection was refined manually to exclude 
regions not associated with the membrane.  
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Fig. 8: Determination of fluorescent lifetimes in the plasma membrane of HeLa cells. Images were taken 
by exciting the NBD fluorescence at 468 nm with a pulsed diode laser as described in 2.2.3.4. (A) The 
intensity image (A,I) and the average lifetime image shown as pseudocolor image (A,II see scale) of a typical 
cell are displayed. From this image, the plasma membrane was selected (III) and the fluorescence overall 
decay curve was generated (B). The part of the curve non affected by the instrument response function 
(approximately from 3 ns after the beginning of the pulse) was fitted with a biexponential decay function (red 
line) obtaining τ1 and τp. The lower plot shows the weighted residuals. For construction of the lifetime 
histograms (C), 2 x 2 or 3 x 3 pixels in the selected region of interest were binned and the fitting procedure 
was repeated for each binned pixel using the lifetime parameters obtained from the overall decay curve as 
starting parameters. In the histograms the intensity weighted frequencies (αi x τi) are plotted. 
 
For the selected regions of interest (ROI), an overall fluorescence decay curve was generated by 
summing up the photons registered for that region. From the decay curve only the part not affected 
by the instrument response function (IRF) was used (“tail-fit”, approximately from 3 ns after 
beginning of the pulse). A typical decay profile in the plasma membrane of HeLa cells with the 
biexponential fitting and the weighted residual distribution is shown in Fig. 8B). Using a nonlinear 
least squares iterative fitting procedure, fluorescence decay curves were fitted as a sum of 
exponential terms to obtain the fluorescence lifetimes of the NBD-group: 
( ) ( )i
i
i txpetF τα −= ∑  
where F(t) is the fluorescence intensity at time t and αi is a pre-exponential factor representing the 
intensity of the time-resolved decay of the component with lifetime τi. Typically, adequate fitting of 
fluorescence decays in cellular membrane, i.e. the plasma membrane and intracellular membranes, 
was achieved with three lifetimes. However, two lifetimes (τ1 and τp, see “Results” for further 
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details) already provided sufficient quality of fit when considering fluorescence decays originating 
only from analogues in the plasma membrane. Due to the tail-fit method, the short component τ1 
detected for NBD (see result section) might be underestimated. Quality of fits was judged by the 
distribution of the residuals and the χ2 value. For construction of lifetime histograms (Fig. 8C), 2 x 2 
or 3 x 3 pixels in the selected regions of interest were binned and the fitting procedure described 
above was repeated for each binned pixel, using the lifetime parameters obtained from the overall 
decay curve as starting parameters. In the histograms the intensity weighted frequencies (αi x τi) are 
plotted.  
Analysis of fluorescence lifetimes in GUVs are GPMVs was performed similarly. 
3.2.3.6 Fluorescence recovery after photobleaching (FRAP) 
FRAP measurements were performed at 25°C with a 60 x (N.A. 1.35) oil-immersion objective using 
an Olympus Fluoview 1000 microscope. Regions were selected in the apical membrane of cells with 
similar expression levels of the wild type or mutant form of ABCA1. After 8 scans (scan speed 4 
μs/pixel) at 1% laser power, a circular spot of 1.2 μm radius was bleached for 10 ms with 100% laser 
power. Under these conditions, 70-80% of NBD fluorescence was bleached. The subsequent 
recovery of fluorescence was recorded at low laser power (1%) for about 90 s, with an interval of 0.3 
s between each postbleach scan. This experimental set up provided minimal bleaching during the 
measurement. All FRAP measurements were performed at 25°C to minimize the influence of 
membrane traffic events on the fluorescent recovery. Analysis was performed in Origin 7.5 
(OriginLab Corp.). Recovery curves were fitted with an approximation of the theoretical recovery 
curve: 
( )τ++= tFFtF r /)( 0  
The diffusion coefficient (D) was calculated from the recovery time by the formula: 21
2 4/ tD γω=  
(ω: radius of the focused circular laser beam, γ: correction factor for the amount of bleaching [192]); 
mobile fraction (Mf) was given by ( ) ( )00 / IIIIMf i −−= ∞  [193]. At least 12-20 cells were 
measured in each experiment.  
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3.2.4 Biochemistry 
3.2.4.1 Preparation of MLVs and GUVs 
Multi Lamellar Vesicles (MLVs) were prepared by resuspending dried lipids in Hepes buffer (145 
mM NaCl, 10 mM Hepes, pH 7.4), followed by vigorous vortexing. 
GUVs were produced from lipid films dried on ITO-coated glass slides by electroswelling, as 
originally described by Angelova and Dimitrov [194,195]. Lipid mixtures were made from stock 
solutions in chloroform stored at -20°C. For each preparation, 100 nmol of lipids (including 
cholesterol) were mixed in 30 μl of chloroform. Single drops of the lipid mixture were pipetted onto 
two ITO or titanium slides and allowed to spread. To obtain homogeneously distributed lipid films, 
the solvent was evaporated on a heater plate at 50-60°C. The glass slides were put under vacuum 
(<10 mbar) for 1 h to remove possible traces of the solvent. The electroswelling chamber was 
assembled from both lipid-coated ITO slides using 1 mm Teflon spacers. Alternatively, chambers 
formed from two hollowed titanium sheets were used instead of ITO-coated glass slides, as it was 
reported by Ayuyan and Cohen that the ITO-coating may catalyse the formation of peroxides from 
unsaturated lipids [196]. One layer of Parafilm (Pechiney Plastic Packaging, Chicago, IL, USA) was 
used as insulation.  
Chambers were filled with 1 ml of pre-warmed (50-60°C) sucrose buffer (250 mM sucrose, 15 mM 
sodium azide) with an osmolality of 280 mOsm/kg. An alternating voltage (rising from 0.02 V to 1.1 
V over 30 min) with a frequency of 10 Hz was immediately applied. GUVs formed during 2 h 
incubation at 50-60°C. To detach the vesicles, a voltage of 1.3 V (4 Hz) was applied for 30 min. The 
vesicles were stored in the dark at room temperature for up to 4 days until use. GUVs were prepared 
and imaged by Dr. Martin Stöckl. For microscopy, GUVs were diluted 1:3 – 1:5 with glucose buffer 
(280 mM glucose, 11.6 mM potassium phosphate, pH 7.2) and allowed to settle on a microscopy 
slide. 
3.2.4.2 Preparation of GPMVs 
Giant plasma membrane vesicles (GPMVs) or “blebs” were prepared from almost confluent HeLa 
cells by chemically induced vesiculation as described previously [17,18]. Cells grown in T25 flasks 
were washed twice with GPMV buffer (2 mM CaCl2, 10 mM Hepes, 0.15 M NaCl, pH 7.4). To each 
flask 1.5 ml of freshly prepared GPMV reagent (25 mM formaldehyde, 2 mM dithiothreitol in 
GPMV buffer) were added. Flasks were incubated for 1 h at 37°C while slowly shaking (60-80 
cycles per minute). After incubation, GPMVs that had detached from the cells were gently decanted 
into a conical glass tube and allowed to settle for at least 30 min on ice. Before imaging, the needed 
dyes were added to the GPMV suspension resulting in the following final concentrations: R18 
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(Octadecylrhodamin-B-chlorid, Invitrogen, Karlsruhe, Germany), 0.5 μM; C6-NBD-PC, 0.8 μM; 
Rho-DOPE, 0.8 μM; C6-NBD-LacCer 0.5 μM; C6-NBD-SM 2 μM. Images of the equatorial plane 
of the blebs were taken at 10°C or at 25°C. Temperature was controlled with a water circulating 
bath.  
Concanavalin A-Texas Red (Molecular Probes, Eugene, Oregon, USA) labelling was performed by 
incubating the cells with a 50 μg/ml solution in GPMV buffer for 5 min at 15°C before formation of 
blebs. Biotin labelling was performed with Sulfo-NHS-LC-Biotin followed by incubation with 
Streptavidin Texas Red (both Pierce, Rockford, IL, USA) following the manufacturers´ instructions. 
To study ABCA1 and ABCA1MM partitioning, GPMVs were prepared from HeLa cells 60 h post 
transfection with ABCA1 or ABCA1MM tagged with the EGFP or ECFP at the C terminal. The 
relative domain size was calculated by approximating the vesicle to a circumference and calculating 
the length of the cord covered by the Ld-like phase, where 1 is the length of the whole 
circumference. CHO-K1 cells expressing GPI-CFP were kindly provided by S. Scolari. 
3.2.4.3 Detergent-free isolation of lipid rafts 
Biochemical isolation of lipid rafts was performed accordingly to the detergent-free method 
developed by Macdonald and Pike [197]. Cells grown in 10 cm tissue culture dishes were scraped 
into 5 ml of base buffer (20 Tris-HCl, pH 7.8, 250 mM sucrose) with 1 mM CaCl2 and 1 mM MgCl2 
and washed by centrifugation (1000 g, 5 min, 4°C). Cells were resuspended in 333 μl of base buffer 
and lysed by mechanical shearing with 20 strokes of a G-25 needle. The PNS was collected after two 
centrifugation steps (1600 g, 10 min, 4°C). The obtained 666 μl were diluted in 666 μl of 50% 
OptiPrep solution (Sigma, Lyon, France) made in base buffer, and overlaid with a 6-25% OptiPrep 
step gradient prepared in base buffer. After centrifugation of the samples at 52000 g in a Beckman 
SW60 rotor (90 min, 4°C), 18 fractions of 222 μl were collected from the top of the gradient. Equal 
volumes per fraction were subjected to Western blot analysis. For Laurdan spectroscopy, MALDI-
TOF mass spectrometry, cholesterol, phospholipid and protein determination, membrane fractions 
were prepared from bulk cultures of cells (25 x 106). Refraction index of the fractions was measured 
using a Bausch & Lomb refractometer at 20°C. Densitometry analysis was performed with AIDA 
2.11 software. Analysis of membrane fractions was performed in collaboration with A. Zarubica and 
Dr. G. Chimini (CIML, Marseille, France). 
  MATERIAL AND METHODS   40 
3.2.4.4 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
For separation of proteins, SDS-PAGE was used [198] with the Mini PROTEAN 3 system (Bio-
Rad). For investigation of ABCA1, 6% acrylamide/bisacrylamide resolving gels were used, whereas 
10% gels were employed to investigate smaller molecules. For stacking gels, 3% 
acrylamide/bisacrylamide was used. The composition of gels and sample buffer is indicated in Table 
1. Electrophoresis was run at 25 mA per gel. 
3.2.4.5 Cholesterol, phospholipid and protein determination 
Cholesterol levels were determined using the Amplex-Red cholesterol assay (Molecular Probes, 
Leide, The Netherlands) according to manufacturers’ instructions.  
Lipids were extracted by the method of Bligh and Dyer [199]. Samples were adjusted to volume 
ratios aqua dest./chloroform/methanol of 0.8/1/2 and kept for 30 min at room temperature after 
vigorous vortexing. Phase separation was achieved by adding 1 volume each of chloroform and 40 
mM acetic acid following by vortexing for 1 min and centrifugation (1000 g, 10 min, 4°C). The 
upper phase was washed with additional 2 volumes of chloroform followed by vortexing and 
centrifugation as above. Pooled lower phases were evaporated in glass tubes under a nitrogen stream 
or under vacuum. 
Phospholipid content was determined by measuring the phosphorous amount adapting the method of 
Hess et al. [200]. This assay employs the fact that, at low pH, malachite green forms a complex with 
phosphomolybdate, which is stabilized by the presence of Tween-20 [201]. Samples and standards 
containing known amounts of DOPC in chloroform were placed in small 150 μl glass vials (Knauer, 
Berlin, Germany) and dried under vacuum. 10 μl of 10 N H2SO4 and 30 μl of 60% perchloric acid 
were added to the dried samples. After vortexing, the tubes were heated for 45 min at 200°C in a 
heating block in order to evaporate the perchloric acid. After cooling down the samples, 75 μl of 
water and then 400 μl of freshly prepared malachite green working solution were added to the tubes 
and mixed. Malachite green working solution was prepared by mixing 3 volumes of 0.045% (w/v) 
malachite hydrochloride (Sigma, Taufkirchen, Germany) with 1 volume of 4.2% ammonium 
molybdate (w/v) in 4 N HCl for 30 min by magnetic stirring. After filtration through a 0.45 μm filter, 
0.02 volumes of 1.5% Tween-20 per volume of filtered solution were added. Samples were 
transferred to 96 well plates and the absorption at 630 nm was measured on a microplate reader 
(FLUOstar OPTIMA, BMG Labtechnologies, Offenburg, Germany) after 10 min. 
Protein content in the plasma membrane fractions was quantified with the Micro BCA protein assay 
kit (Pierce, Rockford, USA), according to manufacturers’ instructions. 
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3.2.4.6 MALDI-TOF mass spectrometry 
All MALDI-TOF mass spectra were acquired on an Autoflex I mass spectrometer (Bruker Daltonics, 
Bremen, Germany) with ion reflector. The system utilizes a pulsed 50 Hz nitrogen laser, emitting at 
337 nm. The extraction voltage was 20 kV and gated matrix suppression was applied to prevent the 
saturation of the detector by matrix ions. All spectra were acquired in reflector mode using delayed 
extraction. A more detailed description of MALDI-TOF MS, in particular of phospholipids, is given 
in [202]. Spectral mass resolutions and signal-to-noise ratios were determined by the instrument 
software Flex Analysis 2.4 (Bruker Daltonics). Selected assignments were also confirmed by post 
source decay fragment ion analysis [203]. The mass spectrometer was calibrated using the molecular 
ions of a lipid mixtures desorbed from a standard DHB preparation applied next to the spots of 
interest (positive ion mode). For negative ion detection, the signals of the DHB matrix were used for 
calibration [204]. Assignments of the most intense peaks are indicated in Table 6. MALDI-TOF 
mass spectrometry experiments were done in collaboration with Dr. Jürgen Schiller (University of 
Leipzig, Germany).  
Table 6: Assignment of the most intense peaks in MALDI-TOF mass spectra of organic extracts of plasma 
membrane fractions. 
 
 
 
 
 
Positive ion mass spectra 
Peak position (m/z) Molecular mass assignment Peak position (m/z) Molecular mass assignment 
703.6 SM 16:0 + H+ 758.6 PC 16:0, 18:2  + H+ 
725.6 SM 16:0 + Na+ 760.6 PC 16:0, 18:1  + H+ 
732.6 PC 16:0, 16:1  + H+ 780.6 PC 16:0, 18:2  + Na+ 
734.6 PC 16:0, 16:0  + H+ 782.6 PC 16:0, 18:1  + Na+ 
754.6 PC 16:0, 16:1 + Na+ 786.6 PC 18:0, 18:2  + H+ 
756.6 PC 16:0, 16:0 + Na+ 808.6 PC 16:0, 18:2  + Na+ 
Negative ion mass spectra 
Peak position (m/z) Molecular mass assignment Peak position (m/z) Molecular mass assignment 
760.6 PS 16:0, 18:1 863.6 PI 18:0, 18:1 
788.6 PS 18:0, 18:1 885.6 PI 18:0, 20:4 
835.6 PI 16:0, 18:1 887.6 PI 18:0, 20:3 
861.6 PI 18:0, 18:2   
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3.2.4.7 Laurdan spectroscopy 
Laurdan (Molecular Probes, Leide, The Netherlands) solutions in DMSO were added to the 
membrane fractions isolated with the detergent-free method as described in 2.2.4.3 for 10 min at 
25°C. The probe:lipid ratio was kept constant at 1:360. For experiments with MLVs, Laurdan was 
added to 1 mM lipid solution with constant probe:lipid ratio of 1:1000. Final concentration of 
DMSO was 0.2 % (v/v). After 10 minutes of incubation, Laurdan was completely incorporated, as 
assessed by the stabilization of the fluorescence signal. Fluorescence spectra were recorded using an 
Aminco Bowman Series 2 spectrofluorometer (Rochester, USA) at 25°C, controlled by a water 
circulating bath. Excitation and emission wavelengths were set at 360 nm and 428 nm, respectively, 
using 4 nm bandwidth for both. 
The fluorescence intensity of Laurdan was quantified by the generalized polarization (GP), which is 
defined as [205,206] 
( ) ( )482437482437 / IIIIGP +−=  
where I437 and I482 are the emission intensities at the corresponding wavelengths.  
3.2.4.8 Annexin V and ApoA-I binding 
HeLa or MDCKII cells stably expressing ABCA7-YFP cultured in T25 flasks were washed with 
DPBS supplemented with 24 mM glucose and 10 mM Hepes (mDPBS), trypsinized and washed 
again. To measure exposure of endogenous PS on the cell surface, about 105 cells were incubated on 
ice in the dark for 10 min with 5 μl of APC-Annexin V (BD Biosciences, Heidelberg, Germany) in 
0.5 ml of binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2). Cells were washed and 
resuspended in 0.5 ml of binding buffer containing 1 μl of 1 mg/ml stock solution of propidium 
iodide. Measurements were performed with a FACSCalibur flow cytometer (BD Biosciences) 
equipped with an Argon laser (488 nm) and a diode laser (630 nm). Data were analyzed with 
WinMDI software gating on YFP negative (non expressing) and positive (expressing) cells and 
analyzing APC-Annexin V fluorescence signal. To measure exposure of PS on the outer leaflet of 
HeLa cells after Ionomycin treatment, Annexin V-FITC was used. In this case, measurements were 
performed on a FACScan (BD Biosciences). 
Fluorescence-based assays for surface binding of cyanilated ApoA-I to ABCA1 were carried out in 
the laboratory of Dr. Giovanna Chimini as described in [183]. 
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3.2.4.9 Outward redistribution of C6-NBD-PS and C6-NBD-PC 
Cells grown in 35 mm dishes were labelled with 1 ml of 10 μM C6-NBD-PS on ice and incubated at 
20°C for 30 min to allow inward movement of the NBD lipid analogues [56,207]. Non inserted 
analogues were removed by washing cells twice with mDPBS (DPBS supplemented with 24 mM 
glucose and 10 mM Hepes). Inward redistribution of analogues was initiated by addition of mDPBS 
pre-warmed to 20°C containing 5 mM diisopropyl fluorophosphates (DFP, Sigma) (as in all 
following incubations) to prevent hydrolysis of analogues [208]. NBD lipid analogues remaining on 
the cell surface were extracted twice by incubation with 2% BSA (w/v) in mDPBS for 10 min on ice. 
After removing the second BSA-containing medium, cells were washed twice with cold mDPBS. 
For t=0 min, cold medium containing 2% BSA and 5 mM DFP in mDPBS was added to the cell dish 
and incubated for 10 min on ice. To measure C6-NBD-PS outward transport, pre-warmed (37°C) 
mDPBS with 2% BSA and 5 mM DFP was added to the dish and cells were incubated at 37°C (15, 
30 min). The BSA-containing medium was removed and a second extraction with 2% BSA in 
mDPBS for 10 min on ice was performed. 
To measure outward redistribution of C6-NBD-PC, this lipid analogue was biosynthetically 
produced from C6-NBD-PA. Transport to the outer leaflet of the plasma membrane was measured at 
15ºC [58]. Cells grown in 35 mm dishes were incubated at 15ºC with 1 ml of 25 μM C6-NBD-PA 
solution in mDPBS. After 3 h, analogues on the exoplasmic leaflet were removed by washing cells 
twice with 2% BSA (w/v) in mDPBS for 10 min on ice. Subsequently, cells were incubated at 15ºC 
in 2% BSA solution (1 h, 3 h). 
After the incubations, the second BSA back exchange medium was pooled with the first. Cells were 
scraped into DPBS. For C6-NBD-PS analysis, lipids from media and scraped cells were extracted 
with isopropyl alcohol (5.5 ml per 1 ml of medium) to prevent substantial loss into the aqueous 
phase. Samples were centrifuged at 1000 g for 10 min and the supernatant was transferred into new 
glass tubes and dried under a nitrogen flow. Lipids were dissolved in chloroform:methanol (1:1), 
applied to TLC plates (Kieselgel 60, Merck) and ran in chloroform:methanol:aqua dest (16:6:1).  
For C6-NBD-PC analysis, cells and incubation media were extracted with the method of Bligh and 
Dyer [199] using 20 mM acetic acid in the aqueous phase. Lipids were subjected to two-dimensional 
separation (I, chloroform, methanol, 25% ammonium hydroxide (65:25:4, v/v); II, 
chloroform/acetone/methanol/acetic acid/ water (10:4:2:2:1, v/v)) on TLC plates. NBD fluorescent 
spots were quantified with a FLA 3000 PhosphoImager (Fujifilm, Dusseldorf, Germany) with the 
excitation set at 473 nm and emission at 520 nm. 
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4 Results 
In order to assess the influence of ABCA1 on the micro-organization of the plasma membrane, our 
strategy was to develop a new approach that allowed the identification and characterization of lipid 
domains in the plasma membrane of living cells.  
GUVs and GPMVs were employed as a basis for the interpretation of the data in living cells. 
Successively, the plasma membrane lipid microenvironment and the effects of its perturbation were 
investigated. 
In the second part of the result section, the application of this approach to the case of ABCA1 is 
illustrated, followed by the analysis of ABCA1 partitioning in GPMVs and in membrane domains 
isolated by density fractionation. Finally, a comparative study with ABCA7 is presented. 
 
4.1 FLIM of C6-NBD lipid analogues – a tool to study the 
lateral heterogeneity of membranes  
4.1.1 Visualization of lipid domains by fluorescence lifetime of C6-
NBD-PC in GUVs 
In our laboratory, a single dye approach based on fluorescence lifetime imaging microscopy (FLIM) 
was developed to investigate formation of phospholipid domains in artificial and cellular membranes 
[209]. This technique relies on the intrinsic properties of the NBD group, which shows differential 
fluorescence lifetimes according to physical properties of the environment in which it is embedded. 
Parts of the results are shortly illustrated to follow. 
To date, giant unilamellar vesicles (GUVs) have been extensively used to study coexisting lipid 
phase behavior, because their large, micrometer scale domains can be directly observed by 
fluorescence microscopy. Indeed, GUVs made from appropriate lipid mixtures show formation of 
laterally segregated domains, which can be visualized by fluorescent compounds that preferentially 
distribute into one of the domains. Besides, properties such as fluorescent lifetime or generalized 
polarization, which depend on the environment surrounding the fluorophore, can also be employed 
to discriminate between coexisting lipid phases [37,210]. Last, the possibility to control the lipid 
composition of such vesicles is a further advantage that makes them an attractive tool for studying 
lateral lipid segregation. 
GUVs prepared from mixtures of DOPC/SSM/cholesterol 1/1/1 (mol/mol/mol) show coexisting 
liquid disordered (Ld) and liquid ordered (Lo) phases at 25°C. In these vesicles, the nature of the 
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different lipid domains can be identified because of the preferential localization of the lipid analogue 
C6-NBD-PC into the Ld phase [209,211]. This is visualized in the microscopy images as a bright 
region (Fig. 9A, upper panel). 
Apart from the differential localization of the lipid analogue, Ld and Lo phases can be identified by 
the different fluorescence lifetime of C6-NBD-PC molecules partitioning in such domains. In both 
the Ld or the Lo phase, the fluorescence decay of C6-NBD-PC shows a bimodal lifetime 
distribution, with a short (τ1) and a long (τ2) lifetime. The long lifetime τ2 represents the major 
component of the distribution, whereas τ1 only provides minor contribution (<5%). 
The analysis of the two phases separately revealed that the long lifetime τ2 is clearly distinct in the 
Ld and Lo phase, being about 7 ns (τ2Ld) and 11 ns (τ2Lo), respectively, at 25ºC (Fig. 9A, lower panel 
and 9B). In Fig. 9B the histograms of the distribution of τ2 for each domain and the envelope 
histogram are presented. Conversely, the short component τ1 was found not to be sensitive to the 
lipid phase. 
 
Fig. 9: Fluorescence lifetime of C6-NBD-PC in the Ld and Lo phase of GUVs. (A) Intensity image (top) of 
C6-NBD-PC in GUVs prepared from DOPC/SM/cholesterol showing the preferential enrichment of this lipid 
analogue in one phase. At the bottom, the fluorescence lifetime image displaying the lateral distribution of the 
lifetime components τ2Lo and τ2Ld of C6-NBD-PC is shown. Comparison of the overlay of τ2Lo and τ2Ld with the 
intensity image shows that τ2Ld is associated with the Ld domain, while τ2Lo is associated with the Lo domain. 
(B) Images and lifetime histograms of the Ld and Lo domain analyzed separately. For each pixel, the 
amplitude of the lifetime components τ2Ld or τ2Lo is presented. In addition, the envelope histogram (black line) 
is shown. White bars correspond to 10 μm. Images and data were kindly provided by Dr. Martin Stöckl. 
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The full characterization of the fluorescence lifetime behavior of C6-NBD-PC in model membranes 
revealed that the longer lifetime component τ2 is sensitive to the lipid environment. Even for GUVs 
showing no visible domains, such as vesicles prepared from POPC/PSM/cholesterol 1/1/1, the 
typical values for τ2Ld and τ2Lo could be recovered from the fluorescence decays. This demonstrates 
the presence of submicroscopic heterogeneities and confirms that fluorescence lifetime is a proper 
tool to study the lateral organization and the lipid-dependent physical properties of membranes. 
 
4.1.2 Partitioning of C6-NBD-PC and other lipid analogues in 
GPMVs 
GUVs, being simple model membranes usually composed of three components, allow studying 
many physical aspects of lipid bilayers thanks to their simplicity and to the possibility to strictly 
control parameters such as lipid composition. On the other hand, heterogeneity is a fundamental 
feature of biological membranes. It has been calculated that the mammalian bilayer can possess up 
to 9,600 species of glycerophospholipids, more than 100,000 species of sphingolipids, thousands of 
mono/di/triacylglicerol variants and numerous fatty acid- and sterol-based structures [212]. 
Combined with the great abundance of protein types, this creates a complex and very heterogeneous 
system.  
Giant plasma membrane vesicles (GPMVs) recently emerged as an adequate tool to investigate 
fluid/fluid phase coexistence and to study the partitioning of lipids and proteins in a biological 
environment. Such vesicles, obtained from the plasma membrane of cells by chemically induced 
vesiculation, or “blebbing”, show simple, low-curvature geometries of GUVs and appear free of 
cytoskeletal constraints and cellular organelles [17]. They have a lipid composition representative of 
the plasma membrane, with phospholipid:cholesterol ratios of about 2:1 [213,214]. By providing a 
compositionally rich biological membrane system, they overcome the possible limitations of GUVs, 
which may fail to capture the multitude of protein-protein and protein-lipid interactions taking place 
in the plasma membrane. In order to investigate whether the properties of NBD are conserved in 
vesicles with a complex biological lipid composition, the study of the fluorescence lifetime of C6-
NBD-PC was extended to GPMVs. 
GPMVs were generated from HeLa cells. These vesicles undergo phase separation into visible, 
coexisting fluid domains at 25°C (about 40% of the total vesicles formed) or at lower temperatures. 
Phase separation can be visualized by probes that differentially partition between the two phases, 
namely the Ld- and the Lo-like phase. C6-NBD-PC was incorporated into the vesicles after their 
preparation. As previously shown, in GUVs C6-NBD-PC preferentially partitions in the Ld phase 
[209,211]. Unexpectedly, in GPMVs the lipid analogue did not display an evident heterogeneous 
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distribution (Fig. 10A). The formation and the nature of the different lipid phases were assessed by 
the non homogeneous distribution of Rho-DOPE. This fluorescent analogue of DOPE was 
previously shown to preferentially enrich into the Ld-like phase in plasma membrane blebs prepared 
from rat basophilic leukemia (RBL) mast cells [17,18]. Even vesicles with preferential enrichment of 
C6-NBD-PC into the Lo-like phase were found (Fig. 10B). This indicates that the partitioning of the 
probe depends not only on the lipid phase, but also on its lipid composition and accompanied 
modulation of its physical properties (see also discussion, chapter 5.1.2). The lipid-like fluorophore 
R18, already known to partition almost exclusively into the Ld phase in GUVs [215], was also 
confirmed to be preferentially enriched in the same phase in GPMVs (Fig. 10C). In principle, 
partition coefficients between coexisting phases could be determined from fluorescence images; 
however, given the uncertainties in the quantum yields and the difficulties in accurately quantifying 
fluorescence intensities from the curved surfaces of the vesicles, it was preferable to analyze 
qualitative information. 
In any given sample, not all the vesicles undergo phase separation. This demonstrates that, in some 
cases, lipids distributed heterogeneously between the vesicles. Those vesicles showing no phase 
separation were found to be organized mainly as Lo-like phase, as suggested by the enhanced 
partitioning of C6-NBD-PC in vesicles exhibiting no domain formation as compared to enrichment 
in the Ld-like phase in blebs with coexisting phases (Fig. 10C) and by lifetime measurements. 
Indeed, τ2 in those vesicles that show no domain formation was similar to τ2 measured in the Lo-like 
phases of vesicles with coexisting domains (description to follow and Table 7). 
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Fig. 10: Partitioning of C6-NBD-PC in GPMVs. C6-NBD-PC incorporated in GPMVs prepared from HeLa 
cells shows a weak preference for the Lo-like phase, identified by exclusion of Rho-DOPE. Domain-forming 
vesicles that did not show a preference of C6-NBD-PC for a specific domain were also found (B). R18, 
already known to be preferentially enriched in the Ld phase in GUVs, was confirmed to prefer the same phase 
also in GPMVs, as indicated by the complementary staining with C6-NBD-PC (C, vesicle on the right). 
Vesicles not showing domain formation were also present. At 10°C and 25°C partitioning behavior of the 
probes was similar. White bars correspond to 5 μm. Arrows indicate the Ld-like phases. 
Lo phases in artificial membranes are enriched in sphingolipids, glycosphingolipids and cholesterol. 
Moreover, GPI-anchored proteins are also considered to be enriched in ordered lipid domains, based 
on detergent fractionation [10,216] and model membrane studies [217].  
To gain insights into the partitioning behavior of these molecules in GPMVs, C6-NBD-SM and C6-
NBD-LacCer were incorporated into the vesicles. The analysis of the phase preference revealed that 
these two lipid analogues display strong enrichment for the Lo-like phase (Fig. 11). This suggests 
that the sphingosine backbone is responsible for this net preference, consistently with model 
membrane studies [142]. Vesicles in which the analogues were localized in both phases, as described 
for C6-NBD-PC, were not found.  
Similarly, GPI-CFP displayed a marked preference for the Lo-like phase (Fig. 11C), in agreement 
with previous results [18,215]. In this case, blebs were prepared from CHO-K1 cells transiently 
transfected with this construct [218] (kindly provided by S. Scolari). 
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Fig. 11: Partitioning of C6-NBD-SM, C6-NBD-LacCer and GPI-CFP in GPMVs. C6-NBD-SM and C6-
NBD-LacCer incorporated in GPMVs prepared from HeLa cells display preferential enrichment in the Lo-like 
phase, as determined by the complementary partitioning with Rho-DOPE (A and B). Also GPI-CFP, a widely 
utilized raft marker, prefers the Lo-like phase, as indicated by the complementary staining with R18 (C). 
Vesicles were visualized at 25°C. White bars correspond to 5 μm. Arrows indicate the Ld-like phases. 
  
4.1.3 Lifetime distribution of C6-NBD-PC in GPMVs 
Analysis of fluorescent lifetime of C6-NBD-PC in GPMVs was performed by separately evaluating 
lifetimes in the Ld- and Lo-like domains. This revealed the presence of a short (τ1) and a long (τ2) 
lifetime component in both phases. Independently of the differential domain-specific distribution of 
the lipid analogue in comparison with GUVs, lifetime values of τ2 were similar: at 25°C, C6-NBD-
PC lifetime was ~ 6.7 ns in the Ld-like phase and ~ 9.6 ns in the Lo-like phase (Table 7). When the 
vesicles were measured at 10°C, longer lifetimes were detected both for the Ld-like and the Lo-like 
phase (8.4 ns and 10.8 ns, respectively). This is likely due to an increase in the packing of the acyl 
chains of the membrane lipids at lower temperatures. Interestingly, lifetime values in vesicles that 
did not show domain formation were only slightly smaller than values assessed in the Lo-like phase 
at the respective temperature. This may indicate that such vesicles have an ordered membrane 
organization and is corroborated by the observation that, in the majority of the cases, the extent of 
the Lo-like phase covered the larger part of the vesicle surface. Other studies have previously  
suggested that liquid ordered domains represent the major fraction of the plasma membrane 
[214,219]. 
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Table 7:  Fluorescent lifetime values of τ2 of C6-NBD-PC in GPMVs prepared from HeLa cells at 25°C and 
10°C, before and after cholesterol depletion by MβCD. Data are presented as mean ± SEM (n>6). The 
percentage of vesicles showing coexisting phases is also indicated. 
 Temperature τ2(Ld) τ2(Lo) 
τ2 (no visible 
domains) 
Domain-
forming 
vesicles 
  ns ns ns % 
25°C 6.7 ± 0.2 9.6 ± 0.3 9.5 ± 0.1 40 
- 10°C 8.4 ± 0.3 10.8 ± 0.1 10.3 ± 0.2 54 
25°C 7.1 ± 0.2 9.6 ± 0.1 8.8 ± 0.1 21 
MβCD 10°C 8.2 ± 0.1 10.3 ± 0.1 9.3 ± 0.2 48 
In Fig. 12 the lifetime histograms at 25°C for the Ld-like and Lo-like domain, as well as their 
envelope histogram, are shown. Even in the case in which GPMVs did not show preferential 
enrichment of C6-NBD-PC (Fig. 12A, I, see arrow), domains could be distinguished by fluorescence 
lifetime imaging (Fig. 12A, II and B). Moreover, fluorescence decay analysis of vesicles for which 
lipid domains of microscopic size were not observed either by intensity or by lifetime imaging, 
showed that the lifetime histogram of those vesicles was very similar to the envelope histogram of 
vesicles forming large domains (Fig. 12B, dotted and full black line, respectively). 
 
Fig. 12: Fluorescent lifetime of C6-NBD-PC in GPMVs. C6-NBD-PC in blebs prepared from HeLa cells 
shows only a weak or no domain preference (A, I: intensity image). Nevertheless, Ld (white arrow) and Lo 
domains can be characterized by lifetime differences (A, II: pseudocoloring according to the average lifetime 
as indicated in the scale). White bars correspond to 10 μm. The lifetime histogram for τ2 for the Ld domain 
(green line) and Lo domain (red line), as well as their envelope (full line, black), are shown in B. The 
histogram of lifetime distribution in GPMVs showing no lipid domains (dotted line, black) is very similar to 
the envelope histogram of GPMVs forming large domains. In the inset, the normalized distribution for the Ld 
and Lo domains is shown. Measurements were made at 10°C. 
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Cholesterol is a major determinant of formation of Lo phases. Therefore, we investigated the 
fluorescence lifetime of C6-NBD-PC in GPMVs formed from cells subjected to cholesterol 
depletion by MβCD. This treatment did not affect the morphology of the vesicles nor the domains. 
Similarly, lifetime values in the Ld and Lo domains did not substantially change. Conversely, 
vesicles that did not show coexisting phases displayed a small reduction in the lifetime values. The 
percentage of domain-forming vesicles at 25°C was drastically reduced after cholesterol depletion 
(Table 7). As already described, lowering the temperature to 10°C slightly increased the lifetimes. 
In conclusion, these results demonstrate that the typical lifetime values for the Ld and Lo domains 
are conserved in vesicles with large differences in lipid composition, such as GUVs and GPMVs. 
NBD lifetimes were independent from the preferential enrichment of C6-NBD-PC in a specific 
domain. In addition, the envelope histograms of vesicles showing or not showing visible domain 
formation were found to be highly similar. This suggests that submicroscopic lipid domains formed 
also in the case where micrometer-scale phase separation was not observed. 
 
4.1.4 Lifetime distribution of C6-NBD analogues in cellular 
membranes 
The membrane raft hypothesis proposes that membrane lipid domains, enriched in cholesterol and 
(glyco-)sphingolipids, form dynamic sorting membrane sites that may function as signalling 
platforms for membrane proteins [12]. However, controversy concerning size, lifetime and even 
existence of lipid rafts in the plasma membrane of cells is still present [27]. This skepticism is also 
raised by the fact that, to date, most conclusions were drawn based on model membrane studies and 
on detergent fractionation methods, approaches that, although potentially informative, may not 
reflect the native situation in biological, intact membranes. Typically, in cells large domains have not 
been observed, suggesting that rafts may be organized at submicroscopic levels, being very small 
and highly dynamic [5]. 
We have used our approach based on fluorescence lifetime of NBD lipid analogues to study the 
presence and properties of lipid domains in the plasma membrane of living cells. Two cell lines were 
used for this purpose: HepG2 cells originate from the liver, the major site of cholesterol biosynthesis 
and catabolism, and express many ABC transporters, whereas HeLa cells are a cervical carcinoma 
cell line. As the latter does not endogenously express ABCA1, it was subsequently utilized to 
investigate the influence of ABCA1 expression (section 4.2).  
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4.1.4.1 Lifetime distribution of C6-NBD analogues in HepG2 cells 
In a first approach, HepG2 cells were labelled with C6-NBD-PC or C6-NBD-PS. Upon incubation 
of cells with C6-NBD-PC on ice, lipid analogues were primarily inserted into the outer leaflet of the 
plasma membrane (Fig. 13A). Intracellular staining was very faint if at all present (Fig. 13A, I). 
Several components could be distinguished by analysing the fluorescence lifetime measured at 25ºC 
(Fig. 13A, III and IV). Whereas the amplitude of the short lifetime τ1 around 1.8 ns was very small, 
we observed two long lifetimes, named τi and τp, with the maximum of the distribution centered at 
6.4 ns and 11.5 ns, respectively (Fig. 13A, IV; τi : dashed line, τp: full line). Image analysis revealed 
that τp was essentially found in the plasma membrane, while τi was associated with analogues in 
intracellular membranes. Indeed, the larger contribution of τp compared to τi was in agreement with 
the preferential localization of the analogues in the plasma membrane. Notably, if the analysis was 
performed selecting only the plasma membrane, then only τp was found in addition to τ1. 
 
Fig. 13: Fluorescence lifetime of C6-NBD-PC (A and B) and C6-NBD-PS (C) in HepG2 cells. 
Fluorescence lifetime of the lipid analogues was measured at 25ºC immediately after labelling (A,C) and after 
1 h of incubation at 37ºC (B). (I): confocal fluorescence image; (II): DIC image; (III): average lifetime shown 
as pseudocolor image (see scale); (IV): histogram of lifetime: τi (dashed line) and τp (full line). A canalicular 
vacuole, where C6-NBD-PC becomes enriched [220], is indicated by the arrow. Images were taken and 
analyzed by Dr. Thomas Korte. 
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The same pattern of lifetimes was observed when cells were incubated, after the labeling procedure, 
for 1 h at 37°C (Fig. 13B). Although the analogue remained mainly confined to the plasma 
membrane, fluorescent spots in the cytosol started to appear due to its progressive internalization 
(Fig. 13B, I). The fact that the intracellular labelling was enhanced is also indicated by an increase 
of the contribution of τi (Fig. 13B, IV). This was due to the transport of the analogues along the 
endocytic pathway or to slow redistribution across the plasma membrane. Similar lifetimes were 
observed for C6-NBD-PS (Fig. 13C), with a maximum at 6.5 ns and 10.9 ns for τi and τp, 
respectively. Again, τp essentially originated from analogues in the plasma membrane, whereas τi 
derived from intracellular membranes. However, in this case, the contribution of τi was much higher 
in comparison to C6-NBD-PC, reflecting the enhanced intracellular localization of the analogue of 
PS. Intracellular staining was even stronger after 1 h of incubation (not shown), due to an 
aminophospholipid translocase activity which is responsible for transport of PS and corresponding 
analogues, such as C6-NBD-PS but not PC (analogues), to the cytoplasmic leaflet of the plasma 
membrane of HepG2 cells, as previously shown [170,221,222]. After translocation, C6-NBD-PS 
redistributes to intracellular membranes. An efficient transport leading to intracellular staining 
during the labelling procedure was observed even at low temperatures. Cellular distribution and 
fluorescence lifetime pattern of C6-NBD-PC or C6-NBD-PS was very similar for HeLa cells (see 
paragraph to follow). Experiments with HepG2 cells were performed in collaboration with Dr. 
Thomas Korte. 
4.1.4.2 Lifetime distribution of C6-NBD analogues in HeLa cells 
In order to have a direct comparison with the values obtained in GPMVs prepared from HeLa cells, 
C6-NBD-PC fluorescence lifetime was studied in the plasma membrane of the same cellular system. 
Similarly to HepG2 cells, HeLa cells were labelled with C6-NBD-PC on ice and fluorescence 
lifetime was promptly measured. At 25ºC, proper fitting of the decay curves corresponding to the 
NBD located in the plasma membrane was achieved with two lifetime components, τ1 and τp, 
centered at about 3.3 ns and 11.7 ns, respectively. At 10ºC, an increase in τp to 12.7 ns was measured 
(p<0.0001, unpaired two-tailed t test), while τ1 remained essentially unchanged (p=0.3, Table 8). 
This is in agreement with measurements in GPMVs (Table 7) and can be attributed to a decreased 
fluidity of the membrane at lower temperatures. The long component of C6-NBD-PC lifetime at the 
plasma membrane is considerably higher compared to that found in GPMVs at the same 
temperature, and even to that measured in the Lo-like phase (compare Table 7). This indicates that 
in the cell parameters other than cholesterol content and lipid and protein composition contribute to 
the lateral properties of the plasma membrane.  
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These other parameters may be influenced, for instance, by the cytoskeleton [223] (see also 
description of cytochalasin D treatment, to follow). Moreover, partial loss of lipid asymmetry 
occurring during formation of GPMVs may also explain the decrease in the lifetime. 
To test whether the lifetime values were dependent on the lipid analogue used, fluorescence lifetime 
was measured after incorporation of C6-NBD-LacCer in the outer leaflet of the plasma membrane. 
This lipid analogue is composed of two carbohydrate moieties attached to a ceramide unit, which 
confer slow redistribution rates across the plasma membrane. The long component τp of C6-NBD-
LacCer was found to be significantly longer compared to that of C6-NBD-PC (p<0.0001, Table 8). 
This is likely due to the preferential localization of C6-NBD-LacCer, because of its ceramide 
backbone, to a more ordered environment. Indeed, a higher distribution to ordered domains was also 
observed in GPMVs (Fig. 11B). 
 
Table 8: Fluorescence lifetimes of C6-NBD-PC and C6-NBD-LacCer in the plasma membrane of HeLa 
cells. Means ± SD are presented. In the second raw, lifetime values after MβCD treatment are indicated. In 
brackets, number of cells analyzed. ND: not detected. For statistical analysis, see text. 
 NBD lifetime 
 25°C 10°C 
 τ1  ns τp  ns τ1  ns τp  ns 
C6-NBD-PC 3.3 ± 0.6 11.7 ± 0.3 (56) 3.2  ± 0.3 12.7 ± 0.1 (20) 
C6-NBD-PC (MβCD) 3.2 ± 0.4 11.3 ± 0.2 (33) ND 
C6-NBD-LacCer 3.7 ± 0.2 12.4 ± 0.4 (43) ND 
 
 
As cholesterol content is a major determinant of lipid packing, we next monitored NBD lifetimes 
after depletion of cholesterol by MβCD-mediated extraction. This treatment induced a shift of the 
lifetime distribution of the long component towards lower values (p<0.0001, unpaired two-tailed t 
test, Table 8 and Fig. 14). In general, cell viability and morphology were not affected. Care was  
anyway taken to analyze cells that did not show altered morphology. Indeed, in those cells NBD 
lifetime was much shorter, indicating that major rearrangements of the plasma membrane structure 
occurred (not shown). 
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Fig. 14: Fluorescence lifetime of C6-NBD-PC in the plasma membrane of HeLa cells at 25ºC. Left panel: 
average lifetime image of the plasma membrane before (A) and after (B) cholesterol depletion by MβCD-
mediated extraction shown as pseudocolor image (see scale in B). Right panel: histogram of τp of C6-NBD-PC 
before (solid line) and after (dashed line) depletion of cholesterol. Histograms were normalized by setting the 
maximum to 1. Measurements were performed at 25°C. 
It is important to mention that techniques based on fluorescence lifetimes are advantageous because, 
within a reasonable range, such values do not depend on the concentration of the fluorophore. For 
HeLa cells, we did not find a significant difference in the lifetimes when the starting labelling 
solution ranged from 0.25 μM to 2 μM (Fig. 15). However, when cells were labeled with a 2.5 μM 
solution of C6-NBD-LacCer, a slight decrease in the lifetime values was observed. At a 
concentration of 10 μM, spots of short lifetime probably corresponding to NBD-lipid analogue 
aggregates appeared at the plasma membrane (Fig. 15D). Again, the shorter component was not 
influenced. In the following chapters only the long component τp will be considered. 
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Fig. 15: Dependence of NBD lifetime on the concentration of the fluorophore. NBD lifetime did not 
substantially change when the solution to label the cells was ranging from 0.2 μM to 2 μM. At 10 μM, blue 
spots indicating regions of short fluorescent lifetime (see scale) appeared at the plasma membrane. Empty 
dots: τ1; filled dots: τP. Values are shown as means ± SEM of at least 10 cells. 
4.1.4.3 Effect of ionomycin, cytochalasin D and sphingomyelinase on C6-
NBD-PC lifetime 
As a further approach, we investigated the sensitivity of the fluorescence lifetime of C6-NBD-PC to 
cell treatments known to interfere with the micro-organization of the plasma membrane, such as 
disruption of lipid asymmetry and of the cytoskeleton meshwork.  
Energy-independent, bi-directional transbilayer movement of all major phospholipids, including PS, 
has been shown in the eukaryotic plasma membrane. This flip-flop, whose half time is in the order of 
one minute [224,225], is activated by cell stimulation and the subsequent increase in intracellular 
calcium and has been ascribed to the lipid scramblase protein (see introduction, section 1.1.4). 
Expression of many ABC transporters, including ABCA1, has also been associated with enhanced 
exposure of PS on the cell surface. 
We triggered lipid scrambling in HeLa cells by enhancing intracellular calcium concentration via the 
calcium ionophore ionomycin, prior to C6-ND-PC labelling. Fluorescence lifetime analysis of the 
analogue in the plasma membrane revealed, upon ionomycin treatment, a shift of the lifetime to 
lower values with respect to control cells (p<0.005, unpaired two-tailed t test) (Fig. 16A). Exposure 
of PS on the outer leaflet of the plasma membrane was confirmed by Annexin V binding (Fig. 16B), 
a well-established indicator of the effective randomization of phospholipids across the bilayer [226]. 
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Cell treatment with 0.1 μM solution of ionomycin decreased the lifetime of ~ 1 ns. However, by 
using a 10-fold more concentrated solution, no further decrease in the NBD lifetime was observed, 
in spite of additional exposure of PS on the outer leaflet, assessed by the increase in FITC-Annexin 
V fluorescence. When cells were incubated with ionomycin in the absence of calcium, the decrease 
in the fluorescence lifetime was no longer observed. This indicates that the effect of ionomycin was 
indeed due to scrambling of lipids and not to its intercalation into the outer leaflet. Addition of 
EGTA, a calcium chelating agent, had similar effects. 
 
Fig. 16: Influence of lipid scrambling on the fluorescence lifetime of C6-NBD-PC. NBD lifetime was 
measured in the plasma membrane of HeLa cells at 25ºC. (A) The average lifetime of τp in cells treated with 
0.1 μM (II) or 1 μM (III) ionomycin solution in DMSO (final 0.1% v/v), in the presence of calcium, is shorter 
as compared to cells subjected to the same treatment but without ionomycin (control, I). Cells subjected to 
ionomycin treatment (1 μM) in the absence of calcium or in the presence of the calcium-chelating agent EGTA 
did not show any effect. Data are presented as mean ± SEM (n>12). (B) PS exposure on the outer leaflet of the 
plasma membrane as assessed by Annexin V binding. (I): control cells; (II): ionomycin, 0.1 μM; (III): 
ionomycin, 1 μM.  
The actin cytoskeleton meshwork acts as one of the major organizer of the plasma membrane 
compartmentalization. Therefore, we would expect that the disruption of the cytoskeleton would 
interfere with the organization of the plasma membrane, reflected in a change of the lifetime of C6-
NBD-PC. To investigate the involvement of the cytoskeleton in the microdomain organization of 
plasma membrane, HeLa cells were treated with cytochalasin D (cyt D) before measuring lifetime of 
C6-NBD-PC. This drug is a mycotoxin that binds to actin microfilaments with high affinity and 
alters its polymerization [227]. The effect of actin depolymerization on the lateral properties of the 
cell membrane and on clustering of proteins has been well documented in literature (see [228] for a 
review). 
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In HeLa cells, a decrease in τP upon cytochalasin D treatment was measured (p<0.005, unpaired two-
tailed t test, Fig. 17B). Suitable experimental conditions were first set up to avoid changes in cell 
morphology and cell viability. HeLa cells appeared quite sensitive to cytochalasin D treatment: after 
30 min of incubation at 37ºC with low drug concentration (1 μM), the majority of cells appeared to 
be inviable under the microscope (not shown). Cell viability was maintained with a short treatment 
(10 min at 37ºC) and a low drug concentration (0.4 μM). Rhodamine-conjugated phalloidin was used 
to visualize actin filaments within the cells [229], as shown in Fig. 17A. Under the conditions used, 
a rearrangement of the actin microfilaments could be observed. 
 
Fig. 17: Influence of cytochalasin D and sphingomyelinase treatment on C6-NBD-PC lifetime. (A) 
Staining of the actin microfilaments was performed with rhodamine phalloidin. After cytochalasin D (cyt D) 
treatment, disruption of actin filaments occurs.  The cell nucleus is counterstained with DAPI (blue). (B) Effect 
of cytochalasin D and sphingomyelinase treatment on the fluorescence lifetime of C6-NBD-PC is depicted. 
Data are presented as mean ± SEM (control and cytochalasin D: n=12, SMase: n=23). For p values (*), see 
text. Measurements were performed at 25°C. 
A similar scenario appeared upon sphingomyelinase (SMase) treatment, which decreases the 
membrane content of sphingomyelin generating phosphocholine and ceramide. Ceramide has 
recently been shown to displace cholesterol from sphingomyelin-cholesterol domains as well as to 
induce strong alterations of the lateral organization in model [230] and cellular membranes [231]. 
Indeed, in comparison to control cells, a shorter lifetime was measured in the plasma membrane of 
SMase-treated cells (p<0.0001, unpaired two-tailed t test, Fig. 17B). 
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4.2 Influence of ABCA1 on the lipid microenvironment at the 
plasma membrane 
4.2.1 Impact of ABCA1 on the plasma membrane lateral 
organization 
The ABCA1 transporter is a key controller of cellular lipid handling. The loss of its function in 
humans leads to the development of Tangier disease, a familial HDL deficiency [232]. ABCA1 is 
required for lipid effluxes from the cell membrane to plasmatic acceptors such as ApoA-I. This is the 
starting and rate-limiting step in the formation of HDL particles. However, how the ABCA1-
dependent lipid loading takes place and how this is related to cholesterol removal is still unclear (see 
introduction, section 1.3).  
Previous work has evidenced that the expression of ABCA1, or its loss, modifies the distribution of 
anionic phospholipids between the two leaflets of the plasma membrane [149,170,178,183]. These 
studies pointed out that lipidation of apolipoproteins requires not only the presence of ABCA1, but 
also specific ABCA1-dependent modifications of the lipid arrangement in the exoplasmic leaflet. 
Recently, several studies have investigated the relationship between ABCA1 and membrane 
microdomains, although controversies remain as to whether these structures are involved in lipid 
efflux to ApoA-I. It has been suggested that the ATPase activity of ABCA1 is responsible for the 
generation of loosely packed domains that facilitate ApoA-I-dependent cholesterol efflux [187]. 
Similar alterations were also observed in primary macrophages isolated from abca1 transgenic mice 
[188]. 
In the attempt to further clarify the issue, we have used the sensitivity of fluorescence lifetime of 
NBD lipid analogues to assess the impact of ABCA1 on the lipid architecture at the plasma 
membrane. The data of the following sections are published in [233]. 
4.2.1.1  ABCA1 expression in HeLa cells 
To characterize the influence of ABCA1 on the physicochemical properties of the plasma membrane, 
we made use of HeLa cells transiently or stably transfected with ABCA1 or ABCA1MM. These cells 
do not express endogenous ABCA1, as shown previously [149] and verified by immunoblotting. 
Mock-transfected cells were used as a control in each experiment. ABCA1MM is a non-functional 
mutant of ABCA1, which bears a methionine (M) substitution for lysine (K) in the Walker A motif of 
both nucleotide binding folds (K939M and K1952M). These mutations impair the function of the 
transporter by abolishing binding and hydrolysis of ATP, without altering its folding or its 
intracellular routing [128,149,178,234]. The wild type and mutant transporters were expressed as 
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chimeras with fluorescent proteins (EGFP, EYFP or ECFP) attached as a C-terminal tailpiece. This 
approach was shown not to interfere with the original activity of the protein [152,178]. 
In HeLa cells, ABCA1-EGFP localizes in the plasma membrane as well as in intracellular 
compartments corresponding to the Golgi apparatus and endolysosomal vesicles, as previously 
shown [149] (Fig. 18A). The mutations in ABCA1 Walker A motifs do not hamper its subcellular 
localization. Cells expressing either the wild type or mutant protein show comparable levels of 
protein expression at the plasma membrane, evaluated by the quantification of the EGFP 
fluorescence intensity (Fig. 18B). 
 
Fig. 18: Subcellular localization of ABCA1 and ABCA1MM in HeLa cells. Confocal microscopy images of 
cells expressing ABCA1-EGFP or ABCA1MM-EGFP chimera. ABCA1MM bears lysine/methionine 
substitutions in both nucleotide binding domains. Both proteins localize to the plasma membrane and 
intracellular compartments corresponding to the Golgi apparatus and endolysosomal vesicles [149] (A). Cells 
expressing either the wild type or mutant protein show comparable level of protein expression at the plasma 
membrane (B), assessed as EGFP fluorescence intensity. Bars indicate mean and SEM values of 24 cells. 
 
4.2.1.2 ABCA1 activity affects the physicochemical properties of the cell 
surface 
To analyze the impact of ABCA1 on the physical properties of the outer membrane leaflet, HeLa 
cells expressing an intact or mutant ABCA1 transporter were incubated with a C6-NBD-PC solution, 
as previously described. Subsequently, fluorescence decay curves of the analogues located in the 
plasma membrane were measured. Upon expression of ABCA1, a shift of τP towards longer values 
was measured in comparison to non-transfected HeLa cells or cells expressing ABCA1MM 
(p<0.0001, unpaired two-tailed t test, Fig. 19 and Table 9). In addition, an increase in the width of 
the distribution of NBD lifetimes was observed in ABCA1-containing plasma membrane, which 
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suggests a higher heterogeneity in the microenvironment of the probe (Fig. 19). A broader 
distribution was also assessed in the presence of ABCA1MM, which likely derives from 
overexpression of the protein itself. Indeed, the presence of membrane proteins in lipid bilayers was 
shown to broaden fluorescence lifetime distribution [235,236]. A similar scenario was found for C6-
NBD-LacCer, with lifetimes shifted to longer values (Table 9).  
 
Fig. 19: ABCA1 influence on C6-NBD-PC fluorescence lifetime. Histograms of the lifetime component τP 
of C6-NBD-PC in the plasma membrane of untransfected HeLa cells and cells expressing the wild type 
ABCA1 or the non-functional mutant ABCA1MM. Histograms were normalized by setting the maximum to 1. 
Means ± SD of the lifetimes calculated as described in the material and method section are reported in Table 9. 
Measurements were performed at 25°C. 
It was previously described that cholesterol depletion from HeLa cells by MβCD caused a decrease 
in the lifetime of C6-NBD-PC. Similarly, also in cells expressing ABCA1 and ABCA1MM 
extraction of cholesterol led to a shift of the lifetime distribution towards lower values. In addition, 
this treatment abolished the difference detected before in the presence of the active transporter 
(Table 9). 
Table 9: Fluorescence lifetime of C6-NBD-PC and C6-NBD-LacCer in the presence of ABCA1 or 
ABCA1MM. Upon expression of ABCA1, a shift of τP towards longer values was detected (p<0.0001 for both 
lipid analogues, unpaired two-tailed t test). For completeness, the short component τ1 is also shown. For values 
corresponding to the plasma membrane of untransfected HeLa cells, see Table 8. Untransfected cells and cells 
expressing ABCA1MM display similar values. Data are shown as mean ± SD. In brackets, the number of cells 
analyzed is indicated. Measurements were performed at 25°C. 
 NBD lifetime 
 ABCA1 ABCA1MM 
 τ1  ns τP  ns τ1  ns τP  ns 
C6-NBD-PC 2.9 ± 0.3 12.4 ± 0.3 (38) 2.7  ± 0.2 11.5 ± 0.3 (49) 
C6-NBD-PC (MβCD) 2.9 ± 0.4 11.6 ± 0.2 (25) 2.7  ± 0.2 11.6 ± 0.2 (25) 
C6-NBD-LacCer 3.0 ± 0.3 12.9 ± 0.2 (35) 3.1  ± 0.3 12.2 ± 0.2 (38) 
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Since the ABCA1-specific increase in the NBD lifetime was sensitive to depletion of cholesterol by 
MβCD treatment, we investigated whether removal of cholesterol by ApoA-I could, as well, 
influence the properties of the plasma membrane. To this aim, cells were incubated with 10 μg/ml 
ApoA-I for 16 h prior to the labelling procedure. As illustrated in Fig. 20, this treatment did not 
influence the lifetime behavior of C6-NBD analogues. This could be due to the lower amount of 
cholesterol extracted by ApoA-I in comparison to the efflux to MβCD (see section 4.3.1.3). More 
likely, the long time-span of the experiment allows the cells to restore the initial conditions through 
the cellular processes involved in the transport of cholesterol to the plasma membrane. Experiments 
showing the extent of cholesterol efflux to ApoA-I are described in section 4.3.1.3. 
To investigate the influence of the expression of a different transmembrane protein linked to the GFP 
to the physical properties of the plasma membrane, assessed by C6-NBD-PC, HeLa cells were 
transiently transfected with the influenza viral protein hemagglutinin tagged with the Cerulean 
fluorescent protein (HA-Cer). This protein localizes into lipid rafts at the plasma membrane (Engel 
et al., unpublished data). No difference in NBD lifetime was observed in the plasma membrane of 
HA-Cer expressing cells and mock-transfected cells (Fig. 20, p>0.1). 
 
Fig. 20: Fluorescence lifetime of NBD in absence or presence of ApoA-I and upon expression of HA or 
ABCA7. Cells were labelled with C6-NBD-PC or C6-NBD-LacCer and lifetime values normalized to the 
value measured in the plasma membrane of HeLa cells. A1MM: ABCA1MM; A1: ABCA1, HA: 
hemagglutinin, A7: ABCA7. Data are normalized to NBD lifetime measured in the plasma membrane of 
untransfected HeLa cells and shown as mean ± SEM (n > 10). *: p<0.05, unpaired two-tailed t test. 
Measurements were performed at 25°C. 
Among the different mechanisms proposed for the ABCA1-mediated lipid efflux to ApoA-I, it has 
been suggested that ApoA-I could either bind directly to ABCA1 or indirectly to a “lipid site” 
created by its activity (see introduction, chapter 1.3.3.2). ABCA7 was also shown to be able to bind 
ApoA-I and to mediate efflux of phospholipids to this acceptor, although efflux of cholesterol is still 
controversial. In contrast to ABCA1, ABCA7 does not mediate formation of HDL particles in vivo. 
As a relationship between formation of lipid domains and efflux of phospholipids and cholesterol to 
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ApoA-I has been suggested, it was of interest to investigate whether ABCA7 is also able to perturb 
the plasma membrane micro-organization. Therefore, cells were transfected with ABCA7-YFP and 
fluorescence lifetime of C6-NBD-PC was measured. As shown in Fig. 20, expression of ABCA7-
YFP at the plasma membrane did not induce any significant change in the lifetime of NBD. 
Taken together, these results prove the influence of ABCA1 on the micro-organization of the plasma 
membrane. Conversely, no effect was detected upon expression of the functional mutant 
ABCA1MM or of ABCA7. Based on the data obtained from GUVs and GPMVs, the longer lifetime 
measured at the plasma membrane in the presence of the wild type ABCA1 indicates that the C6-
NBD probes are sensing a more packed lipid environment. 
4.2.1.3 Efflux of cholesterol to MβCD and ApoA-I 
In parallel to the FLIM measurements, cholesterol extractability by MβCD and by ApoA-I was 
measured after labelling of the cellular cholesterol pool with [3H]-cholesterol. 
Under the experimental conditions used (5 mM MβCD for 1 min on ice), MβCD extracted 19.8% ± 
0.8 (mean ± SEM, n=3) of the total cell [3H]-cholesterol from HeLa cells. This value may be 
overestimated due to the relative high signal background in the presence of MβCD; it was therefore 
decided to present the data as ratio to efflux in non-transfected HeLa cells. An increase in MβCD-
extractable cholesterol was found for ABCA1 expressing cells (Fig. 21A). A higher amount of [3H]-
cholesterol in the medium was also measured from cells expressing ABCA1MM. This effect may be 
due to non-specific disturbances on the plasma membrane by overexpression of the protein, 
potentially related to the presence of its twelve transmembrane domains. In parallel, for each 
experiment the percentage of cells expressing the protein was analyzed at the cytofluorimeter, by 
monitoring GFP fluorescence intensity. This revealed that ABCA1-GFP expressing cells were ~ 
30%, whereas ~ 54% of the cells expressed ABCA1MM-GFP. When values were normalized to 
protein expression, a 5-fold increase in cholesterol efflux to MβCD could be measured in ABCA1- 
versus ABCA1MM- expressing cells. 
Similarly, efflux of [3H]-cholesterol to ApoA-I was analyzed (Fig. 21B). To this aim, cells were 
incubated with 10 μg/ml of ApoA-I for 16 h. We found that ABCA1 expression induced more than 
2-fold increase in cholesterol efflux compared to untransfected and ABCA1MM expressing HeLa 
cells (2.5% ± 0.6 and 2.2% ± 0.2 of total [3H]-cholesterol was extracted by ApoA-I from HeLa and 
ABCA1MM-expressing cells, respectively, and 6.2% ± 0.6 from ABCA1-expressing cells).  
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Fig. 21: Efflux of [3H]-cholesterol to MβCD (A) and ApoA-I (B). ABCA1 promotes cellular release of [3H]-
cholesterol to both MβCD and ApoA-I. See text for detailed explanation. Data are presented as mean ± SEM 
of 3 (MβCD) and 2 (ApoA-I) independent experiments. Data are normalized to the efflux measured in HeLa 
cells incubated with the indicated acceptors. *: p<0.05, unpaired two-tailed t test. A1: ABCA1; A1MM: 
ABCA1MM. 
Interestingly, ABCA1 expression alone was sufficient to induce a larger cholesterol efflux over 
untransfected and ABCA1MM expressing cells in the absence of ApoA-I. This basal cholesterol 
efflux was approximately 30% of the total efflux when ApoA-I was present. Very recently, similar 
results were reported by Nandi et al. [191]. 
4.2.1.4 C6-NBD-PC lifetime in condensed membranes: activated Jurkat 
cells 
To explore the possibility that enhanced lifetime measured in ABCA1-expressing plasma membranes 
was associated with formation of condensed, raft-like domains, we analyzed C6-NBD-PC lifetime in 
the plasma membrane of Jurkat cells after activation of the T cell receptor (TCR) via anti-CD3 
antibodies. This treatment has been shown to trigger formation of condensed membrane domains at 
the activation sites, as assessed by the fluorescent probes Laurdan [237] and PMI-COOH [37]. Cells 
were incubated with OKT3 antibodies which were, in turn, cross-linked with a fluorescently labelled 
secondary antibody before staining with C6-NBD-PC. The analysis of fluorescence lifetime at the 
plasma membrane revealed a shortening of τP in activated Jurkat cells as compared to untreated cells 
(Fig. 22). In a second approach, Jurkat cells were incubated with sphingomyelinase to induce 
hydrolysis of SM and production of ceramide, a process also described to be involved in the natural 
activation sequence of these cells [238]. Again, a decreased NBD lifetime was observed for the 
longer component τP (Fig. 22). No visible domains were detected both upon OKT3 antibody 
activation or sphingomyelinase treatment. In some cells, regions in which the NBD probe became 
enriched were observed. However, lifetime analysis revealed that these regions were characterized 
by a shorter τP in comparison to the rest of the plasma membrane, probably due to self-quenching of 
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the probe, and were therefore excluded from the analysis. Experiments with Jurkat cells were 
performed in collaboration with Dr. Martin Stöckl. 
 
Fig. 22: Fluorescence lifetime of C6-NBD-PC in Jurkat cells. (A) Fluorescence lifetime images of Jurkat 
cells (2x2 pixels binned). The average lifetime is shown as pseudocolor, according to the scale. Bars 
correspond to 10 μm. Regions in which C6-NBD-PC is enriched (arrows) were excluded from the analysis (see 
text). (I): untreated cells (control); (II): activated cells; (III): cells after sphingomyelinase treatment. (B) 
Analysis of τp in the plasma membrane of Jurkat cells. Cells activated by treatment with OKT3 antibodies 
cross-linked by secondary antibodies display shorter lifetime as compared to non treated cells (control). 
Sphingomyelinase treatment (SMase) also induced a decrease in τP (p<0.0001 for both treatments). Mean ± 
SEM are indicated in the graph (23 cells per sample analyzed). Measurements were performed at 25°C. 
It was previously concluded that, in the presence of ABCA1, the NBD lipid analogues sense a more 
packed lipid environment. However, based on the observation that condensation of lipid domains 
rather provokes a decrease in the lifetime, we could exclude that the increment in lifetime observed 
upon expression of ABCA1 originated from condensation of lipid domains. 
Considering the correlation between lifetime and cholesterol content [209], this increment should 
reflect an increase in the cholesterol content in the compartments where the probes are enriched. 
Therefore, to gain further information about the spatial distribution of the C6-NBD-PC, its lateral 
mobility in the plasma membrane of HeLa cells was measured by Fluorescence Recovery After 
Photobleaching (FRAP).   
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4.2.1.5 Lateral mobility of C6-NBD-PC 
FRAP is one of the non-invasive methods of choice to study lateral mobility and dynamics of lipids 
in living cells [239,240]. With this technique, fluorescent molecules in a small region of the cells are 
irreversibly photobleached using a high-powered laser beam. The subsequent movement of the 
surrounding non-bleached fluorescent molecules into the photobleached area is then recorded at low 
laser power. The diffusion mobility of lipids is recognized to be in close relationship with membrane 
viscosity and membrane cholesterol content [241]. Moreover, diffusion of membrane proteins and 
lipids is influenced by the lipid environment in which they are embedded. In model membranes, 
mobility of lipid analogues was shown to be reduced in the Lo phase in comparison to the Ld phase 
[7,242,243], reflecting the higher cholesterol content in the Lo phase. 
In the previous chapter, it was proposed that C6-NBD-PC is embedded in a more viscous, 
cholesterol-enriched environment at the plasma membrane in the presence of ABCA1. In this case, a 
reduction in the mobility of the lipid analogue has to be expected. Therefore, the diffusion 
coefficient of C6-NBD-PC, under the same conditions used for FLIM experiments, was determined 
by FRAP. 
Measurements were performed in the apical membrane of cells, to avoid the high background 
fluorescence present when focusing on the basal membrane. To minimize the influence of membrane 
trafficking events, experiments were performed at 25°C. Typical FRAP recovery curves for ABCA1-
and ABCA1MM-expressing cells are shown in Fig 23. During the acquisition of the recovery signal, 
no decrease of the fluorescence intensity due to repeated bleaching occurred under the conditions 
used (Fig. 23, inset). From the recovery curves, the diffusion coefficient (D) and the mobile fraction 
(Mf) can be calculated as explained in section 3.2.3.6. D is a measure of the rate of movement of the 
fluorescent molecules, while Mf represents the fraction of fluorescent molecules that can diffuse into 
the bleached region during the time course of the experiment. 
C6-NBD-PC in the plasma membrane of HeLa cells shows a D value in the order of 0.1 μm2/s. This 
value is in agreement with diffusion coefficients previously reported for NBD lipid analogues in the 
plasma membrane of mammalian cells [240,244,245]. In the presence of an active ABCA1, a slower 
diffusion was observed in comparison to both ABCA1MM-expressing cells and non-transfected 
HeLa cells (p<0.0001, unpaired two-tailed t test; D = 0.033 ± 0.002 μm2/s for ABCA1-expressing 
cells and D = 0.080 ± 0.007 μm2/s for ABCA1MM-expressing cells, Table 10). 
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Fig. 23: Representative fluorescence recovery curves of C6-NBD-PC in the plasma membrane of HeLa cells 
transiently transfected with ABCA1 or ABCA1MM. Experimental conditions were optimized to ensure that no 
bleaching of the probe occurred during measurement of the fluorescence recovery (inset). The lipid analogue 
shows slower diffusion in the presence of an active ABCA1. Recovery curves from non-transfected HeLa cells 
were similar to those of cells expressing ABCA1MM (not shown, see Table 10 for diffusion coefficients and 
mobile fraction). Measurements were performed at 25°C. 
Table 10: Diffusion parameters of C6-NBD-PC in the plasma membrane of HeLa cells expressing the 
indicated proteins. D: diffusion coefficient, Mf: mobile fraction. Mean values ± SEM are indicated. 
Measurements were performed at 25°C. p(HeLa vs MβCD)<0.01; p(ABCA1 vs ABCA1MM)<0.0001; 
p(ABCA1 vs HeLa)<0.0001; p(HeLa vs ABCA1MM)>0.05, unpaired two-tailed t test. In brackets, number of 
cells analyzed. 
Protein expressed D Mf 
 μm2/s % 
- 0.102 ± 0.009 (14) 85 ± 3 
ABCA1 0.033 ± 0.002 (16) 57 ± 5 
ABCA1MM 0.080 ± 0.007 (13) 83 ± 3 
- (MβCD) 0.162 ± 0.018 (11) 77 ± 4 
 
The slower diffusion in the presence of an active ABCA1 is consistent with the enhanced packing 
sensed by C6-NBD-PC, as assessed by FLIM. Indeed, depletion of about 20% of the total cell 
cholesterol with MβCD from the cells resulted in an increase of the diffusion coefficient of C6-
NBD-PC of 1.6-fold (Table 10), [239,246] because of decreasing lipid packing order of the 
membrane [10]. 
In the presence of ABCA1, a lower mobile fraction of the fluorescent molecules was detected, 
indicating that a significant part of NBD molecules were essentially immobile in the cell membrane. 
This could indicate that a fraction of the fluorescence molecules could be bound to a fixed substrate. 
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Alternatively, discontinuities within the structures where the molecules localize may also be 
responsible for the reduced mobile fraction [247].  
4.2.2 ABCA1 partitioning in GPMVs 
GPMVs obtained by blebbing of the plasma membrane display large, visible Ld- and Lo-like 
domains at temperatures ≤ 25°C and can be used to characterize the phase preference of lipids and 
proteins [17,18]. In these vesicles, protein partition can be studied in their natural lipid environment 
and can be directly visualized by optical microscopy, by analyzing those vesicles that show phase 
coexistence and that contain the protein of interest conveniently labelled. 
GPMVs were generated from HeLa cells. First, to evaluate the phase preference of membrane 
proteins in general, cells were labelled with concanavalin A-Texas Red (ConA) prior to formation of 
blebs. This protein binds to α-methyl mannoside-containing glycoproteins and glycolipids on the cell 
surface (Fig. 24, image on the left). 
 
Fig. 24: Phase preference of concanavalin A-Texas Red labelled glycoproteins and glycolipids in 
GPMVs. Upon incubation of HeLa cells with concanavalin A-Texas Red as described in 2.2.4.2, mainly the 
plasma membrane is labelled. Concanavalin A-Texas Red labelled glycoproteins and glycolipids show 
enrichment in the Ld-like phase, as determined by complementary partitioning with C6-NBD-PC, previously 
shown to be slightly enriched in the Lo-like phase. Bars correspond to 10 μm. Imaging was performed at 25°C. 
As shown in Fig. 24, at 25°C ConA-labelled glycoproteins and glycolipids show a marked 
enrichment in the Ld-like phase, as determined by complementary partitioning with C6-NBD-PC. 
ConA receptor proteins that segregate in the blebbing vesicles represent a substantial fraction of the 
ConA binding sites on the cell surface, as estimated by comparison of their fluorescence intensity in 
cell-attached GPMVs (not shown and [17]). Similar results were obtained at 10°C. 
Unspecific labelling of different types of proteins can be also obtained with N-hydroxysuccinimide 
esters of biotin. These reagents react with primary amino groups of proteins and are commonly used 
for the labelling of the cell surface [248], in combination with fluorophore-conjugated streptavidin. 
However, we found that this treatment, although efficiently labelling the cell surface of cells (not 
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shown), dramatically decreased the yield of vesicles obtained, most likely because of the cross 
linking of proteins induced by streptavidin [249]. 
The approach of GPMVs was subsequently utilized to determine the phase preference of ABCA1 
and ABCA1MM between coexisting membrane phases. Indeed, intensive investigations have been 
performed to study the relationship between ABCA1 and membrane lipid phases. In initial studies, 
Drobnik et al. showed that ABCA1 is partially localized in Lubrol WX but not in Triton-X 100 
resistant membranes in monocyte-derived macrophages [250]. ABCA1 was also detected in Brij 98 
resistant membranes (A. Zarubica, unpublished data) and in the light density fractions of membranes 
isolated with a detergent-free method (section 4.2.3.1, to follow). Comparison of the partitioning of 
the non-functional mutant ABCA1MM revealed that the latter is enriched in the low density 
fractions. However, until present no study in laterally intact cellular bilayer has been performed. 
GPMVs were formed from HeLa cells expressing ABCA1 or ABCA1MM fused with the EGFP or 
ECFP at the C-terminal and from non-transfected cells. At 25°C, more than 50% of the vesicles 
exhibit phase separation as indicated by selective enrichment of R18. As shown in Fig. 25A, in 
vesicles with coexisting phases both ABCA1 and ABCA1MM were almost exclusively present in 
the Ld-like phase, colabelled with R18. This is in agreement with the partitioning of most 
transmembrane proteins, which are found to be preferentially excluded from Lo phases in model 
membranes [217,251]. 
Interestingly, a larger Ld-like phase at 25°C was observed in GPMVs prepared from ABCA1-
expressing cells, in comparison with both non-transfected cells (HeLa) and ABCA1MM-expressing 
cells (Fig. 25, A and B). Typically, 1-3 domains per vesicles were found. The frequency distribution 
of the relative extent of the Ld-like phase calculated as described in 3.2.4.2 is shown in B.  
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Fig. 25: ABCA1 partitions into the Ld-like phase in GPMVs and modulates its size. GPMVs were 
prepared from mock transfected HeLa cells (mock) and cells expressing ABCA1 and ABCA1MM tagged with 
EGFP (A). Both proteins are almost exclusively present in the Ld-like phase, identified by co-staining with 
R18. Images were taken at the equatorial plane of the vesicles at 25ºC. Bars correspond to 5 μm. (B) 
Histograms showing the distribution of the relative size of the Ld-like phase in the corresponding samples. In 
the presence of ABCA1, a shift of the distribution to higher values was observed (p<0.001, unpaired two-tailed 
t test). Means ± SEM are indicated in the top left corner. In brackets: number of domains analyzed. Typically, 
1-3 domains per vesicle were found.  
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4.2.3 Fractionation of the plasma membrane 
4.2.3.1 Raft partitioning and ABCA1 activity 
To complement and confirm the biophysical measurements with more widely used biochemical 
approaches, we analyzed the partitioning behavior of ABCA1 in membrane domains isolated 
according to the detergent-free method developed by Macdonald and Pike [197]. Traditional 
biochemical approaches to isolate lipid rafts made use of detergents, classically the non-ionic Triton 
X-100, to extract the whole cells followed by separation of the low-density, detergent resistant 
membrane fractions on density gradients. However, several observations pointed out that this 
procedure does not reflect the original situation in intact membranes [27,252]. A number of other 
methods that do not require the use of detergent have been developed [253,254]. The procedure we 
used is based on floatation on OptiPrep density gradients and allows obtaining good yield of a 
membrane fraction enriched in cholesterol and protein markers of lipid rafts. 
The approach was first validated on non-transfected HeLa cells (Fig. 26A). Fractions corresponding 
to the plasma membrane (1 to 6) were defined based on the enrichment of plasma membrane marker 
proteins and devoid of contamination from the Golgi or ER compartments, indicated from β-COP 
and calnexin (CNX), respectively. 
 
Fig. 26: Detergent-free membrane fractionation. Fractions are numbered from the top to the bottom of the 
gradient. Data shown in the panels are representative of at least three independent experiments. TfR: 
transferrin receptor, FL: flotillin; CNX: calnexin; PM: plasma membrane. Figures are kindly provided by Ana 
Zarubica, Marseille, France. B) and C). ABCA1MM is enriched in the first three fractions as compared with 
ABCA1 FL distribution was not influenced by the presence of either the wild type or the non-functional 
ABCA1, whereas an altered partitioning of TfR was evidenced in the presence of ABCA1. 
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Raft fractions were identified as the first three fractions, based on the enrichment of the 
transmembrane protein flotillin (FL) [197,255]. Non-raft fractions were identified by the enrichment 
of transferrin receptor (TfR), a marker for non-raft plasma membrane [197]. 
ABCA1 was recovered in fractions corresponding to the plasma membrane (Fig. 26B), Golgi 
apparatus and endo-lysosomal vesicles, witnessed by the enrichment in β-COP and LAMP 2, 
respectively (not shown). This distribution is in agreement with the subcellular localization of the 
protein in living cells (section 4.2.1.1). Interestingly, a minor but consistent fraction of the 
transporter partitioned in the lighter fractions of the plasma membrane. 
As shown in Fig. 26, B and C, an altered partitioning of ABCA1MM versus the wild type protein 
was detected in the plasma membrane fractions. Quantitative assessment was performed by 
densitometry analysis of the hybridization signals in the first three fractions as compared to the total 
signal at the membrane. This revealed that while 32.5% ± 6.2 (mean ± SEM, n=4) of the total 
ABCA1 at the membrane partitions in fractions 1 to 3, 65.2% ± 5.1 (n=3) of ABCA1MM showed 
similar floatation characteristics (p<0.05, unpaired two-tailed t test, Table 11). To assess whether the 
ABCA1-mediated modulation of the plasma membrane properties affected the organization of other 
membrane proteins, in the same preparation the partitioning of TfR and FL was analyzed. FL 
distribution was not influenced by the presence of either the wild type or the non-functional ABCA1, 
whereas an altered partitioning of TfR (Fig. 26, B and C) was evidenced in the presence of ABCA1 
(p<0.05, unpaired two-tailed t test). 
We then investigated the correlation between the partitioning in membrane domains and the surface 
phenotypes elicited by the expression of ABCA1, i.e. the binding of ApoA-I and Annexin V. These 
two events are both prerequisites for the efflux of cellular phospholipids and cholesterol to ApoA-I 
[178,183]. We took advantage of two ABCA1-related molecules, CED-7 and HA819, which show 
different patterns of phenotypes in comparison to ABCA1. CED-7 is an ABC transporter of the A 
class, functional ortholog of ABCA1 in C. elegans [168], whereas HA819 is a previously described 
gain-of-function variant of the transporter [183]. When expressed in HeLa cells, ABCA1, CED-7 
and the HA819 variant elicited binding of Annexin V to similar values, while the binding of ApoA-I 
varied broadly (Table 11). CED-7 failed to elicit any binding or significant efflux of lipids while 
HA819 was more efficient than native ABCA1 in inducing both binding and efflux [183].  
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Table 11: Functional parameters of ABCA1 and related transporters in comparison to raft partitioning. The 
ability to bind ApoA-I or Annexin V and to efflux phospholipids (PL) was assessed on HeLa cells expressing 
ABCA1, ABCA1MM, HA 819 or CED-7 [183]. Values are expressed as percent of the binding/efflux observed 
upon expression of the active ABCA1 transporter. The percent of partitioning in raft was assessed by 
densitometry of gradient fractions resolved by SDS-PAGE and analyzed for the content of the transporters. 
Means ± SEM are indicated. In brackets: number of individual experiments. These experiments were done in 
collaboration with A. Zarubica and Dr. G. Chimini, CIML, Marseille, France. 
 Apo-AI binding 
Annexin V 
binding PL efflux 
Raft 
partitioning 
 % of ABCA1 % of ABCA1 % of ABCA1 % 
ABCA1 100 100 100 32.5 ± 6.3 (4) 
ABCA1MM 13 ± 5 (5) 10 ± 2 (4) 10 ± 3 (3) 65.2 ± 5.1 (3) 
HA 819 151 ± 11 (7) 109 ± 31 (4) 113 ± 24 (4) 35.8 ± 1.8 (2) 
CED-7 20 ± 3 (3) 102 ± 14 (3) 31 ± 7 (5) 33.9 ± 1.2 (2) 
 
The biochemical analysis of partitioning evidenced that the three molecules - ABCA1, CED-7 and 
the HA819 mutant - floated similarly (Table 11). This excludes a causal link between the induction 
of ApoA-I binding or cholesterol effluxes and membrane partitioning. Rather, the partitioning in 
lighter fractions correlates with the binding of Annexin V, indicative of the exposure of PS on the 
cell surface. Therefore, the destabilization of the membrane lipid microenvironment may be a direct 
consequence of the ABCA1-dependent PS redistribution, and upstream to the final efflux of 
membrane cholesterol. 
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4.2.3.2 Lipid composition of plasma membrane fractions 
To ascertain more precisely the organization of membrane cholesterol under the influence of 
ABCA1, we analyzed the lipid composition of the membrane fractions isolated from cells expressing 
ABCA1 or ABCA1MM. Cholesterol content in the plasma membrane fractions was similar, in the 
presence of either the active or the non-functional mutant transporter (nmol cholesterol/mg of 
proteins loaded onto the gradient, mean ± SEM: 5.1 ± 1.3 and 6.2 ± 2.3 for A1 and A1MM (n=3), 
respectively). Likewise, its distribution across the fractions corresponding to the plasma membrane 
was similar (Fig. 27A). As expected, cholesterol was more than ~3-fold enriched in the raft 
fractions. 
To exclude the possibility that cholesterol may be sequestered in some intracellular compartments in 
ABCA1-expressing cells, we performed cell fractionation to characterize its distribution after 
labelling the cellular pools with [3H]-cholesterol, as described in 3.2.2.5 [187] (Fig. 27B). This 
procedure allows to separate cytosolic fractions, found at low density and witnessed by the presence 
of heat shock protein 70 (Hsp70), from fractions corresponding to the plasma membrane, that follow 
(indicated by enrichment of caveolin, here highlighted by the grey rectangle) and from the ER, 
witnessed by enrichment in calreticulin (not shown). No major differences in the three cell types 
were found. This supports the conclusion, previously drawn [177], that ABCA1, while not affecting 
the membrane cholesterol content, induces its redistribution into pools readily accessible to external 
acceptors. 
 
Fig. 27: Cholesterol distribution in fractions obtained after OptiPrep (A) and sucrose gradient (B) 
fractionation. (A) Percent distribution of cholesterol across fractions 1 to 6 (mean ± SEM), corresponding to 
the plasma membrane, collected in 3 independent detergent-free gradients prepared from bulk cell cultures. (B) 
[3H]-cholesterol subcellular distribution analyzed by cell fractionation. Each fraction (1 to 12, see 2.2.2.5 for 
further details) was analyzed for [3H] counts and marker proteins for cytosol (Hsp70), plasma membrane 
(caveolin) and ER (calreticulin) (not shown). Data were normalized to the density of the fractions to correct for 
variations between gradients made in different experiments. The grey rectangle highlights the cholesterol peak 
corresponding to the plasma membrane fractions. Error bars are SEM of two independent experiments. 
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In the attempt to identify the differences between the isolated fractions and to find a rationale for the 
differential partitioning of ABCA1 and ABCA1MM, we have analyzed the fractions corresponding 
to the plasma membrane (1 to 6) with MALDI-TOF (matrix assisted laser desorption ionization - 
time of flight) mass spectrometry after extraction of the lipids. This technique has, among others, the 
advantage of giving excellent reproducibility because the analytes and the matrix compound, both 
readily soluble in organic solvents, can form high homogeneous crystals between them [256]. To 
meet the requirement of sufficient amount of lipids, bulk cultures of HeLa cells (25 x 106) were 
transfected with ABCA1 or ABCA1MM and subjected to membrane fractionation. The low amount 
of lipids present in the fractions (1-6 nmol) convinced us to avoid the use of an internal standard 
when analyzing the samples. This, although useful to quantify the absolute amount of the different 
lipids identified, would have increased the probability of suppressing signals originating from those 
lipid species present in low amounts. 
In Fig. 28 representative positive (pos) and negative (neg) ion MALDI-TOF mass spectra of 
fractions 1 to 6 of ABCA1 and ABCA1MM are presented. In the positive ion spectra (left side), the 
most abundant species, PC 16:0 18:1, is highlighted (m/z = 760.6 for the H+ and 782.6 for the Na+ 
adduct). This lipid species represents more than 50% of the total positive phospholipids. In the 
negative ion spectra, several peaks corresponding to negatively charged PL can be distinguished. 
Besides of the presence of the peaks associated with the DHB matrix (m/z = 851 and 857), indicated 
with an asterisk, the main lipid peaks correspond to PS 18:0 18:1 (m/z = 788.5), PI 18:0 18:1 (m/z = 
863.6) and PI 18:0 20:4 (m/z = 885.6). The assignments of the most intense peaks are indicated in 
Table 6 in section 3.2.4.6.  
In the case of the fractions prepared from ABCA1-expressing cells, in the positive ion mode lipids 
are mainly found in the fractions 3 to 6, whereas negative lipids were mainly enriched in fractions 5 
and 6. Conversely, in fractions isolated from ABCA1MM-expressing cells, lipids were similarly 
detected in raft (1 to 3) and non-raft (4 to 6) fractions. The presence of negatively charged lipids in 
lipid rafts was already reported by other groups [257,258].  
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Fig. 28: Positive and negative ion MALDI-TOF mass spectra of plasma membrane fractions. Lipids in 
fractions 1 to 6, isolated with a subcellular membrane fractionation procedure and corresponding to the plasma 
membrane, were extracted and analyzed. All spectra were recorded using DHB as matrix. Assignments of the 
most intense peaks are indicated in Table 6. 
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In order to plot also the minor lipid species present in the samples and to compare the raft and non-
raft fractions isolated from ABCA1- and ABCA1MM-expressing cells, the intensity signals of the 
peaks in fractions 1 to 3 and 4 to 6 were summed up. Data are presented in Fig. 29. 
 
Fig. 29: Distribution of lipids in fractions 1-3 (raft) and 4-6 (non-raft). The intensities of the different lipid 
species shown in Fig. 28 were quantified and values in fractions 1-3 and 4-6 summed up. The major lipid 
species detected in the positive ion mode are shown in A, in the negative ion mode in B. In A, values are 
expressed as mean ± SEM of two independent experiments. 
As already suggested from the raw mass spectra, a ~2-fold depletion in both negative (A) and 
positive (B) lipids is detected in fractions 1-3 isolated from ABCA1-expressing cells. ABCA1MM 
presents, on the contrary, similar amounts of almost all lipid species in the raft and non-raft fractions. 
An exception is SM, being, as expected, enriched in the first fractions. Unfortunately, the spectra of 
negative lipids could not be recorded in an independent experiment, due to the massive amount of 
starting material required. It has to be mentioned that PE species are notoriously difficult to be 
detected by MALDI-TOF mass spectrometry, since this phospholipid is hardly detectable as negative 
ion [203] and is suppressed in the positive ion mode by lipids with quaternary ammonia groups, that 
are more sensibly detected [259]. Moreover, PE possesses an amino group with exchangeable 
protons; this gives rise to a complicated spectrum that presents peaks corresponding to the H+ 
adducts, the Na+ adducts, and to an exchange of one H+ by Na+ [202]. Thin layer chromatography 
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analysis of part of the fractions revealed that PE represented about 40% of the total lipids (not 
shown).  
The larger amount of lipids in the non-raft fractions of ABCA1-containing membranes was not 
specific for any of the lipid species analyzed, but, rather, indicated a general enrichment of material 
in these fractions. This could suggest that the presence of ABCA1 alters the properties of the plasma 
membrane, such as density, which are likely to influence its overall floatation behavior in a density 
gradient. The reduction in the content of lipids in the raft fractions could be an indication of a 
general reduction of the surface area occupied by these lipid domains [260]. On the other hand, we 
found no differential distribution of any particular lipid species analyzed. 
4.2.3.3 Lipid order of plasma membrane fractions 
To gain further insights in the organization of the membranes in the different fractions and to assess 
whether the detected different floatation properties of ABCA1 and ABCA1MM plasma membrane 
could be related to differences in the lipid order of the fractions, we measured the Generalized 
Polarization (GP) of the lipid membranes using the fluorescent probe Laurdan. This molecule detects 
changes in membrane phase properties through its sensitivity to the polarity of the environment in 
the bilayer [206,261,262,263]. 
In artificial membranes, the coexistence of separate phase domains can be distinguished by Laurdan 
fluorescent properties. In Fig. 30, Laurdan steady state excitation and emission spectra at 25°C, 
measured in multilamellar vesicles composed of DOPC, with cholesterol concentrations varying 
from 0 to 40 mol %, are shown. In pure DOPC vesicles, Laurdan fluorescent spectra show a 
maximum at ~ 350 nm and ~ 490 nm for excitation and emission, respectively (Fig. 30A, a). These 
values are typical of the liquid crystalline phase [263]. Addition of cholesterol induces an increase in 
the red excitation band and a blue shift in the emission spectra, with concomitant decrease in the 
intensity at about 490 nm (Fig. 30A, from a to b). Similar results were obtained with POPC vesicles 
(not shown). The red excitation band derives from the stabilization of Laurdan ground state 
conformation Lα, which is stronger in the gel phase because of more favorable orientation of the 
solvent dipole molecules surrounding the probe dipole. The red shift of Laurdan emission spectra in 
the liquid crystalline phase (a) is due to the faster rate of dipolar relaxation processes that can occur 
in comparison to the gel phase.  
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Fig. 30: Laurdan excitation, emission spectra and GP in lipid vesicles. (A) Normalized Laurdan excitation 
and emission spectra in DOPC vesicles at 25°C at different cholesterol concentrations. Cholesterol mol% with 
respect to DOPC is indicated in the legend; raft: DOPC/brain SM/cholesterol 1/1/1. Excitation and emission 
wavelengths were set at 360 nm and 428 nm, respectively. Addition of cholesterol (from a to b) induces an 
increase in the red excitation band and a blue shift in the emission spectra, with concomitant decrease in the 
intensity at 490 nm. (B) GP values of Laurdan calculated from the emission spectra as a function of cholesterol 
concentration. 
The effect of cholesterol is to reduce the relaxation rate of the solvent molecules in the proximity of 
Laurdan dipole, resulting in the characteristic spectra. An additional shift towards shorter emission 
wavelengths is detected in MLVs composed of DOPC/brain SM/cholesterol 1/1/1 (raft), indicating a 
tighter molecular packing. This lipid mixture is known to form coexisting Ld and Lo domains at 
25°C [264]. The shift in the Laurdan emission spectra can be quantified by calculating the GP value, 
according to the formula ( ) ( )482437482437 / IIIIGP +−= . This value theoretically ranges from -1 to 
+1, where -1 indicates a more fluid and +1 a more condensed membrane. The increase of the GP 
value with increasing cholesterol concentration is shown in Fig. 30B.  
Fluorescence excitation and emission spectra of Laurdan in the plasma membrane fractions isolated 
with the detergent-free method from HeLa cells are shown in Fig. 31A. These spectra, with an 
excitation maximum at ~ 390 nm and emission maximum at ~ 440 nm, resemble those of MLVs 
with a raft mixture (Fig. 30A) and are typical of membranes containing high concentration of 
cholesterol [265]. GP values in the plasma membrane fractions were above 0.4, in agreement with 
values previously described in isolated membranes [266]. Though very small differences were 
observed among the different fractions, a flattening of the GP profile can be noticed in ABCA1-
expressing membranes in comparison to those expressing the mutant transporter (Fig. 31B). As lipid 
packing is tightly related to cholesterol content, these data may substantiate the assumption that 
ABCA1 influences the distribution of cholesterol within the plasma membrane. On the other hand, it 
is also possible that the method utilized is not sensitive enough for the detection of this fine 
modulated process. 
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Fig. 31: Laurdan excitation and emission spectra and GP values in plasma membrane fractions. (A) 
Laurdan fluorescence spectra in membranes isolated from HeLa cells with the detergent-free method. Here, 
spectra measured in fraction 1 at 25°C are shown. Excitation and emission wavelengths were set at 360 nm 
and 428 nm, respectively. In (B), GP values calculated from the intensities at 437 nm and 482 nm (see formula 
in the text) of the emission spectra in ABCA1- (closed circles) and ABCA1MM-containing membranes (open 
circles) are plotted (mean ± SEM of two independent experiments in duplicates). In the inset, values 
normalized to fraction 1 are shown. 
 
4.2.4 ABCA1 and ABCA7: similarities and differences 
Among the A subfamily of ABC transporters, ABCA7 shares the highest amino acid sequence 
homology with ABCA1. Based on this structural homology and on the fact that many ABC proteins 
are linked with the transport of lipids across cellular membranes, the study of ABCA7 function has 
focused on lipid metabolism (see introduction, section 1.2.4.2). To shortly summarize, ABCA7 
transfected in several cell lines was shown to stimulate efflux of phospholipids to ApoA-I 
[99,102,104], although efflux of cholesterol is still controversial. Some groups reported no 
cholesterol efflux to ApoA-I, [102,103], whereas others showed low but positive cholesterol release 
[99,104,105]. Moreover, studies on abca1 knock-out mice and Tangier disease patients showed that 
ABCA1, but not ABCA7, is essential to maintain the plasma HDL concentration [101], but further 
investigations are required to establish the function of this protein in vivo. Up to now, the studies on 
ABCA7 have been concentrated on efflux of lipids to lipoproteins, while no study on ABCA7-
dependent lipid exposure has been performed. 
We have investigated the exposure of endogenous PS and of fluorescent lipid analogues in the 
plasma membrane of MDCKII and HeLa cells expressing ABCA7. A comparative study between 
ABCA7 and ABCA1 was performed, focusing on the influence of the protein on the lateral and 
transbilayer lipid distribution. 
ABCA7-YFP was expressed in HeLa and MDCKII cells. Tagging of the protein at the C-terminal 
does not affect phospholipid and cholesterol release to ApoA-I with respect to the wild type 
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transporter [99,104]. ABCA7-YFP was localized at the plasma membrane and intracellularly both in 
HeLa and in non polarized MDCKII cells (Fig. 33), similarly to ABCA1-GFP. 
To confirm that ABCA7-YFP was active in our expression system, lipid efflux to ApoA-I was 
analyzed. To this aim, cellular phospholipids were labelled with [32P]-orthophosphate and cells were 
subsequently incubated with 10 μg/ml of ApoA-I for 16 h at 37ºC. Lipids in the medium and in the 
cells were extracted and analyzed after separation by two-dimensional TLC. The percentage of 
efflux was calculated as the radioactivity in the medium relative to the total radioactivity in cells and 
medium. In Fig. 32, the data normalized to efflux in the absence of ApoA-I are presented. In the 
presence of ABCA7-YFP, ApoA-I extracted about 3.9 % ± 0.6 of the total PC detected in the 
medium and cells. We found that ABCA7-YFP promoted efflux of PC and SM to ApoA-I at similar 
levels to cells expressing ABCA1, as previously reported after labelling of phospholipids with [3H]-
choline [103]. No efflux was measured in non transfected HeLa cells subjected to the same treatment 
(C) and in ABCA7-YFP expressing cells in the absence of ApoA-I. This confirmed that ABCA7-
YFP was functional in our expression system. 
 
Fig. 32: Efflux of [32P]-containing phospholipids from non-transfected and ABCA7-YFP-expressing cells 
to ApoA-I. HeLa cells were labelled with [32P]-phosphate and efflux to ApoA-I (10 μg/ml) was performed for 
16 h at 37ºC. The results are expressed as the amount of radioactivity corresponding to the indicated 
phospholipids found in the medium divided by the total radioactivity in the medium and cells. Results are 
normalized to the control efflux in the absence of ApoA-I. C: non-transfected HaLa cells. Mean ± SEM of 3 
independent experiments in duplicates are plotted. 
ABCA1-expressing cells expose a higher amount of PS on the outer leaflet of the plasma membrane, 
as detected by prothrombinase activity and binding of Annexin V [149,170,178]. Moreover, by using 
C6-NBD-labelled phospholipid analogues, redistribution of PS- but not of PC-analogues from the 
cytoplasmic to the exoplasmic leaflet of the plasma membrane was observed in ABCA1-expressing 
cells [170]. However, whether ABCA7 also promotes exposure/efflux of phospholipid (analogues) is 
unknown. 
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Exposure of endogenous PS on the exoplasmic plasma membrane leaflet of HeLa and MDCKII cells 
was assessed by APC-Annexin V binding quantified by flow cytometry. Regions were set to exclude 
subcellular particles and damaged cells, the latter identified by co-labelling with propidium iodide. 
Expressing and non-expressing cells (A7 pos and A7 neg, respectively) in the same sample were 
distinguished by gating on the YFP fluorescent signal. As can be seen in Fig. 33, APC-Annexin V 
binding was enhanced in ABCA7-YFP expressing cells, in comparison to non expressing cells, in 
both HeLa (A) and MDCKII cells (B). This effect was not observed in HeLa cells transiently 
transfected with a mutant ABCA7-YFP with impaired ATPase activity (data not shown). 
 
Fig. 33: Subcellular localization of ABCA7-YFP and exposure of endogenous PS in ABCA7-YFP-
expressing cells. (A) Subcellular localization of ABCA7-YFP and flow cytometric analysis of APC-Annexin 
V binding to the cell surface of HeLa cells (A) and MDCKII cells (B). ABCA7-YFP localizes to the plasma 
membrane and to intracellular compartments in both cell lines. After appropriate gating to exclude damaged 
cells and debris, cells expressing (A7 pos) and non-expressing (A7 neg) ABCA7-YFP were identified by 
gating on the YFP fluorescent signal. Cells expressing the transporter show enhanced exposure of endogenous 
PS, assessed by APC-Annexin V binding. Bars correspond to 10 μm. 
To study the outward redistribution of C6-NBD-PS from the inner to the outer leaflet of the plasma 
membrane, MDCKII cells and ABCA7-YFP expressing cells were incubated at 20ºC for 30 min with 
C6-NBD-PS. This step allows the inward movement of the lipid analogues by an aminophospholipid 
translocase activity present in the plasma membrane of the cells [207]. Analogues remaining in the 
exoplasmic leaflet were removed by repeated washing with BSA. To follow the redistribution of the 
lipid analogues to the outer leaflet, cells were incubated at 37ºC in BSA-containing medium in order 
to extract any analogue that reached the cell surface during the time course of the experiment. The 
kinetics of the outward redistribution in MDCKII cells are shown in Fig. 34. 
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Fig. 34: Outward redistribution of C6-NBD-PS (A) and C6-NBD-PC (B) in ABCA7-YFP-expressing 
MDCKII cells. (A) Kinetics of outward redistribution in non transfected MDCKII cells and cells expressing 
ABCA7-YFP at 37°C. Data are shown as mean ± SEM of at least two independent experiments.  
About 60% of the analogues distributed in the inner leaflet became accessible to BSA within 15 min 
of incubation in BSA-containing medium. No difference between non transfected MDCKII cells and 
ABCA7-YFP expressing cells was detected. Similar results were obtained for HeLa cells (not 
shown). These results indicate that ABCA7, differently from ABCA1, does not redistribute PS 
analogues to the outer leaflet of the plasma membrane. However, it remains possible that this 
fluorescent analogue of PS is not recognized by the transporter.  
As a next step, the outward redistribution of C6-NBD-PC was examined. To this aim, cells were 
incubated with C6-NBD-PA as a complex with 1% BSA for 1 h or 3 h at 15°C. This lipid analogue is 
partially converted to C6-NBD-diacylglycerol, which can translocate across the plasma membrane 
and become available for intracellular synthesis of C6-NBD-PC [58]. After the incubation, the 
medium was collected and cells were washed with DPBS containing 1% BSA. Washes and media 
were pooled and lipids extracted from the media and cells were analyzed after two-dimensional 
separation (as explained in 3.2.4.9). After 1 h or 3 h of incubation at 15°C in the presence of BSA, 
the amount of C6-NBD-PC extracted was in the order of ~ 50% of the total C6-NBD-PC present in 
the medium and cells. No difference between non transfected and ABCA7-YFP-expressing cells was 
detected (Fig. 34B). 
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To gain further insight into the differences and similarities between ABCA7 and ABCA1, GPMVs 
were prepared from HeLa cells expressing ABCA7-YFP as described in 3.2.4.2. The preferential 
partitioning of the protein in these vesicles was determined by comparison to the distribution of the 
marker of the Ld-like phase R18. Similarly to ABCA1-GFP and ABCA1MM-GFP, ABCA7-YFP 
was enriched in the Ld-like phase (Fig. 35).    
 
Fig. 35: Partitioning of ABCA7-YFP in GPMVs. GPMVs were prepared from HeLa cells expressing 
ABCA7-YFP. At 25°C, the majority of the vesicles show coexisting lipid phases. (A) ABCA7-YFP 
preferentially partitions in the Ld-like phase identified by co-staining with R18. Images were taken at the 
equatorial plane of the vesicles. Bars correspond to 5 μm. The histograms showing the distribution of the 
relative size of the Ld-like phase in these vesicles are shown in (B). Mean ± SEM is indicated in the top left 
corner. In brackets: number of domains analyzed. Typically, 1-3 domains per vesicle were found.  
As previously described, the extent of the Ld-like phase in the presence of the protein was 
quantified. This revealed that blebs prepared from cells expressing ABCA7-YFP share a similar 
morphology to those originating from HeLa cells and ABCA1MM-GFP expressing cells (compare 
paragraph 4.2.2). In line with this result, the lifetime of C6-NBD-PC was also not modified in 
ABCA7-containing membranes (section 4.2.1.2, Fig. 20). 
In summary, these results indicate that ABCA7 shares with ABCA1 some functional features: they 
both show enhanced binding of Annexin V, which suggests an enhanced exposure of endogenous PS 
on the cell surface, and both promote efflux of phospholipids to ApoA-I in vitro. However, 
differently from ABCA1, ABCA7 does not mediate outward redistribution of C6-NBD-PS. In 
addition, the analysis of C6-NBD-PC fluorescence lifetime and the study of the influence of ABCA7 
on the lipid domain organization in laterally intact cellular bilayer membranes suggest that ABCA7 
has no influence on the lateral organization of the plasma membrane. 
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5 Discussion 
5.1 FLIM of C6-NBD lipid analogues: a tool to study the 
lateral heterogeneity of membranes 
The plasma membrane is currently considered to be a complex and heterogeneous composite in 
which transient and short lived domains may form. However, the properties of such domains and 
even their existence has divided discussions, in particular because of the lack of proper tools capable 
of resolving such nanoscaled and short lived heterogeneities. 
In the last couple of years, new approaches towards studying such domains have emerged. Among 
them, are specific fluorophores sensitive to the environment in which they are embedded. These 
have been employed to study the lateral organization of model and cellular membranes. In contrast 
to steady-state fluorescence techniques, which are dependent on the resolution limit, fluorescence 
lifetime can show the characteristic components of the lipid environment surrounding the 
fluorophores, even if they are localized in the same focal spot [35]. To resolve two distinct lipid 
environments by FLIM, lipid analogues must not interchange between them during emission. Thus, 
domains should be stable for at least three times the fluorescence lifetime of the fluorophore, e.g. for 
about 30 ns in the case of C6-NBD-PC. In this time period, assuming a lateral lipid diffusion of 10 
μm2/s, an analogue would diffuse ~ 2 nm. Therefore, lipid domains as small as ~ 10 nm2 should be 
detectable by FLIM. As in the plasma membrane of HeLa cells, the lateral diffusion of C6-NBD-PC 
was 0.1 μm2/s, in agreement with diffusion coefficients measured in fibroblasts [240] and red blood 
cells [267], domains resolvable by FLIM could be even smaller.  
We applied this approach first to GUVs, a well controlled and simple system, to characterize the 
dependence of the lifetime on the lipid environment. Subsequently, GPMVs were studied to 
investigate the influence of a highly heterogeneous lipid and protein composition. This allowed a 
direct comparison to the data obtained in cellular membranes. Finally, this technique was applied to 
study the influence of ABCA1 on the physicochemical properties of the plasma membrane.  
5.1.1 Visualization of lipid domains by fluorescence lifetime of C6-
NBD-PC in GUVs 
The sensitivity of the fluorescence lifetime of the NBD group to the phase state of lipid membranes 
was first employed to study the lateral organization of lipids in model membranes. The NBD group 
of different NBD-labeled lipids localizes at a distance of 18.8 - 20.8 Å from the center of the bilayer, 
which suggests the preferential localization of the fluorophore in the vicinity of the glycerol 
backbone and the carbonyl region of adjacent lipid molecules [268]. Similar results were reported by 
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Huster et al., using NMR cross-relaxation rate measurements [269], and by Loura and Ramalho, by 
molecular dynamics simulations [270]. This localization places the fluorophore in a suitable position 
to detect changes in the viscosity of its environment and in the acyl chain packing of the surrounding 
lipids. 
In DOPC/SSM/cholesterol GUVs, forming visible phase separation at 25ºC, the long component of 
NBD fluorescence lifetime τ2 was shown to be sensitive to the lipid phase in which the lipid 
analogues were embedded. In Ld domains, the lifetime τ2Ld was about 7 ns, whereas it was shifted to 
about 11 to 12 ns in Lo domains (τ2Lo). The longer values assessed in the Lo phases, enriched in 
cholesterol and saturated lipids, can be attributed to slower rate of emission of the excited state due 
to the higher degree of order in this phase. An alternative explanation is suggested from recent 
findings, which indicate that the NBD group of acyl chain-labelled lipids resides in a more 
hydrophobic region in gel phase membranes [271]. Therefore, the longer lifetime in the Lo phase 
may be due to a relocation of the NBD group from the membrane interface to more hydrophobic 
membrane interior.  
Besides τ2, a second component τ1 of low amplitude was also detected. This component may derive 
from the NBD groups exposed to the aqueous environment [272]. Alternatively, it may originate 
from the red edge excitation shift of NBD in membranes, as in our experimental setup the excitation 
wavelength of the NBD fluorescence was 468 nm, about 3 nm above the excitation maximum. As a 
consequence, photons emitted early with a small Stokes shift are preselected and give rise to the 
faster decay component [273]. In addition, it was suggested that this fast component may reflect 
rotational motion involving the NBD fluorophore [270]. 
Measurements performed on GUVs prepared from POPC/PSM/cholesterol, which do not form 
visible domains at 25ºC [6], demonstrated that domains of submicroscopic size were formed [209], 
as already suggested by previous studies via fluorescence energy transfer [274,275]. In fact, in these 
vesicles, two lifetime components similar to τ2Ld and τ2Lo were found. This indicates that measuring 
the lifetime of the NBD group is a suitable approach to detect the presence of lipid domains even 
below the resolution limit of the microscope.  
5.1.2 Fluorescence lifetime of C6-NBD-PC in GPMVs 
To characterize the properties of the NBD lifetime in membrane bilayers with biological lipid 
composition, GPMVs were prepared from HeLa cells. These vesicles were recently shown to 
undergo domain formation at temperatures below ≤ 25ºC [17]. Interestingly, in these vesicles C6-
NBD-PC was either almost homogeneously distributed between the Ld and the Lo phase, or 
displayed even a slight preference for the Lo phase. In the first case, the effective formation of 
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domains was confirmed by the heterogeneous distribution of other probes, such as Rho-DOPE or 
R18. Such partitioning is in contrast to the preferential localization of the lipid analogue in the Ld 
phase in GUV [209,211]. This indicates that the preferential enrichment of C6-NBD-PC depends not 
only on the nature of the lipid phase, but also on its direct lipid environment. Indeed, in GUVs in 
which a large difference in physical properties exist between the two phases (e.g. 
DOPC/SSM/cholesterol, which display phase separation at 25ºC), C6-NBD-PC was clearly enriched 
in the Ld domain (Fig. 36A). On the contrary, GUVs made from POPC/PSM/cholesterol do not 
show phase coexistence at 25ºC, but domain formation can be seen at temperatures ≤ 10ºC. In such 
vesicles, in which the difference of enthalpy between the phases is smaller, the preference for the Ld 
domain was much weaker (Fig. 36B). In GPMVs, which consist of different lipid species and 
proteins, the transition between the different membrane states should be more easily achievable. 
Indeed, in these vesicles C6-NBD-PC displayed no phase enrichment or even a slight preference for 
the Lo phase (Fig. 36C). These results indicate that C6-NBD-PC is excluded from tightly packed but 
can penetrate less compact Lo phases, such those of GPMVs. They also show that the assignment of 
fluorescent lipid probes as specific for distinct lipid domains has to be verified for each membrane 
system. 
 
Fig. 36: Phase partition and fluorescence lifetime of C6-NBD-PC in GUVs and GPMVs at 10ºC. C6-
NBD-PC strongly partition in the Ld phase in GUVs prepared from DOPC/SM/cholesterol 1/1/1 (A), whereas 
its phase preference is weaker in POPC/SM/cholesterol 1/1/1 GUVs (B). In GPMVs prepared from HeLa cells, 
C6-NBD-PC even displays a preference for the Lo phase (C). Top row: fluorescence intensity images of C6-
NBD-PC; bottom row: average fluorescence lifetime images, pseudocolored according to the scale. The Ld 
phase is indicated by the arrow. Bars correspond to 10 μm. Images of GUVs (A and B) were kindly provided 
by Dr. Martin Stöckl.  
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Notably, despite the differential phase preference, the typical NBD lifetime pattern in the Ld and the 
Lo phase was preserved. However, in GPMVs, the difference between the lifetimes in the two 
phases was less pronounced, with values centered around 6.7 ns and 9.6 ns. This can be due to the 
fact that in these vesicles Lo phases are likely less condensed than those of GUVs. In addition, 
partial loss of lipid asymmetry may also account for the decrease in the lifetime of the Lo phase, as 
the presence of PS was shown to shorten lifetime values in GUVs [209] and in the plasma membrane 
of HeLa cells (section 4.1.4.3). Moreover, this can be concluded from the fact that the envelope of 
the two lifetime distributions of domain-forming GPMVs gives rise to a continuous and not to a 
bimodal lifetime distribution as found for GUVs. Remarkably, the envelope histograms of domain-
forming GPMVs and of vesicles showing no phase separation were strikingly similar. This may 
indicate that, in the latter case, large domains disintegrated into smaller ones below the microscopic 
resolution, while the essential physical properties, e.g. lipid packing, were preserved. Being aware of 
the limitation of GPMVs, a similar situation may be applied to the plasma membrane of cells (see 
chapter to follow).  
5.1.3 Fluorescence lifetime of C6-NBD-PC in cellular membranes 
In all the cell lines tested - HeLa, HepG2 and Jurkat - a bimodal distribution of the fluorescence 
lifetime τ2 of C6-NBD-PC, C6-NBD-LacCer or C6-NBD-PS was observed. Based on the analysis of 
the FLIM images, the short component τi was associated to intracellular membranes, whereas the 
long component τp to the plasma membrane. Support for this conclusion was given by the fact that, 
when cells were labeled with C6-NBD-PS, an increase in the amplitude of the short component was 
detected. It is known that PS, as well as its analogue C6-NBD-PS, is transported from the 
exoplasmic to the cytoplasmic leaflet of the plasma membrane of HepG2 and HeLa cells by an 
aminophospholipid translocase activity [170,221] and is then redistributed to intracellular 
membranes. The plasma membrane-associated lifetime of C6-NBD-PS was found to be slightly 
shorter than that of C6-NBD-PC. This can be explained by the presence of a higher fraction of the 
PS analogue in the cytoplasmic leaflet. Indeed, it was previously concluded that the inner leaflet has 
reduced lipid packing with respect to the exoplasmic leaflet [240,267]. Conversely, the lifetime of 
the plasma membrane-associated C6-NBD-LacCer was shifted to higher values, in agreement with 
the preferential localization of ceramide-based lipids to a more ordered environment. 
The difference in lifetime between the plasma membrane and intracellular membranes can be 
explained by the higher cholesterol content of the plasma membrane. Indeed, cholesterol depletion 
by MβCD induced a shift of the lifetime distribution towards shorter values. The lifetime distribution 
of the C6-NBD-analogues in the plasma membrane was centered at about 11.5 ns, values typically 
found for Lo phases of GUVs. These results highlight the sensitivity of this approach to the local 
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lipid composition of membranes and would agree with the hypothesis, previously drawn, that the 
plasma membrane may consist of a continuous Lo-like phase with embedded possible small Ld 
domains [276]. Moreover, the lifetime distribution in the plasma membrane was rather broad as 
compared to GUVs and GPMVs, even though no separated components were observed. This 
continuous distribution supports the existence of a large variety of domains varying in size, 
composition and stability. Previous work has already discussed the presence of an array of domains 
of different sizes, compositions and fluctuating in time [5,277].  
The lifetime of NBD-lipid analogues was demonstrated to be sensitive to cell treatments known to 
interfere with the lateral and transbilayer organization of membranes. Scrambling of phospholipids 
between the two leaflets of the plasma membrane via the calcium ionophore ionomycin induced a 
decrease in the lifetime of NBD. As previously mentioned, this is likely due to the creation of a less 
ordered environment upon exposure of PS to the outer leaflet of the plasma membrane. A similar 
effect was observed after disruption of the cytoskeleton by cytochalasin D, confirming that the 
cytoskeleton meshwork may also contribute to the micro-organization of the plasma membrane. 
Indeed, in the absence of cytoskeletal constraint, GPMVs blebbed from the plasma membrane of 
cells can undergo phase separation. 
In conclusion, our study suggests the existence of a variety of short-lived submicroscopic domains in 
the plasma membrane of cells. This view is consistent with the complex network of connections 
driving the organization and dynamics of the plasma membrane, in which, besides lipid-lipid 
interactions, protein-lipid and protein-protein interactions also play a fundamental role. The 
cytoskeleton meshwork and the presence of vesicles continuously fusing and budding to and from 
the membrane likely also contribute to its dynamics. Finally, also membrane proteins, either by their 
mere presence or by their influence on the lipid distribution between the two leaflets (section 1.1.4), 
may contribute to the modulation of the physical properties of the plasma membrane. Indeed, FLIM 
allowed detecting and characterizing the effect of ABCA1 on the physicochemical properties of the 
plasma membrane (see chapter to follow).  
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5.2 Influence of ABCA1 on the lipid microenvironment at the 
plasma membrane 
The described approach based on FLIM of C6-NBD-lipid analogues was employed to assess the 
influence of ABCA1 on the physicochemical properties of the plasma membrane. 
Soon after the identification of ABCA1, it was proposed based on large experimental evidence that 
its lipid translocase activity can modify the lipid distribution at the plasma membrane, creating a site 
required for the docking of ApoA-I and the subsequent formation of HDL particles (section 1.3.3). 
Moreover, a redistribution of cholesterol between different pools at the plasma membrane was 
hypothesized to explain the increased sensitivity of ABCA1-expressing cells to cholesterol oxidase  
[177], as this enzyme is believed to be sensitive to the physical properties of the membrane in which 
cholesterol is embedded [186]. Recently, the influence of the transporter on the overall lipid packing 
at the plasma membrane has been reported, although this conclusion was mainly supported using 
detergent-based methods [187,188]. Indeed, the limitations of these approaches have lately emerged 
[27].  
5.2.1 ABCA1 affects the lateral organization of the plasma 
membrane 
We present here for the first time a study of the influence of ABCA1 on the plasma membrane 
micro-organization by a biophysical approach applied on living cells. Using this technique, the 
influence of the transporter on the lipid packing at the plasma membrane was demonstrated. In the 
presence of the wild type transporter, but not of its non-functional mutant, an increase in the 
fluorescence lifetime of C6-NBD-PC was detected. Considering the correlation between lifetime and 
cholesterol content, this increment indicated that, in the presence of ABCA1, the NBD probes were 
embedded in a cholesterol-enriched environment. Support to this conclusion was provided by the 
decreased mobility of C6-NBD-PC measured, under the same conditions, by FRAP analysis. Indeed, 
a reduced diffusion mobility of lipids is recognized to be correlated with a higher membrane 
viscosity and cholesterol content [241]. In line with this assumption, cholesterol depletion induced 
both a decrease in the lifetime and an increase in the mobility of C6-NBD-PC. Similarly, an 
ABCA1-dependent increment in lifetime was detected for C6-NBD-LacCer, indicating that the 
effect observed was not due to preferential interactions between ABCA1 and C6-NBD-PC.  
To explore the possibility that the enhanced lifetime measured was associated with formation of 
condensed, raft-like domains, C6-NBD-PC lifetime was analyzed in the plasma membrane of Jurkat 
cells after activation of the TCR via an anti-CD3 antibody. This treatment was demonstrated to 
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trigger formation of condensed membrane domains at the activation sites [37,237]. Similarly, 
generation of ceramide by sphingomyelinase treatment was also shown to be involved in the natural 
activation sequence of these cells [238]. After both procedures, a decrease in the fluorescence 
lifetime was detected. This result may, at a first glance, be in contradiction with the effective 
formation of condensed domains. However, we have previously highlighted that C6-NBD-PC is 
excluded from strongly ordered lipid domains, whereas it is able to penetrate the less compact Lo 
domains of GPMVs (Fig. 36). Hence, we conclude that the induction of strongly ordered domain 
compartments after cell activation or sphingomyelinase treatment leads to an enrichment of the 
probe in the surrounding disordered environment, causing the observed decrease of the fluorescence 
lifetime.  
We surmise from this data that ABCA1 destabilizes raft domains, resulting either in an enhanced 
partitioning of the NBD analogues to these domains, or in a redistribution of cholesterol outside rafts 
enhancing lipid packing in the non-raft domains. This membrane reorganization was dependent on a 
functional nucleotide binding fold, suggesting the involvement of ATPase-related functions. 
Alternatively, it could be argued that ABCA1-containing plasma membrane has a higher amount of 
cholesterol. However, as the plasma membrane cholesterol content between cells expressing the wild 
type and the non-functional mutant protein was similar (section 4.2.3.2), in agreement with previous 
results [187], a redistribution of cholesterol between different plasma membrane pools is more 
likely.  
This hypothesis was confirmed by the analysis of ABCA1 partitioning with a detergent-free 
biochemical approach, described in the chapter to follow. 
5.2.2 Mechanism of ABCA1-dependent destabilization of raft 
domains 
The analysis of plasma membrane fractions isolated via density fractionation revealed a differential 
partitioning between the wild type ABCA1 and its non-functional mutant ABCA1MM (section 
4.2.3), as previously shown based on detergent solubility [278]. A higher recovery of ABCA1 in the 
non-raft fractions of the plasma membrane was detected in comparison to ABCA1MM, which is 
consistent with an alteration of the physicochemical properties of the plasma membrane apt to 
influence its overall flotation behavior in a density gradient. Corroborated by the higher recovery of 
lipids in the non-raft fractions in the presence of ABCA1, this is in agreement with the generation of 
a more loosely packed fraction of the plasma membrane. 
Interestingly, the differential partitioning of ABCA1 did not correlate with the binding or with the 
efflux of phospholipids to ApoA-I (section 4.2.3.1). Conversely, a dependence on the extent of 
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binding of Annexin V, a well-established indicator of PS exposure on the cell surface [226], was 
evidenced.  
At this point, no conclusions can be drawn as to whether PS is actively translocated by ABCA1. 
Nevertheless, we speculate that outward exposure of PS, a polar phospholipid bearing unsaturated 
acyl chains, would justify the changes in the plasma membrane lipid microenvironment exerted by 
ABCA1. In synthetic phospholipid mixtures, PS can enhance the miscibility of cholesterol and 
phospholipids leading to a lateral redistribution of cholesterol [279]. Moreover, chemical treatments 
able to generate outward movement of PS, such as scrambling of phospholipids, were shown to lead 
to an increase in the MβCD-extractability of cholesterol and in its susceptibility to cholesterol 
oxidase [280,281,282]. In line with this hypothesis, in ABCA1-expressing cells a larger efflux of 
cholesterol to MβCD (section 4.2.1.3) [171,187] and a higher sensitivity to cholesterol oxidase [177] 
was detected in comparison with ABCA1MM-expressing cells. It was recently proposed that the 
movement of inner-leaflet phospholipids, which have reduced avidity for sterol complexation, to the 
outer leaflet of the plasma membrane may increase the chemical activity of cholesterol (defined as 
its escape tendency) [281,283]. Similarly, the sensitivity to cholesterol oxidase is also considered an 
indicator of cholesterol activity [283]. Moreover, it was demonstrated that lowering the abundance 
of plasma membrane sphingomyelin, which also increases the chemical activity of cholesterol [284], 
promoted cholesterol export by ABCA1 [285]. However, it has to be underlined that the order of 
magnitude of these two events i.e. the exposure of PS on the outer leaflet measured upon activation 
of lipid scrambling and in the presence of ABCA1 is considerably different.  
One of the models proposed for the mechanism of ABCA1 function suggests that the lipid 
translocase activity of ABCA1 can modify the lipid distribution at the plasma membrane creating a 
site required for the docking of ApoA-I and subsequent formation of HDL particles (see 
introduction, section 1.3.3.2). However, from our and other studies, it emerges that exposure of PS 
alone cannot account for the ABCA1-dependent modification on the lipid microenvironment at the 
plasma membrane. In fact, expression of ABCA7, which is also associated with enhanced exposure 
of PS on the cell surface, has no influence on the plasma membrane micro-organization, assessed by 
the lifetime of C6-NBD-PC (section 4.2.1.2). In addition, it was previously shown that neither 
apoptotic cells are able to efflux cholesterol to ApoA-I, nor Annexin V to impair cholesterol efflux or 
ApoA-I binding [286]. 
Indeed, the deficiency of ABCA7 does not alter ApoA-I-stimulated cholesterol and phospholipid 
efflux in vivo [100]. Despite the fact that in transfected cells ABCA7 is able to promote efflux of PC 
and SM to ApoA-I (section 4.2.4), it has to be underlined that, under physiological condition, the 
contact between ABCA7 and ApoA-I may be limited. In fact, immunofluorescence microscopy of 
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endogenous ABCA7 in macrophages revealed a predominantly intracellular localization of this 
protein [102]. Moreover, the tissue distribution of ABCA1 and ABCA7 is considerably different, as 
the former is especially abundant in the liver, the major site of HDL production, whereas the latter is 
mainly localized in the brain, lung, spleen and adrenal gland and does not show induction by LXR 
activation [103]. It is possible that, in vitro, the observed efflux of lipids to ApoA-I is triggered by a 
small pool of apolipoprotein binding to ABCA7.  
Based on our data and on the findings described in literature we propose the following model (Fig. 
37).  
 
Fig. 37: Model for ABCA1 function. ABCA1 actively translocates phospholipids to the outer leaflet of the 
plasma membrane (1), leading to the creation of less packed membrane domains (2) in which cholesterol 
redistributes and becomes available for extraction by ApoA-I (3). For more details, see text. 
We hypothesize that ABCA1 actively translocates phospholipids (and/or cholesterol) to the outer 
leaflet of the plasma membrane (Fig. 37, 1). Given the fact that the ATP-binding domain and the 
putative substrate entry site of the protein are oriented toward the cytoplasmic leaflet, it is expected 
that a cytoplasmic phospholipid would be preferentially transported. Alternatively, cholesterol could 
also be translocated to the outer leaflet, although controversy is present whether energy-dependent 
transport proteins are indeed required for its transbilayer movement, based on the fact that 
cholesterol can rapidly diffuse across the bilayer (see [287] for a review). On the other hand, the 
transbilayer dynamics of cholesterol may be restricted by specific interactions with lipids and 
proteins. Previous studies reported an influence of lipid composition on cholesterol translocation 
[288,289]. Moreover, simulation models suggest that cholesterol molecules confined to lipid 
domains, such as Lo domains, may not easily flip-flop between the two leaflets of the bilayer [290]. 
The ABCA1-mediated translocation event leads to a local increase in the fluidity of the membrane, 
causing the redistribution of cholesterol from tightly packed to more fluid domains (Fig. 37, 2). This 
is consistent with the higher lifetime measured in the plasma membrane upon expression of ABCA1, 
as the NBD-labelled probes can now penetrate into these less condensed membrane portions. The 
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generation of loosely packed membrane microdomains in ABCA1-expressing cells was previously 
reported by biochemical methods [187,188]. Furthermore, this would imply the localization of 
ABCA1 in disordered regions of the membrane (sections 4.2.2 and 4.2.3.1) at the boundary between 
raft and non-raft domains. Indeed, in detergent resistant membranes, ABCA1 was partially detected 
in fractions insoluble to the mild detergents Lubrol WX and Brij 98, but was excluded from Triton 
X-100 insoluble membranes (A. Zarubica, unpublished data). 
The transfer of molecules from the inner to the outer leaflet and the increased membrane fluidity 
facilitates the generation of curved structures, as bending the phospholipid bilayer toward the 
extracellular space would relieve the lateral stress in the membrane [179,291]. At the same time, in 
these regions, the chemical activity of cholesterol increases, as uncomplexed, high-activity 
cholesterol resides in disordered regions [283]. In agreement with this hypothesis, it was recently 
shown that ABCA1-expressing cells produce cholesterol/phospholipid microparticles even in the 
absence of ApoA-I and that this process could be prevented by rigidifying the plasma membrane 
[191].  
Finally, cholesterol molecules localized in these regions would be more accessible to extracellular 
acceptors, such as ApoA-I (Fig. 37, 3). In addition, ApoA-I may be preferentially recruited to these 
domains [179]. The increased accessibility of cholesterol to MβCD extraction in the presence of 
ABCA1 that we and others reported [171,187], as well as its enhanced susceptibility to cholesterol 
oxidase [177], would also be a consequence of its higher chemical activity. 
It was already suggested for ABC proteins, in particular for ABCAG5/G8, to stimulate the exposure 
of cholesterol molecules out of the membrane surface, presenting them to external acceptors (in this 
case mixed bile salt-phospholipid micelles or vesicles) [74]. According to our data, we surmise that 
this “liftase” or “exponase” function is indirectly achieved in the case of ABCA1. 
In conclusion, the ability of ABCA1 to promote cholesterol efflux seems to be independent and to 
precede its binding to plasmatic acceptors such as ApoA-I. We propose that the ABCA1-induced 
plasma membrane modifications are necessary for lipidation of ApoA-I and generation of HDL 
particles. Moreover, the effect of ABCA1 on the lateral lipid distribution is also a determinant for 
other receptors, as shown for the case of the TfR. A redistribution of this receptor in different 
domains at the membrane (section 4.2.3.1) could be the underlying cause of its reduced mobility 
[233] and of the reduced receptor-mediated endocytosis [169,170] in ABCA1-expressing cells. 
By analogy with other ABC transporters and from several experimental hints, it is possible that this 
is achieved by the floppase activity of ABCA1. However, the lipids that may be the substrate for 
ABCA1 transport have not been unequivocally identified. Therefore, despite the intense studies 
being carried out in this area, the story of this protein still has to be fully written.   
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